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Abstract 
Introduction: MAGI -1 plays an essential role in cancer metastasis. We aimed to study 
the expression of MAGI -1, -2 and -3 in colorectal cancer tissue with specific focus on the 
role of MAGI -1 in colorectal cancer metastasis, through its function in the maintenance 
of cell-to-cell tight junctions. 
Materials and Methods: MAGI -1, -2 and -3, expression was determined in colorectal 
cancer tissue by using Q-PCR and RT-PCR. MAGI -1 knockdowns were created in cancer 
cell lines by electroporation method and were confirmed on RT- PCR, morphology and 
immunofluorescence. The impact of aberrantly expressed MAGI -1 on adhesion, 
invasion and migration of colorectal cancer tissue was studied by using trans-epithelial 
resistance (TER) and electrical cell impedance (ECIS) assays. 
Results: Q-PCR was consistent with the reduced expression of MAGI-1, -2 and -3 in 
colorectal cancer tissue. Survival curves showed reduced survival in cohort with reduced 
MAGI expression. MAGI -2 lacked expression on RT-PCR. MAGI -1 KDs showed decrease 
trans-epithelial resistance in the KDs. Reduced electrical resistance across epithelial cell 
lines in MAGI -1 KDs and also reduced adhesion and increase in migratory function was 
observed in MAGI -1 KDs on Trans-epithelial resistance (TER) and electronic cell 
impedance sensing (ECIS) experiments respectively.  
Conclusion: Our experimental work suggests that MAGI-1 plays a vital role in 
maintaining the barrier function of tight-junctions in colorectal cancer tissue, which 
when knocked down, has a significant implication in colorectal cancer metastasis.      
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C H A P T E R  1 :  I N T R O D U C T I O N 
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C H A P T E R  1 :  I N T R O D U C T I O N 
1.1. Introduction 
Cancer is the leading cause of human morbidity and mortality worldwide. 14 million new 
cases were diagnosed in 2012, with more than 8 million cancer-related deaths reported 
in one year. The global cancer burden is on the increase. The World Health Organisation 
(WHO) publishes annual cancer mortality statistics for most countries. It is expected that 
the number of new cases will increase by 70% over next two decades. The majority of 
human cancers are carcinomas, which are malignant epithelial tumours, followed by 
lymphomas (malignant tumour of lymph tissue). Worldwide, the most prevalent cancer 
in men is lung, followed by prostate, colorectal, stomach and liver. In women, the most 
common cancers are breast followed by colorectal, lung, cervical and stomach. Lung 
cancer leads the mortality count by causing 1.59 million deaths, with liver cancer 
following by causing 745000 deaths, stomach cancer causing 723000 deaths, colorectal 
cancer-causing 694000 deaths, breast cancer-causing 521000 deaths and oesophageal 
cancer-causing 400000 deaths, as reported mortality in 2012 by WHO (WHO cancer 
statistics 2012). 
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Figure 1.1.1. WHO cancer statistics 2012 
 
1.1.1. Risk factors 
Smoking single-handedly causes 20% of overall cancer deaths and 70% of lung cancer 
deaths.  Cigarette smoking is responsible for at least a quarter of cancer deaths, 
especially from cancers of the lung, larynx, oral cavity and to a lesser extent the urinary 
tract. Most of the effects are due to direct contact with carcinogens in smoke, but these 
are also absorbed and excreted through the kidneys. Many carcinogens are present in 
smoke including benzopyrene and dimethylnitrosamine. There is a direct relationship 
between the number of cigarettes smoked and the risk of lung cancer, and, although 
stopping smoking reduces this risk, its effects are not reversible. One-third of the cancer 
morbidity and mortality risk is associated with dietary and behavioural factors - the top 
five of which include high BMI (obesity), low fruit and vegetable intake, lack of regular 
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exercise, alcohol, and smoking. The risk of developing cancer depends on many different 
factors, including age, sex, geographical location, race, occupational history, social 
habits and socio-economic class. Cancer mortality could be reduced more than 30% by 
altering the modifiable risk factors such as avoiding smoking, obesity, alcohol, radiations 
(ionising and non-ionizing), pollution, viral infections like hepatitis B virus (HBV) and 
human papillomavirus (HPV). A healthy lifestyle by maintaining regular exercise with a 
healthy diet also contributes towards avoidance of cancer. (WHO cancer statistics 2012) 
 
1.1.2. Regional variations 
More than 60% of the overall world's new cancers are diagnosed in Africa, Asia, Central 
and South America. The cancer mortality in these regions accounts for 70% of global 
cancer deaths.  20% of overall cancer deaths happen in low and middle socio-economic 
countries with viral infections such as HBV, HCV, and HPV. There are striking regional 
variations in cancer incidence throughout the world. Many of these variations appear to 
be due to environmental factors such as carcinogens rather than genetic factors. In 
south-east Asia and Africa, hepatocellular carcinoma is common due to the high 
prevalence of hepatitis B infection and environmental exposure to carcinogens, for 
example, aflatoxins present in mouldy ground nuts. Chewing betel-quid and areca-nut, a 
practice common in Asia is recognised to be carcinogenic. Malignant melanoma is 
mainly a disease of white-skinned people and is especially common in sunny climates 
such as Queensland, Australia, where many of the population are fair-skinned 
individuals of northern European extraction. Exposure to high levels of ultraviolet light 
can cause cancer. Gastric carcinoma is common in China, Japan, and Russia, whereas its 
incidence in Western countries has progressively fallen, perhaps due to altered dietary 
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habits and to the decline of infection with Helicobacter pylori. Breast and colorectal 
carcinoma are far commoner in Western countries. Careful epidemiological studies of 
large populations who have migrated around the world have demonstrated that the 
incidence of cancers in migrant populations rapidly moves towards that of the recipient 
country. For example, the incidence of gastric carcinoma in Japanese migrants to the 
west coast of America falls from the high level seen in Japan to the lower incidence in 
the USA by the second generation of immigrant families. The data strongly suggest that 
environment is more important than heredity in determining geographical variation in 
cancer risk. It is thought that environmental factors can account for over 80% of human 
tumours. (WHO cancer report 2014).  
 
1.1.3. WHO action plan for cancer prevention and control 
In 2013 WHO launched its global action plan for prevention and control of non-
communicable and preventable diseases which aimed to reduce cancer mortality by 
25% by 2025. The agenda included an increased political commitment for cancer 
prevention and control. There is a need for improved coordination and research on 
human cancer aetiology and mechanisms of cancer metastasis and need for the 
development of scientific strategies for cancer prevention and treatment. Emphasis was 
placed on the development and strengthening of cancer networks and health systems to 
improve cancer patient care. The generation and dissemination of new and existing 
knowledge were emphasised along with the development of protocols and tools for 
cancer prevention, early detection (screening and diagnosis), treatment and care of 
cancer patients. 
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1.1.4. Cancer incidence in the United Kingdom 
There were 352000 new cases of cancer in the United Kingdom in the year 2013, which 
means 960 new cases diagnosed every single day, 40 new cases every single hour, 
literally someone diagnosed with cancer every other minute. 179000 new diagnoses of 
cancer were in men, and 173000 were in women. Only half of those with a cancer 
diagnosis are  going to survive in the long term. Cancer killed 161823 individuals in the 
year 2013, and its vengeance is on the increase. In the Great Britain, cancer incidence 
has raised by more than a quarter over last 40 years, which is 15% in males and 35% in 
females. Bowel, lung, prostate and breast cancer make more than 50% of the new 
diagnoses of cancer patients and also makeup 46% of overall cancer deaths. Again, more 
than 50% diagnosed with cancer are 70 years and above. In particular an increase in 
cancers that are linked to lifestyles, e.g. the skin, has been observed. Many cancers are 
more common in white Caucasians than Asians by ethnicity, and almost all cancers are 
more common in socially deprived areas. It is said that, in the United Kingdom, people 
born after the 1960s, have one out of two chance of being diagnosed with some cancer 
during their lifetime. Individual risks for developing cancer depend on many factors, 
mainly age, genetics and exposure to external risk factors. The incidence can be reduced 
by addressing the preventable causes (42%) of cancer, of which smoking (19%) is the 
most significant single preventable cause. 4 out of ten are at risk due to their lifestyle, 
and modifying lifestyle may reduce this risk. It is estimated that 600,000 cancer cases 
were preventable in the UK. Lung cancer has highest evidence of linked cases to 
smoking. Currently, more than 10 million people continue to smoke in the UK that is one 
in five. It is estimated that up to 9% of cancers are related to the diet. Too little fruit, 
vegetable, fibre and high processed meat, salt are linked to cancer risk. Obesity is 
estimated to be linked to 5% of the new cancer cases each year, particularly oesophagal, 
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uterine and kidney cancer. Alcohol is linked to 4% of cancer cases in the UK, including 
oral cavity, larynx, pharynx and oesophagus. 6 out of 10 adults consume alcohol at least 
once a week in the UK, at least half of which drink more than the recommended 
amount. Alcohol consumption is more prevalent common in unemployed than 
employed and financially inactive class. (WHO cancer report 2014)   
1.1.5. Bowel Cancer 
It is estimated that 1.36 million new cases of bowel cancer were diagnosed in the year 
2012. In Europe, 477000 new cases of bowel cancer were diagnosed 2012. In the UK, it 
accounts for 12% of all new cases and is overall the fourth most common cancer. It is 
the third most common in men (23000) after lung and prostate and also third most 
common in women (18200) after breast and lung. Approximately 41000 new cases of 
bowel cancer were diagnosed in the UK during 2013 equivalent to 110 people diagnosed 
with bowel cancer each day. Nearly 60% of patients diagnosed are over 70 years of age. 
Over the last forty years, the incidence of bowel cancer has increased by 14%. The most 
common site of occurrence is the rectum. 1 in 14 men and 1 in 19 women have a chance 
of developing bowel cancer in their lifetime. 
It is estimated that bowel cancer killed around 694000 individuals worldwide, out of 
which 215000 were in Europe.  White males have significantly higher incidence of bowel 
cancer compared to other ethnicities (55 per 100000). Significantly lower rates are 
found in the Asian population (19 – 28 per 100000 in men and 11 – 17 per 100000 in 
women). Bowel cancer is only second to lung cancer in killing individuals in the UK. 
16200 died in the UK in 2012 due to bowel cancer, and this equals to 44 people each 
day. In England and Wales, 6 out of 10 (57%) diagnosed with bowel cancer are likely to 
survive the disease for ten years or more. Three quarters (76%) survive it for more than 
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a year. The 5-year survival curve drops, to 4 out of 10 from 6 out of 10, in patients aged 
80 years and over. On a positive note, the mortality from this grave disease is declining. 
(WHO cancer report 2014)   
Survival depends on the degree of spread of cancer at the time of diagnosis. When the 
cancer is diagnosed at its early stage, 9 out of 10 patients can survive their bowel cancer 
for five years or more, compared to metastatic disease, where five-year survival is poor 
(less than 1 in 10). Unfortunately, more than a quarter (26%) have the distant metastatic 
disease (stage 4) on diagnosis, and more people are diagnosed at a late stage (3 and 4) 
(55%) than early stage (1 and 2) disease (45%). It is estimated that bowel cancer can be 
prevented in up to 54% of cases linked to major lifestyle changes and other risk factors, 
which include processed meat consumption (21%), obesity (13%), alcohol consumption 
(12%), smoking (8%) and ionizing radiation (2%). Increased fibre consumption and 
physical activity reduce the risk of bowel cancer. 
The majority of bowel cancer is located in the rectum, followed by sigmoid, caecum and 
ascending colon. A higher incidence of rectum (35%) and sigmoid (23%) cancer was 
recorded in men in comparison to the women (23% and 20% respectively), whereas 
higher incidence of caecum (17%) and ascending colon (9%) cancer was recorded in 
women in comparison to men (12% and 7% respectively). More than 90% of bowel 
cancers are adenocarcinoma which arises from adenomatous polyps. Benign 
adenomatous polyps can be as common as one-third of the western population. Only a 
tiny proportion (between 1 -10%) progress to malignant polyps, depending upon their 
size, type, and dysplasia. (WHO cancer report 2014). 
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1.2. Inherited bowel cancer 
The lifetime risk for an individual to develop bowel cancer in the United Kingdom is 5%. 
Many people will have a chance of having an affected relative; as the number of 
relatives increases, the risk also increases. The risk due to genetic factors varies very 
widely from no risk to patients who will inevitably develop bowel cancer. 30% of the 
population is at a low to moderate risk of developing inherited colorectal cancer, while 
5% of the population will be at high risk. The high-risk population has more than 50% 
chance of developing colorectal cancer. The high-risk groups include Lynch syndrome 
and familial adenomatous polyposis (FAP).  
 
1.2.1. Lynch syndrome 
Lynch syndrome is characterised by early onset of colorectal cancers, on average at 45 
years of age. These tumours have certain distinguishable pathological features. There is 
a predilection for proximal colon and tumours are often multiple. 
They tend to be mucinous, poorly differentiated and have a signet ring appearance with 
lymphocytes infiltration and lymphoid aggregation at margins. Other associated 
tumours of Lynch syndrome are endometrial, stomach, ovarian and urothelial in origin. 
The Amsterdam criterion I and II are used for diagnostic purposes. 
Amsterdam criteria I 
• At least three relatives with colorectal cancer, one of whom should be a first-degree 
relative 
• At least two successive generations should be affected 
• At least one colorectal cancer should be diagnosed before an age of 50 years 
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• FAP should be excluded 
• Tumours should be verified by pathological examination. 
 
 Amsterdam criteria II 
• At least three relatives with a Lynch syndrome-associated cancer (colorectal, 
endometrial, small bowel, ureter, renal pelvis), one of whom should be a first-degree 
relative 
• At least two successive generations should be affected 
• At least one colorectal cancer should be diagnosed before age 50 years 
• FAP should be excluded 
• Tumours should be verified by pathological examination. 
 
Lynch syndrome is an autosomal dominant inherited disease which constitutes 2% of 
colorectal cancers. It results from a germline mutation in tumour suppressor mismatch 
repair (MMR) gene, whose role is to correct errors in base pair matching. A hallmark of 
tumours with defective MMR gene is microsatellite instability (MSI). MSI are regions 
where a short sequence of DNA (up to 5 nucleotides) is repeated, in which any errors 
during DNA replication are corrected by MMR gene. Hence in MMR deficiency, large 
segments of mutated DNA results. Around 15% of colorectal cancer patients show MSI. 
As genetic testing is expensive, Bethesda criteria are used for determining whether the 
tumour tissue from an individual with colorectal cancer should be tested for MSI. It is as 
follows, 
• Colorectal cancer diagnosed at age <50 years 
• Multiple colorectal or other Lynch syndrome-associated tumours, either at the same 
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time or occurring over a period 
• Individuals diagnosed with colorectal cancer at <60 years, in whom a tumour has 
microscopic characteristics indicative of MSI 
• Individuals with colorectal cancer who have one or more first-degree relatives 
diagnosed with a Lynch a syndrome-related tumour at age 50 years or younger 
• Individuals with colorectal cancer who have two or more first or second-degree relative 
diagnosed with a Lynch a syndrome-related tumour 
If a mutation is detected, treatment options include either 1-2 yearly surveillance 
colonoscopy from 25 years of age or 5 years earlier from youngest family member 
diagnosed; or a prophylactic colectomy. (Phillips, Robin K. S. Colorectal Surgery: A 
Companion to Specialist Surgical Practice, 4th Edition) 
 
1.2.2. Familial adenomatous polyposis 
FAP is less common than Lynch syndrome, but the risk of developing into colorectal 
cancer is 100%. The site of mutation is adenomatous polyposis coli (APC) gene and has 
autosomal dominant inheritance. It is characterised by the following. 
• Hundreds of adenomatous polyps at a young age (second or third decade of life) 
• Duodenal adenomatous polyps 
• Extraintestinal manifestation 
 
Diagnosis is made by either genetic testing or by the detection of FAP surveillance of at-
risk family member. Treatment is prophylactic surgery before cancer develops. (Phillips, 
Robin K. S. Colorectal Surgery: A Companion to Specialist Surgical Practice, 4th Edition) 
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1.3. Tumour suppressor genes in colorectal cancer 
The tumour suppressor gene maintains cell stability by regulating cell proliferation and 
differentiation. Therefore, uncontrollable cell proliferation and the formation of a 
tumour may be a result of inactivated tumour suppressor genes caused by somatic 
mutation or hereditary. The APC (Adenomatous polyposis coli), P53 and K-ras are 
involved in adenoma-cancer sequence (figure 1.2.1.)  It is uncommon to have all the 
three mutations of APC, p53, and K-ras to coexist with same colorectal cancer, which 
suggests that mutations in these genes have separate pathways in colorectal 
tumorigenesis. (Smith et al. 2002). 
 
1.3.1. APC (Adenomatous Polyposis Coli) Tumour Suppressor gene  
APC gene controls many cellular functions of intestinal cells (e.g., proliferation, 
differentiation, migration and polarity). A good number of colorectal cancers have been 
reported to have loss or mutation of adenomatous polyposis coli. The APC gene is a 
negative regulator of beta-catenin concentrations and interacts with E-cadherin, which 
results in loss of cell adhesions. Thus, mutations in the APC gene result in the 
development of colorectal cancer (Markowitz et al. 2009). 
1.3.2. p53 tumour Suppressor gene 
p53 encodes the transcription factor that is involved in the regulation of cell cycle, 
apoptosis, cellular senescence (McBride et al. 1985, Benchinol et al. 1985, Rowley et al. 
1986). Abnormalities of the p53 gene, transcript, and protein expression have been 
widely reported in human cancers, including colorectal cancer. Allelic loss of 
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chromosome 17p is observed in three of four colorectal carcinomas but fewer than 10% 
of adenomatous polyps. Mutations in p53 appear during the transition from adenoma to 
carcinoma. (Messerini et al. 1995). 
1.3.3. K-ras tumour suppressor gene 
Patients who have a K-ras mutation in their colorectal tumour have a significantly 
poorer prognosis than those without a K-ras mutation. Mutated K-ras cause increased 
and unregulated signalling down of pathways that normally are involved in growth and 
differentiation, such as the mitogen-activated kinase pathway. K-ras mutation is a 
marker of aggressive tumour phenotype. (Smith et al. 2002). 
 
 
 
 
 
 
 
 
 
Figu
re 
1.2.2. Flowchart demonstrates these gene mutations are consistent with the order of 
cancer progression (from adenoma to carcinoma). (1988. Bert Vogelstein). 
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1.4. Anatomy and physiology of the colon and rectum 
The bowel is a part of the human digestive system. It is divided into two parts; small and 
large bowel. The large intestine is a muscular tube that extends from the ileocecal 
junction (where small bowel enters into the colon) to the anus. The colon is 
anatomically divided into the following parts (figure 1.4.1.). 
• Caecum 
• Ascending colon 
• Transverse colon 
• Descending colon  
• Rectum  
The caecum is the first part where the terminal ileum (the last part of small bowel) joins 
the large bowel through the ileo-caecal valve. The appendix is also attached to the 
caecum posterior-medially, lateral to the ileo-caecal valve. The taeniae coli of caecum 
converge on the base of the appendix. Taeniae coli three straps of muscle fibres, which 
run along the length of the colon from caecum to the rectum, where they fan out and 
become diffuse with the rectal wall muscle.  The caecum is located in the right iliac 
fossa. It is completely covered in the peritoneum and relatively fixed in its position due 
to lack of any length its mesentery. From the caecum, large bowel travels upwards and 
becomes ascending or right colon as it is on the right side of the abdominal cavity. The 
ascending colon is covered with peritoneum on its front and sides only. It leads to 
hepatic flexure, where it lies in front of the right kidney and the second part of the 
duodenum. At the hepatic flexure, the colon curves to the left to become transverse 
colon. The transverse colon is very mobile, completely wrapped with the peritoneum 
and greater omentum hangs down from the anterior surface of the transverse colon. 
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The transverse colon leads to the splenic flexure, where it lies in front of the left kidney 
and is closely related to the spleen, which lies superior-laterally. From splenic flexure, 
the colon curves downwards to become descending or left colon as it lies to the left of 
the abdominal cavity, relatively fixed in position. The descending colon continues 
downwards and makes an "S" shape twist. Hence this part called the sigmoid. The 
sigmoid colon is mobile, and the length of mesentery varies. 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.1. The anatomy of the colon with the vascular supply (Source: DeVita VT, 
Lawrence TS, Rosenberg SA: DeVita, Hellman, and Rosenberg’s Cancer: Principles & 
Practice of Oncology, 9
th 
Edition, 2011. By Lippincott Williams & Wilkins). 
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The sigmoid distally fans out to become the rectum (figure 1.4.2.). The recto-sigmoid 
junction usually lies against the third sacral vertebra. The rectum lies in the concavity of 
the sacrum, and it connects to the anus.  It is covered by the peritoneum in its upper 
third, the middle third is covered anteriorly only, and the lower third is devoid of 
peritoneum. In men, in the lower third rectum is anteriorly separated from prostate, 
seminal vesicles, and base of the bladder by Denonvillier's fascia, which represents 
embryological fused peritoneal layers. In women, the rectum is related to the vagina 
anteriorly.  The blood vessels, nerves, lymphatics and lymph nodes to the bowel are 
contained in a wrapped double layer of peritoneum called mesentery. Large bowel 
mesentery is called mesocolon and mesentery attached to the rectum is called 
mesorectum, the bulk of which lies posteriorly in the concavity of the sacrum. There is 
areolar plane between mesorectum and structures of the pelvis, which is essential for 
total mesorectal excision in cancer surgery of the rectum.     
 
 
 
 
 
 
 
 
Figure 1.4.2. Rectal anatomy.  (Source: Shrieve DC, Loeffler JS: Human Radiation Injury. 
2011. By Lippincott Williams & Wilkins) 
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To understand and have an orientation of anatomy of the colon, it is crucial that one has 
some basic understanding of the embryological development of the gut as it is 
complicated by intrauterine folding of the gastrointestinal tract. In early intrauterine life, 
the entire gastrointestinal tract is one straight tube, which is hanging from midline 
dorsal mesentery. The blood supply is from three midline visceral vessels, supplying 
foregut, midgut, and hindgut.  These blood vessels persist as the celiac axis, superior 
mesenteric artery, and inferior mesenteric artery, all arising in the midline from the 
front of the aorta. The small bowel persists on a mesentery arising approximately from 
the midline. On the other hand, the large bowel rotates in an anti-clockwise fashion 
attaining its adult life shape of ascending, transverse and descending colon. The 
mesentery of ascending and descending colon fuses with retroperitoneal tissue, which 
can be used as dissecting plane behind the colon to get to the root of mesentery for 
radical large bowel resections for its cancers. The fusion of the peritoneum in depth of 
pelvis creates rectovaginal or recto-vesical pouch forms the Denonvillier's fascia which is 
essential in radical resections of the rectum for cancer. 
The wall of the colon is made up of the following layers (figure 1.4.3.): 
• Mucosa 
• Submucosa 
• Muscularis propria 
• Serosa 
Mucosa is the innermost layer of the colon and is made of epithelium, lamina propria, 
and muscularis mucosa. Sub-mucosa is the layer of connective tissue that surrounds the 
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mucosa. The blood vessels, lymphatics, nerves and mucous glands lie in the sub-mucosa. 
The next layer is the muscularis propria, which is a layer of circular and longitudinal 
muscle fibres in the wall of the colon. The serosa is the outermost layer comprised of 
the peritoneum. 
 
 
Figure 1.4.3. Layers of colon and rectum 
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The main function of the colon is to absorb important nutrients, electrolytes and water, 
and to give faeces their final form, store it and expel it when appropriate.  
  
1.5. Natural history of the disease 
It is said that in approximately 50% cases, colorectal cancer arises from the left side of 
the colon, whereas about 25% cases arise from the right colon. Moreover, 4-5% of cases 
have synchronous cancers, which is why a colonoscopy to look at the full length of the 
colon is indicated if cancer is found in the rectum or sigmoid. It is widely accepted that 
the majority of colorectal cancers arise from pre-existing adenomas. The distribution of 
adenomas is similar to that of cancer in the colon. Also in one-third of the cancer 
specimens, adenomas are found. The pathway of oncogenesis from adenoma to 
carcinoma in sporadic disease is broadly the same as for Familial Adenomatous 
Polyposis (FAP) coli, a pre-cancerous condition where the colon develops multiple 
polyps, which inevitably lead to cancer. (Leslie et al. 2002) Underlying genetic events 
were described above, not only for the common adenocarcinoma sequence, but also for 
the other most common alternative tumourigenic pathway, which is reflected by the 
Lynch syndrome.   
1.6.    Presentation 
Unfortunately, many symptoms of colonic cancer are common and nonspecific, so a high 
index of suspicion is warranted. The presentation may be acute or chronic depending on 
the location, stage, and grade of the disease. Anaemia, change in bowel habit more than 
six weeks, episodes of per rectal bleeding, family history of colorectal cancer, smoking 
and alcohol intake are not infrequently described symptoms by the patients at the 
colorectal cancer outpatient clinics. Patients can present as large bowel obstruction or 
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perforation as an emergency. Occasionally patient presents with abdominal mass or 
pneumaturia due to the encroachment of a tumour into the bladder and resulting into a 
colo-vesical fistula. 
1.7. National Institute for Health Care and Excellence (NICE) – suspected cancer 
referral pathway 
A patient suspected of colorectal malignancy should be referred for further investigation 
by using suspected cancer pathway referral in the UK to be seen by a colorectal surgeon 
within two weeks. The following criteria are used: 
• 40 years and over with unexplained weight loss and abdominal pain 
• 50 years and over with unexplained rectal bleeding 
• 60 years and over with iron deficiency anaemia or change in bowel habit 
• Rectal or abdominal mass  
• In adults under the age of 50 years with rectal bleeding, consider a suspected cancer 
pathway in case of the following unexplained symptoms or findings: 
• Abdominal pain 
• Change in bowel habit 
• Weight loss 
• Iron deficiency anaemia 
• Faecal occult blood – offered to patients without rectal bleeding  
50 years and above with unexplained abdominal pain or weight loss or 60 years and 
under with change in bowel habit or iron deficiency anaemia or 60 years and above with 
anaemia in the absence of iron deficiency. (Colorectal cancer NICE guidelines [CG131] 
Dec 2014 update) 
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1.8. UK department of health criteria for high risk and low-risk colorectal cancer  
Higher risk: 
• Rectal bleeding with a change in bowel habit to looser stools or increased 
frequency of defecation persisting for six weeks (all ages). Change in bowel habit 
persisting for six weeks (>60 years).  
• Persistent rectal bleeding without anal symptoms* (>60 years). 
• Palpable right-sided abdominal mass (all ages).  
• Palpable rectal mass (all ages). Unexplained iron deficiency anaemia (all ages).  
Low risk: 
• Rectal bleeding with anal symptoms with no persistent change in bowel habit (all 
ages).  
• Patients with no iron deficiency anaemia, no palpable rectal or abdominal mass 
• Rectal bleeding with an obvious external cause, e.g. anal fissure (all ages) 
• Change in bowel habit without rectal bleeding (<60 years). 
• Transient changes in bowel habit, particularly to harder or decreased frequency of 
defecation (all ages). 
• Abdominal pain as a single symptom without signs and symptoms of intestinal 
obstruction (all ages). (Thompson et al. 2003). 
*Soreness, discomfort, itching, lumps, prolapse or pain. 
 
1.9. Diagnostic investigations 
Usually, more than one investigation is necessary for confirmation of colorectal cancer. 
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Patients with suspected colorectal cancers, who have not got any major co-morbidity, 
should be offered colonoscopy as a first line investigation. 
If a suspicious lesion is seen, a biopsy should be taken at the time for histological 
diagnosis, unless contraindicated. Computerized Tomography (CT) colonography can be 
an alternative to colonoscopy or flexible sigmoidoscopy. A subsequent biopsy to confirm 
tissue diagnosis will be needed if a lesion is detected on CT. If the CT is indeterminate, a 
colonoscopy should also be considered. Since the Siggar Trial, (SIGGAR), Barium Enema 
is now rarely used, and many hospitals in the UK no longer provide this service. Once the 
diagnosis of colonic or rectal cancer has established, the next step would be to 
determine the grade and stage of cancer. 
 
1.9.1. Screening 
Colon cancer is a suitable disease for screening. Prognosis after treatment is much 
better in the early-stage disease, and the polyp carcinoma sequence offers an 
opportunity to prevent cancer by treating premalignant disease. The ideal screening test 
should detect the majority of tumours without a large number of false positives, i.e., it 
should have high sensitivity and specificity. Also, it must be safe and acceptable to the 
population offered to screen. In colorectal cancer, the most widely studied test is faecal 
occult blood testing, a guaiac-based test which detects the peroxidase-like activity of 
haematin in faeces. But unfortunately, the sensitivity of faecal occult blood testing is 
only about 50–70%. Another approach is to use endoscopy as a primary screening test. 
As 70% of cancers and large adenomas are found in the distal 60cm of the large bowel, 
which is more sensitive than FOB testing. Currently, all men and women between 60 to 
74 years of age are invited to participate in faecal occult blood testing once every two 
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years. A screening colonoscopy is offered at the age of 55. 
 
1.9.2. Surveillance  
Surveillance strategies for patients with adenomatous polyps are divided into low, 
moderate and high-risk groups. The low-risk category includes patients with one or two 
adenomatous polyps that are less than 1cm in diameter. No follow-up or a repeat 
colonoscopy at five years is recommended. Intermediate risk group is defined as 
patients with three to four adenomatous polyps, or at least one adenoma greater than 
1cm in diameter. Colonoscopy at three years is recommended. The high-risk group 
includes patients with five or more small adenomatous polyps or three or more, where 
at least one is greater than 1cm in diameter. Colonoscopy at one year is recommended.  
 
1.10. Staging of colorectal cancer 
A contrast-enhanced CT of the chest, abdomen and pelvis is done to establish the extent 
of the spread of cancer. Magnetic resonance imaging (MRI) is done to assess the 
localised spread of rectal cancer in the pelvis. An endo-rectal ultrasound scan is of value 
in rectal cancer if the MRI shows disease amenable to local resection. 
 
1.10.1. Duke’s classification 
In 1932 Cuthbert E. Dukes developed a classification for colorectal cancer metastasis, 
predicting the prognosis of colorectal cancer patients. In 1936 Dukes had modified the C 
stage by the different levels of para-rectal lymphatic spread from the superior rectal 
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artery to inferior mesenteric artery. Astler and Coller further divided stages B and C in 
1954 (table 1.10.1). 
 
Table 1.10.1.  Modified Dukes classification of colorectal cancer. 
A Invasive carcinoma not breaching the muscularis propria 
B Invasive carcinoma breaching muscularis propria, but not involving 
regional lymph nodes 
C1 Invasive carcinoma involving the regional lymph nodes (apical lymph 
node negative) 
C2 Invasive carcinoma involving the regional lymph nodes (apical lymph 
node positive) 
D Distant metastasis 
Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of the 
colon and rectum. Ann Surg 139:846, 1954 
 
1.10.2. TNM Classification  
In 1954, Pierre Denoix proposed the TNM (Tumour, Node and Metastasis) Classification 
based on local invasion and lymphatic metastasis (table 1.10.2). TNM classification for 
colorectal cancer is widely accepted.  
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Table 1.10.2. TNM classification of colorectal cancer 
 
T Primary tumour 
Tx A primary tumour cannot be assessed 
T0 No evidence of a primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through muscularis propria into subserosa or non-
peritonealised peri-colic or peri-rectal tissue 
T4 Tumour perforates the visceral peritoneum or directly invades other organs 
or structures 
N Regional lymph nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Metastasis in 1-3 peri-colic or peri-rectal lymph nodes 
N2 Metastasis in 4 or more peri-colic or peri-rectal lymph nodes 
N3 Metastasis in any lymph nodes along a named vascular trunk 
M Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
Source: www.cancerstaging.org/staging/index.html 
1.11. Management of colorectal cancer 
Management depends on whether the patient has the localised or metastatic disease. 
The multidisciplinary team should determine at the outset, whether curative treatment 
can be achieved, or whether the situation is palliative. NICE Guidelines (Colorectal 
cancer `NICE guidelines [CG131] Dec 2014 Update) can be useful in guiding management 
plans. There are different aspects of the management of rectal and colonic cancers 
which will be considered in the sections below. Patients with non-metastatic rectal 
cancer can also be classified into three different groups of patients according to the risk 
of local recurrence (table 1.11.1). 
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Table 1.11.1: Risk of local recurrence for rectal tumours as predicted by MRI 
Risk of local recurrence Characteristics of rectal tumours predicted by MRI  
High A threatened (<1mm) or breached resectional margin or  
Low tumours are encroaching on to the inter-sphincteric plane 
with levator involvement. 
Moderate Any T3b or greater, in which potential surgical margin is not 
threatened or 
Any suspicious lymph node not threatening the surgical 
resection margin or 
The presence of extra mural vascular invasion 
(Associated with high risk of systemic recurrence)   
Low T1 or T2 or T3a and  
No lymph node involvement 
 
 
1.11.1. Patients with resectable primary rectal cancer 
For patients who have low risk operable rectal cancer, surgery is the mainstay of 
treatment if the patient is fit for anaesthetic. Patients who have moderate risk operable 
rectal cancer can be considered for SCPRT in the immediate preoperative period 
(Colorectal cancer `NICE guidelines [CG131] Dec 2014 Update), although the evidence 
for and against this approach is controversial. (Dutch Colorectal Cancer Group, COIN 
Trial Investigators, Sailor Trial). 
1.11.2. Patients with high-risk rectal cancer  
A patient who have locally advanced rectal cancer, preoperative long course chemo-
radiotherapy should be offered with an interval before surgery to allow for tumour 
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shrinkage with high risk. Habr-Gama et al. have reported excellent outcomes on a wait 
and watch approach following complete shrinkage of a tumour following the long course 
of chemo-radiotherapy. (Habr-Gama et al.) 
1.11.3. Role of colonic stents in acute large bowel obstruction  
Patients presenting with acute large bowel obstruction should have a CT scan of 
abdomen and pelvis to confirm the diagnosis of the mechanical cause of their 
obstruction, but also to rule out perforation. If cancer is suspected as the cause of 
obstruction, further CT chest should be done to look for chest metastasis. Contrast 
enemas studies as the only imaging modality are not best suited for diagnosis and 
staging. Patients who present as an emergency with left-sided obstruction secondary to 
colorectal cancer, which is deemed to be resectable, could be managed with emergency 
surgical resection. Following the recent publication of CREST trial results, the use of 
stenting as a "bridge to surgery" in otherwise operable patients should be reconsidered. 
However, for patients who present as an emergency with left-sided obstruction 
secondary to colorectal cancer, which is deemed to be unresectable and metastatic, a 
self-expanding metallic stent should be inserted with the help of an endoscopist and 
interventional radiologist with suitable experience. Self-expanding stents should not be 
inserted in patients with low rectal cancers, nor in cases where there is evidence of 
perforation or peritonitis (CReST trial).  
1.11.4. Patients with stage 1 colorectal cancer  
Patients with stage 1 colorectal cancer should have MDT discussion as to whether a 
tumour is amenable to local excision. If this is undertaken, further MDT discussion to 
confirm histological grade whether the excised cancer had clear margins and lymph 
node status. Further resection should be offered to patients who had less than 1 mm of 
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a clear resection margin. (Colorectal cancer NICE guidelines [CG131] Dec 2014 update) 
There are several technical methods for removal of early rectal cancers including 
Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Trans-
Anal Microscopic Surgery (TEMS) and Trans-Anal Minimally Invasive Surgery (TAMIS), a 
detailed discussion of which is beyond the scope of this thesis. 
1.11.5. Surgical Resection of colorectal cancer 
If the cancer is deemed to be resectable and the patient is fit for surgical intervention, it 
is the preferred and first line of treatment. Cancers of colon often involve the lymph 
nodes at presentation, even in the absence of distant metastasis. Therefore, to offer 
potentially curable resection of cancerous part of the colon, it is vital to be removed en-
bloc with its lymphatic drainage. As the lymphatic drainage follows the arterial supply, 
radical colonic resection for cancers with its lymphatic drainage is carried out along the 
lines of arterial supply of the colon. The length of colon needed to be excised 
determines the reconstruction options. Once the cancerous part has been removed 
during the operation, the healthy ends are aimed to be joined together if possible. The 
healthy ends must have a good blood supply and should be able to reach each other 
without any tension for the anastomosis to successful. The radical resection of lymph 
nodes inevitably ends up compromising the blood supply. Therefore, a longer segment 
of the bowel has to be resected. Hence the extent of lymph node removal determines 
the length of the colon that has to be excised.  The standard operations for colonic 
cancer resection include: 
• Right hemicolectomy  
• Extended right hemicolectomy        
• Transverse colectomy 
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• Left hemicolectomy 
• High anterior resection 
• Low anterior resection 
• Abdominoperineal resection 
• Hartmann’s procedure 
Every operation has to be tailored to the individual patient depending upon their 
vascular anatomy, length and mobility of the colon, the exact position and extent of 
cancer, all of which might dictate adaptabilities to the standard resections listed above. 
A bypass procedure can be considered with palliative intent where resection not 
possible. 
The decision between laparoscopic and open resection is made after informed 
discussion with the patient, considering the suitability of the lesion for laparoscopic 
resection, evaluating risks and benefits of the two procedures and experience and 
technical skill of the surgeon. The surgeon's skills should meet the criteria and standards 
set by the trust and colorectal cancer network. (Farquharson's Text Book of Operative 
General Surgery) 
 
1.11.6. Adjuvant chemotherapy in patients with colorectal cancer 
After the colorectal cancer MDT discussion, a detailed discussion should be carried out 
with patients and their family involving risks and benefits. For patients with high-risk 
stage 2 and stage 3 rectal cancer, adjuvant chemotherapy should be considered to 
reduce the risk of local and systemic recurrence. For patients with high-risk stage 2 
colonic cancer, adjuvant chemotherapy should be considered. For patients with high-risk 
stage 3 colonic cancer, adjuvant chemotherapy (capecitabine and oxaliplatin) should be 
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offered. (Colorectal cancer `NICE guidelines [CG131] Dec 2014 Update). 
1.11.7. Management of metastatic disease 
If both a primary and metastatic tumour is considered to be resectable, anatomical site-
specific MDT discussions are carried out with consideration of initial systemic 
chemotherapy followed by surgery. FOLFOX (folinic acid plus fluorouracil plus oxiplatin) 
or XELOX (capecitabine plus oxiplatin) is used as first-line systemic chemotherapy for 
advanced metastatic disease. Second line chemotherapeutic agents would include 
FOLFIRI (folinic acid fluorouracil plus irinotecan) or single-agent irinotecan. Raltitrexed 
should be only considered in patients who are intolerant to 5 fluorouracil. A full 
discussion should take place between the oncologist and the patient taking individual 
patient's preferences into account. 
(Colorectal cancer `NICE guidelines [CG131] Dec 2014 Update).  
1.11.8. Imaging hepatic and extrahepatic metastasis  
A contrast-enhanced CT of chest abdomen and pelvis should be offered to all patients 
diagnosed with colorectal cancer not only to stage but to pick up hepatic and 
extrahepatic metastasis. Each case, depending on the anatomical site of metastasis, is 
discussed by the corresponding MDT. A positron emission tomography CT (PET CT) of 
the whole body may be appropriate if metastasectomy is being considered. (Colorectal 
cancer `NICE guidelines [CG131] Dec 2014 Update).   
1.11.9. Ongoing care 
Patients following major curative resection are offered outpatients' clinic appointment 
in 4-6 weeks after their surgery. Six monthly blood tests with measured serum 
carcinoembryonic antigen (CEA) and a minimum of 2 CT scans of chest abdomen and 
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pelvis are offered as surveillance during the first three years. Surveillance colonoscopy is 
offered at the one-year interval, and after that at five years interval provided no 
concerns raised on any of the other investigations. (Colorectal cancer `NICE guidelines 
[CG131] Dec 2014 Update). 
1.12. Mechanism of spread  
Cancer metastasis is a complex multi-step process, involving cell and cell-matrix 
interactions, in which cell adhesion molecules of various types are involved. Cancer cells 
can spread by one or more of the following mechanisms. 
1.12.1. Reduction in cell to cell adhesion 
Normal epithelial cells bind tightly to one another by adhesion molecules. Malignant 
epithelial cells are less firmly attached to one another, due at least in part to reduced 
expression of binding proteins. The cancer cells invade the basement membrane by the 
interaction between cell surface integrins and matrix proteins. The cancer cells produce 
proteolytic enzymes such as matrix metalloproteinases (MMPs), which break up the 
matrix proteins laminin, fibronectin and collagen. These proteolytic enzymes are under 
complex control mechanisms. (Patel et al. 2011) 
1.12.2. Tumour cell motility 
Movement is generated by the cytoskeleton of cross-linked actin molecules and is 
stimulated by a wide variety of growth factors, stromal components and cytokines, for 
example, auto toxins.  
1.12.3. Angiogenesis 
Angiogenesis is the process by which new blood vessels are formed. Normally 
angiogenesis is seen in wound healing and embryogenesis. The importance of 
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angiogenesis in tumour development has been established. The development of blood 
supply to a tumour is critical in progression. The mechanisms involved are complex. New 
blood vessels are formed by outgrowth of endothelial cells into the tumour mass. The 
stimulus for this is the increased production of angiogenic factors by the tumour cells, 
especially vascular endothelial growth factor (VEGF), fibroblast growth factors and 
angiogenin. The steps involved in angiogenesis include: 
• Proteolytic digestion of basement membrane  
• Migration of endothelial cells 
• Proliferation of endothelial cells 
• Organization of endothelial cells into new blood vessels with lumens. 
(Patel et al. 2011) 
1.12.4. Vascular invasion 
Tumour cells must breach the basement membrane and penetrate between endothelial 
cells; the thin walls and poorly formed basement membranes of newly formed blood 
vessels are easy to penetrate. Once tumour cells are free within the lumen of the blood 
vessel, they are carried into the circulation and lodge in a capillary bed. At this site, 
further complex interactions are required. The tumour cells bind to endothelial cells. 
The cells then penetrate the capillary basement membrane by mechanisms similar to 
those described above. (Patel et al. 2011) 
1.12.5. Establishment of a new colony 
This involves cell proliferation and the development of a tumour blood supply by 
stimulation of angiogenesis as previously described. It will be apparent that the process 
of metastasis is not simply determined by simple mechanical factors. Stephen Paget in 
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1889 proposed that cancer metastasis depends on the cancer cells (the seed) and the 
microenvironment of the host organ (the soil), which still holds true. The potential of 
cancer cells to metastasise depends on their interaction with the homeostatic factors 
that promote cancer cell growth, survival, angiogenesis invasion and metastasis. The 
phenomena are known as ‘seed and soil'. Also, not all cells in a tumour are equally likely 
to metastasise: the acquisition of the ability to metastasise is determined by the 
expression of a series of genes whose normal function appears to be the control of cell 
migration during embryogenesis, normal tissue homeostasis and inflammation and 
repair. (Patel et al. 2011) 
1.13. Pathophysiology of metastasis 
Cancer cells can invade the surrounding tissues. In epithelial tumours, the cells breach 
the basement membrane, i.e. proceed from the stage of intraepithelial neoplasia to 
invasive cancer. At this point tumour, cells are classified as malignant. Usually, the 
cancer cells take the paths of least resistance. Cancer cells continue to spread through 
lymph, blood or can spread across the peritoneal cavity. Metastatic spread is not 
uncommon and directly impacts the patient's survival. Metastasis is a complex multi-
step process involving cell and cell-matrix interactions in which various types of cell 
adhesion proteins are involved. Patients who are diagnosed at an early stage have a 
much better prognosis than those who present with more extensive disease. Over 93% 
of patients diagnosed with Dukes stage A (the earliest stage of the disease) survived five 
years compared with less than 7% of patients with advanced disease (Dukes stage D). 
(Cancer Research UK). At the time of diagnosis of cancer, at least half of the patients 
have metastatic disease. The metastatic spread of cancer is most commonly responsible 
for death in most of the patients. (Devita et al. 1975) Another significant number of 
patients will have micro-metastases which might not get detected with the conventional 
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investigation modalities. The spread of the cancer is the key event, which leads to 
mortality in most of the cancer patients.  The spread of cancer is known to be a process 
which involves some sequential events, termed the metastatic cascade. The metastatic 
cascade can be broadly divided into three main processes: Invasion, intravasation and 
extravasation (figure 1.14). (Martin et al. 2011) 
 
Figure 1.14. Schematic illustrating events in the metastatic cascade (Martin et al. 2009) 
This initial dissociation of malignant cells from a primary tumour happens by loss of cell 
adhesion between cells, which subsequently leads to invasion of the cells to the 
surrounding stroma, hence process of angiogenesis begins involving specific proteins 
expression and suppression, degrading basement membrane and extracellular matrix 
and also affecting cell motility and migration (Brooks et al. 1996). Once a tumour cell has 
detached, it makes entry to the nearest blood or lymph vessel (by process of 
intravasation) and metastasises to distant sites. (Folkman et al. 1992, Folkman et al. 
1996). Once the tumour cell arrives at the distant site, it develops adhesions to the 
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blood vessel endothelial cells by undergoing chemical interactions and penetrates 
through the endothelium and basement membrane (by process of extravasation), 
leading to proliferation at the distant metastatic site. 
1.14. Tight junctions 
Tight junctions (TJ) are a fundamental structural adhesive structure which is sited firstly 
between adjacent epithelial cells (which can prevent detachment of cancer cells) and 
secondly between the epithelial/endothelial cells and their basement membrane (which 
can prevent intravasation and extravasation of cancer cells). Tight junctions have been 
of much focus of research recently in cancer metastasis, as for cancer cells to 
metastasise successfully, TJs must be disrupted. (Martin et al. 2011) 
Farquhar and Palade first described tight junctions (TJ) in 1963. They provided evidence 
that, in epithelial cell linings, the apically located belt-like structures form an 
impermeable barrier that restricts diffusion process through the luminal spaces 
(Farquhar et al.  1963). Body cavities, lumens and surfaces are lined by epithelial cells. 
These epithelial cells are exposed to repeated insults by the environmental agents and 
carcinogens, which cause repeated damage. To cope with the repeated, ongoing 
damage, the body constantly renews these epithelial cell linings, which have a very high 
regeneration and proliferation rate. This leads to a high probability of acquiring genomic 
mutation, which is probably why nearly ninety percent of cancers arise from epithelial 
cells. There is good evidence in the literature on the loss of TJs and spread of cancer. 
(Martin et al. 2010, Kominsky et al. 2003, Sauer et al. 2005, Seok et al. 2007, Usami et al. 
2006, Krämer et al. 2000, Osanai et al. 2006). 
As discussed earlier, one of the important early steps in cancer metastases is interaction 
and penetration of the vascular endothelium by the cancer cells. The TJs in the vascular 
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endothelium act as a barrier to molecules and cells. TJs in the epithelium acts as an 
adhesive, which prevents cells from detachment. (Hollande et al. 2001). 
There has been enough evidence to prove that TJs are the first line of defense, which 
cancer cell must overcome to metastasise. (Martin et al. 2002, Hoevel et al. 2002, Ren et 
al.1990, Satoh et al.1996). TJs have been reported to control cell polarity which effects 
epithelial-mesenchymal-transition (EMT), as the acquisition of tumour of epithelial 
origin, which is regarded as a pathological version of EMT. EMT is a cellular mechanism 
long recognised as a feature of the normal development process. In EMT cells lose their 
epithelial characteristics and gain mesenchymal characteristics. This results in the cell to 
cell cohesiveness, which leads to the increased migratory capacity of the cell. Multiple 
genes and proteins are involved in EMT by up and down regulation. The most critical 
molecule which down regulates in EMT is E-cadherin. E-cadherin acts as a tumour 
suppressor by inhibiting invasion and metastasis. (Ikenouchi et al. 2003, Martin et al. 
2005, Ohkubo et al. 2004, Gopalakrishnan et al. 1998)    
1.14.1. Structure of TJs: 
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TJs are the most topically located structures, and they govern the endothelial and 
epithelial permeability. The TJs appear to be completely occluding the extracellular 
space by creating an intracellular barrier, which acts as an inter-membrane diffusion 
fence. They exist in the plasma membranes of adjacent cells by forming a series of 
contacts (Figure 1.14.1.1). (Jiang et al. 1999) 
 
Figure 1.14.1.1. Schematic illustration of TJs structure and location between adjacent 
cells.  (Martin et al. 2011). 
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The TJs are characteristic in structure and appear as discrete fusion sites between the 
outer plasma membrane of adjacent cells. On freeze-fracture and electron microscopy, 
they appear as continuous intramembrane particle strands on the protoplasmic face 
with complementary grooves in the extracellular face in adjacent cells. (Furuse et al. 
1998). The appearance of these networks of complete circumscribed apices of 
intramembrane fibrils has also been described as of kissing points. (Wong et al.1997) 
The structure of TJs can be represented by a conglomerate of proteins (figure 1.14.1.2), 
which has remained an area of interest for scientists and has been extensively 
investigated. TJs consists of 3 regions (table 1.14.1.1): 
1. Integral trans-membrane proteins: These include occludin and other  
TJ associated Marvel proteins (TAMP), claudins and junctional adhesion molecules 
(JAM), together with other cholera toxin proteins (CTX). The integral membrane proteins 
are essentially the adhesions proteins which have the responsibility of for maintaining 
correct assembly of the TJs structure. The integral membrane proteins are also involved 
in the control of the TJ functions. 
2. Peripheral or plaque anchoring proteins: These include PDZ motifs like Zonula Occludens 
(ZO) -1, -2, -3 and Membrane Associated Guanalytes Inverted Orientation (MAGI) -1, -2, 
-3 etc. The PDZ domain is a common structural domain of 80 to 90 amino acids found in 
signalling proteins. PDZ domain plays a key role in anchoring receptor proteins in the 
cytoskeleton. PDZ are initials of the first three proteins discovered. The P is from 
postsynaptic density protein (PSD), the D is from Drosophila large disc protein (Dlg), and 
the Z is from zona occludins (ZO). The anchoring proteins play their key role in the 
assembly and maintenance of the TJs by the anchorage of transmembrane proteins. 
They also play their role in the signalling mechanism of the cell and binding of the 
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cytoskeletal. 
3. The peripheral TJs-associated regulatory proteins: These include alpha-catenin and 
cingulin etc. The TJ associated regulatory proteins work in conjunction with the 
anchoring proteins. 
 
 
 
 
 
 
 
 
 
Figure 1.14.1.2. Schematic presentation of TJs and its associated proteins.  (Martin et 
al. 2011) 
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Table 1.14.1.1: List of proteins involved in TJ structure, function and regulation. 
(Martin et al. 2011) 
Location Protein 
Integral 
transmembrane 
proteins 
  
 
Occludin, Tricellulin, MARVELD3 
Claudins 1-24 
JAM 
CAR, ESAM, Vmp1 
Peripheral plaque 
proteins 
  
 
ZO-1, ZO-2, ZO-3 
MAGI-1, -2, -3 
MUPP-1 
PAR-3/ASIP 
PAR-6 
AF-6/s-afadin 
CASK 
CAROM 
 
 
Associated 
proteins 
 
Cingulin, 7H6, Symplekin, ZONAB, Rab-13, 19B1, Ponsin,  
Rab 3B, PKC, l-afadin, c-src, Gi-2, Gi-12, alpha-catenin,  
Pals, PATJ, PKA, JEAP, Pilt, PTEN, ZAK, SCRIB, ITCH,  
Rho-GTPases, WNK4, Vinculin 
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1.14.2. Functions of TJs  
The cell adhesions to adjacent cells and the extracellular matrix play a vital role in the 
regulation of cellular processes like gene expression, differentiation, growth and 
motility. These regulatory functions are mediated by TJ molecules, cytoskeletal proteins 
and transmembrane receptors, all of which constitute multi-molecular complexes, 
involved in signaling pathways. TJs separate the apical and basolateral fluid epithelial 
and endothelial compartments and seal the intracellular space. TJs work as a diffusion 
barrier to plasma membrane lipids and proteins, hence define apical and basolateral 
membrane domain of the polarised epithelial and endothelial cell lining. This is why TJs 
are crucial for the generation of chemical and electrical gradients across mono-layered 
epithelial cell linings, which is needed for vectorial transport processes. TJ molecules are 
involved in cell signaling as intermediates and transducers, playing a role in processes of 
maintaining cell growth, cell polarity, cell differentiation and proliferation. TJs function 
as barriers to cell migration. These regulatory functions are mediated by TJ molecules, 
cytoskeletal proteins and transmembrane receptors, all of which constitute multi-
molecular complexes, involved in signaling pathways. 
In addition to the above roles, evidence suggests that TJs play an important role in 
tumorigenesis. (Chlenski et al. 1999). Furthermore, there is increasing evidence that the 
spread of human cancer is frequently associated with failure of TJs in epithelial cells. 
(Latorre et al. 2005). The loss of cell-to-cell adhesion has been widely accepted as the 
starting point for metastasis in the epithelial cell linings of cancer tissues. (Kominsky et 
al. 2003). Tobioka et al. showed that optimising the function of TJs can decrease in the 
penetration of cancer cells through the mesothelial cell linings. (Tobioka et al. 1996). 
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1.14.3. Tight junctions in colorectal cancer cells 
Increased leakiness in TJs during the metastatic process has also been related to the 
oncogene mutations in cancer cell lines. It was also reported by Soler et al. that the 
Trans-Epithelial Resistance (TER) and para-cellular influx rate of TJs were effected in 
colonic cancer cells when compared to normal colonic cells, suggestive of increased 
permeability and decreased barrier function, hence leakier colon cancer epithelial cells 
than that of normal colonic epithelial cells. (Soler et al. 1999, Mullin et al. 2005). 
Stromberg et al. reported that invasiveness of colorectal cancer cells had a co-relation 
with cell adhesion proteins and polymorphism in their genes. (Stromberg et al. 2008). 
Landy et al. suggested that the dysregulation of TJs proteins precede the development 
of inflammatory bowel disease (IBD) and also lead to the development of IBD associated 
colorectal cancer (CRC). IBD results from the compromised integrity of epithelial barrier. 
Intestinal epithelium acts as a static barrier and has complex mechanisms to control and 
regulate bacterial interactions with the mucosal surface, during which apical tight 
junction proteins are critical. Alterations in tight junction proteins compromise epithelial 
barrier function in inflammatory bowel diseases. (Landy et al. 2016) 
1.15. MAGI proteins 
MAGI (Membrane Associated Guanylate Kinase with the Inverted arrangement of 
protein interaction domains) is one of the peripherally associated cytoplasmic proteins, 
active in TJs (figure 1.15.1). MAGI proteins were first reported by Dobrosotskaya et al. in 
1997, recognised as prototypical members of membrane-associated guanylate kinase 
(MAGUK) family, which is a part of DLG (Drosophila disc large tumour suppressor 
protein).  The MAGUK family of proteins are mainly found in the assembly of multiple 
protein complexes on the inner surface of the plasma membrane at regions of the cell to 
cell contact points (TJs) in epithelial cells and synaptic junctions in neurons. MAGUK 
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proteins are characterised by their specific three type of protein-to-protein interactions: 
1) Guanylate kinase (GuK) domain 
2) PDZ domain (one or three in number) 
3) Src homology 3 (SH3) domain 
Guanylate kinase (GuK) domain helps to catalyse reactions. PDZ domain plays a role in 
the anchoring of proteins. Src homology 3 (SH3) domain is active in signalling pathways. 
The pattern of the above domains was conserved in previously known MAGUK proteins, 
which would be, either one or three PDZ domains in the NH2 – terminal half would be 
followed by SH3 domain, which would then be followed by a COOH-terminal GuK 
domain. However, in MAGI, the GuK domain is at the NH2 terminus, the SH3 domain is 
substituted by two WW (in full) domains, not found in other MAGUK proteins. Also, 
MAGI contains five PDZ domains. MAGI is the only protein that contains a GuK domain, 
which is combined with five PDZ domains and two WW domains. This combination of 
PDZ and WW domains in MAGI proteins can be used to predict their interactions with 
other proteins. (Dobrosotskaya et al. 1997). 
There are three types: MAGI -1, MAGI -2, and MAGI -3, based on their highest degree of 
to the central PDZ domains with the inverted orientation of the GuK domain and SH3 
domain and their significant resemblance in protein to protein interactions. MAGI -1 is 
located on chromosome 3p14.1. MAGI -2 is located on chromosome 7q21 and MAGI -3 
is located on chromosome 1p12-p11.2. MAGI is reported to be widely expressed in 
tissues and tumours. MAGI -1 reported being expressed widely expressed in different 
tissues and tumours, whereas MAGI -2 was reported to be predominantly expressed in 
the brain and renal tissue. MAGI -3 is reported to be expressed in various tissues, 
including fetal and adult, and also in tumours. (Wu et al. 2000). 
60 
 
Figure 1.15.1. Unique Arrangement of PDZ Domains in MAGI. 
1.15.1. MAGI -1 
MAGI -1 is located on chromosome 3p14.1. MAGI -1 occurs in three splice variants 
(MAGI -1a, MAGI -1b and MAGI -1c), which is primarily due to the divergence in the 
COOH termini of fifth PDZ domain. MAGI -1b also has a small insert near second PDZ 
domain. The COOH termini of MAGI -1a and MAGI -1b contain 16 and 48 unique 
sequence amino acids respectively, with a 3.5 kDa molecular weight difference. The 
COOH terminus of MAGI -1c extends 251 amino acids beyond the splice site and is highly 
charged. The short COOH-terminal sequence is unique to MAGI -1a and MAGI -1b and 
does not constitute any features that would suggest the functional difference between 
the two. (Dobrosotskaya et al. 1997). 
MAGI -1 is widely expressed at and have been found to be localised to the epithelial and 
endothelial cell to cell TJs, and acts as a scaffolding molecule to stabilise cadherin-
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mediated adhesions and to recruit molecules in TJ. (Laura et al. 2002). 
MAGI-1 cleavage has proven to be an important step in the disassembly of cell-to-cell 
adhesion during apoptosis.  (Gregorc et al. 2007). Roles attributed to MAGI include 
organisation of protein complexes at the cell and synaptic junctions, regulation of cell 
polarity, connecting trans-cellular proteins with the cytoskeleton in TJs. (Martin et al. 
2011), and regulation of synapse formation and plasticity. (Emtage et al.2009). Kimura 
et al. suggested that Endothelial cell-selective adhesion molecule (ESAM) regulates 
MAGI-1 recruitment to the cell contacts and subsequently promotes actin 
polymerisation and mature cell-to-cell adhesion (Kimura et al. 2010).   
Stetak et al. reported that the knockdown of MAGI protein causes a loss of junctional 
compartmentalisation along the lateral membrane, and reduces the overall robustness 
of cell-to-cell adhesion. Stetak et al. also concluded from their experiments that MAGI-1 
proteins functioned in organisation and segregation of different cell adhesion complexes 
into distinct domains along the lateral plasma membrane. (Stetak et al. 2010). MAGI 
have also been reported to be involved in cancer cell signalling as a tumour suppressor 
regulator protein (Matsuda et al. 2013). It is advocated in the literature that MAGI -1 has 
not only an important role to play in providing a connection with the cytoskeleton and 
components of the electromechanical transduction cell complexes (XU et al. 2008), but 
it also forms an important component of the glomerular slit diaphragm, which is closely 
associated with nephrin (a protein necessary for the proper functioning of the renal 
filtration barrier) (Hirabayashi et al. 2005).  
Furthermore, MAGI-1 has also been proposed as the recruiter of PTEN (a tumour 
suppressor gene in mammals) at adherens junctions, as an effector system at the site of 
cell-to-cell contact junctions, which are focal points for restraining of not only the 
disruption of junctional complexes, but also commencement of tumour cell invasion 
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(Kotelevets et al. 2005). Kranjec et al. highlighted the fact that MAGI-1 expression can 
induce cell growth arrest and apoptosis in Human Papilloma Virus (HPV) tumour cells. 
(Kranjec et al. 2014).  
1.15.2. MAGI -2 
MAGI -2 is located on chromosome 7q21. There are three protein isoforms of MAGI -2, 
previously known as AIP1, S-SCAM and ARIP1, derived from alternative splicing and 
different initiation of ATG methionine. MAGI -2 was initially identified by Hirao et al. as 
novel proteins with the inverse structure of membrane-associated domains that bind 
with SAPAP through the GK-like domain and NMDA receptors and neuroligins through 
the PDZ domains. MAGI -2 were initially named as S-SCAM due to their assembly in the 
cell adhesion proteins at synaptic junctions. Initial high expressions of MAGI -2 were 
noted at synaptic junctions in the brain tissue of mice. (Hirao et al. 2000, Shoji et al. 
2000, Hirao et al. 1998, Wood et al. 1998). MAGI-2, in association with PTEN, has been 
shown to play a critical role in inhibition of cell migration and proliferation function in 
hepatic cancer cells (Hu et al. 2007). 
Wu et al. published their work on MAGI -2 and identified it for its possible tumour 
suppressor activity by its interaction, which results in stabilising PTEN expression. They 
suggested that MAGI-2 enhances PTEN function, which raises the possibility of MAGI-2 
in itself to act as a tumour suppressor gene. MAGI-2 was found to be localised on 
chromosome 7q21, which was found deleted in tumours like a region that is deleted in 
uterine leiomyomas, prostate cancer, and glioblastoma. (Wu et al. 2000). MAGI -2 has 
also been identified as playing an important role in human prostate cancer. (Berger et al. 
2011). Recent deep sequence studies have shown that genetic deletions and 
rearrangements in MAGI -2 are involved in human melanomas. (Pleasance et al. 2010). 
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MAGI -2 has been identifying cervical cancer. (Chen et al. 2014). MAGI -2 mRNA are 
potential target areas which are up-regulated in tumours. (Sachdeva et al. 2011, 
Kitamura et al. 2014). MAGI -2 has been identified in renal glomeruli in mice, where it is 
found to interact with the nephrin, which is one of the essential components in the cell 
to cell junctions and prevents urinary protein loss. (Lehtonen et al. 2005, Welsh et al. 
2010, Patrakka et al. 2007). Moreover Balbas et al. published their evidence that in vivo 
that MAGI -2 is essential for the kidneys for their functions such as filtration and 
preservation of podocytes. (Balbas et al. 2014). Kitamura et al. identified MAGI -2 is a 
potential target in patients with advanced adenocarcinoma of the lungs, as suppression 
of MAGI -2 resulted in the loss of PTEN stability, leading to Epithelial-Mesenchymal 
Transition (EMT). (Kitamura et al. 2014). 
1.15.3. MAGI -3 
MAGI -3 is located on chromosome 1p12-p11.2. Wu et al. reported MAGI -3 as one of 
the MAGUK proteins with inverted orientation, based on its homology to the group in its 
domains and its protein to protein interactions. (Wu et al. 2000). Lee et al. found that 
over-expression of MAGI -3 inhibited LPA induced migration and invasion of colon 
cancer cells, whereas by knocking down MAGI -3 continues the repeated effect of 
Sodium hydrogen antiporter regulator (NHERF -2) over-expression, which led to the 
evidence that MAGI -3 has a negative regulatory effect on LPA2 mediated cellular 
pathways and the PDZ domain-containing proteins has critical role in regulation of LPA2 
mediated effects in colorectal cancer cell lines. The signaling and functioning of LPA2 are 
reciprocally modulated by the dynamic coordinated interaction of the two PDZ 
scaffolding proteins and NHERF -2 and MAGI -3. (Lee et al. 2011). Adamsky et al. 
suggested a possible role of MAGI-3 as a scaffolding molecule that acts on receptor 
tyrosine phosphatase and its substrates at the plasma membrane. (Adamsky et al. 
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2003).  Ohashi et al. suggested that HTLV-1 viruses, the causative agent of Human T Cell 
Lymphoma, interact with MAGI -3 in rat cells, which possibly play a role in 
transformation. This may relate to the pathogenesis of HTLV-1-associated diseases. 
(Ohashi et al. 2004). Thomas et al. suggested MAGI -3 as a possible target site for the 
Human Papilloma Virus 6 (HPV-6), which is responsible for some human cancers. 
(Thomas et al. 2002)  
1.15.4. MAGI proteins in colorectal cancer 
Zaric et al. reported that COX -2 was inhibited by up-regulation of MAGI -1. Colorectal 
cancer cells when treated in vitro with COX -1/2 inhibitors (COX is cyclooxygenase 
pathway involved in the synthesis of prostaglandins in humans), showed an increase in 
expression of MAGI -1 mRNA and MAGI -1 proteins. The increased expression of MAGI -
1 was seen to induce stabilisation of E-cadherin and B-catenin between cell to cell 
junctions, increased paxillin-positive focal adhesions and increased actin stress fibres 
and cell adhesion to matrix protein. Increased expression of MAGI -1 was seen to 
suppress migration and invasion of the cancer cells. It was also seen that knocking down 
MAGI -1 decreased the localisation of E-cadherin at the cell to cell junction, increased 
disruption of stress fibres and focal adhesion points resulting in increased migration and 
invasion. Also, that MAGI -1 over-expression in colorectal cancer cells suppressed the 
cancer growth and lungs metastasis in vivo in an orthotopic transitional intestinal 
model. Zaric et al. also suggested that morphological and functional effects modulated 
by the over-expression of the MAGI -1 in colorectal cancer cell lines were independent 
of the epithelial-to-mesenchymal transition. In conclusion, over expression of MAGI -1 
was identified as a suppressor of colorectal cancer and its metastatic activity. (Zaric et 
al. 2012) Lee et al. found that over-expression of MAGI -3 inhibited LPA induced 
migration and invasion of colon cancer cells, whereas by knocking down MAGI -3 
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continues the repeated effect of NHERF -2 over-expression, which led to the evidence 
that MAGI -3 has a negative regulatory effect on LPA2 (Lipophosphaditic acid pathway – 
involved in platelet aggregation) mediated cellular pathways and the PDZ domain-
containing proteins has critical role in regulation of LPA2 mediated effects in colorectal 
cancer cell lines. The signaling and functioning of LPA2 are reciprocally modulated by the 
dynamic coordinated interaction of the two PDZ scaffolding proteins and NHERF -2 and 
MAGI -3. (Lee et al. 2011). 
In our experimental work on MAGI proteins in colorectal cancer cell lines, we had a 
constant lack of MAGI -2 RNA expression on PCR in colorectal cancer cell lines (RKO, 
HT115, HRT 18), which was consistent with the literature, as there is nothing reported to 
date in regard to MAGI -2 expressions in colorectal cancer cell lines. MAGI -1 and MAGI -
3 were used as positive controls, which were expressed and gastric cell lines (AGS and 
HGC -27) were used as controls for MAGI -2 expressions. Our study had significant 
differences from Zaric et al. study, who looked at the tumour suppressor activity of 
MAGI -1 in colorectal cancer cells. The key difference being in the cell lines as Zaric et al. 
used SW40, SW680, HCT116, T84 and HT29. Also, that we used different methods than 
Zaric et al., that is we used ECIS and TER to study cancer cell behaviour. 
1.15.5. MAGI associated proteins in colorectal cancer 
Martin et al. revealed that low expression levels of Claudin -1 and ZO -1 were directly 
related to high-grade colorectal cancer cells. ZO -1 levels were frequently found to be 
reduced in primary colorectal cancers with liver metastasis, possibly to their tyrosine 
phosphorylation, which down-regulates their function in TJs in colorectal cancer cell 
lines. Low levels of Claudin -1 were also deemed as independent predictors of 
recurrence and associated with poor survival. (Martin et al. 2011). Oshima et al. found 
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that Claudin -1, -3, and -4 have a relatively higher expression in colorectal cancer cell 
lines, whereas Claudin -7 had a reduced expression in venous and liver metastases of 
colorectal cancer. Thus, decreased Claudin -7 suggests invasiveness of colorectal cancer, 
and increasing the expression of Claudin -7 can have an important therapeutic role. 
(Oshima et al. 2008). 
Korn et al. suggested a significant correlation between expression of CAR and the grade 
of gastrointestinal cancers. Moderate to poorly differentiated cancers showed reduced 
or loss of CAR expression. (Korn et al. 2006) 
1.16. Hypothesis and aims of study 
There is evidence in the literature that MAGI proteins along with the other TJ proteins 
play an important role in regulation and maintenance of TJs. Disruption of TJs is one of 
the crucial steps in the initiation of cancer metastasis. There is limited information on 
individual types of MAGI protein, especially on their types (MAGI -1, MAGI -2 and MAGI -
3), their expression and their roles in human colorectal cancer metastasis. The focus of 
this project is on MAGI in cancer metastasis and the role of MAGI-1 protein in colorectal 
cancer cell lines. 
It was hypothesised that MAGI protein plays a role in human colorectal cancer by way of 
aberrant expression and, by molecular and cellular mechanisms to be identified, that 
translates into disease progression of patients. 
Thus, the aims of this study were as follows: 
1. Investigation of the mRNA expression of MAGI -1, MAGI -2 and MAGI -3 in human 
colorectal cancer cell lines using Q-PCR and RT-PCR.  
2. Generation of cell models (sublines) from human colorectal cancer cell lines with 
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differential expression of MAGI -1 (that is MAGI -1 knockdowns).  
3. Investigation of the impact of aberrantly expressed MAGI -1 on adhesion, invasion 
and migration of colorectal cancer cells using trans-epithelial resistance (TER) and 
electrical cell impedance (ECIS) assays, and subsequently, to deduce the underlying 
mechanisms by the results of these tests. 
4. Investigation of the expression of MAGI -1, MAGI -2, and MAGI -3 in human colorectal 
cancer and deduce the potential clinical and prognostic implications. 
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C H A P T E R  2 :  M A T E R I A L S  A N D  M E T H O D S  
2.1.1. Materials 
2.1.2. Culture mediums, buffers and standard solutions 
2.1.3. 0.05M EDTA 
EDTA solution at 0.05M was made as follows:  
One gram of potassium chloride KCl (Fisons Scientific Equipment, Loughborough, UK), 
5.72g of disodium phosphate Na2 HPO4, 1g of monopotassium phosphate KH2PO4, 40g 
of NaCl and 1.4g EDTA (Duchefa Biochemie, Haarlem, The Netherlands) was added to 
distilled water with a final volume of 5 litres. The pH of the solution was adjusted to 7.4 
and sterilised by autoclaving before use. 
2.1.4. Trypsin 
Five hundred milligrams of Trypsin was dissolved in 20 ml 0.05 M EDTA. The solution 
was mixed and filtered through a 0.2-micron minecart filter (Sartorius Epson, UK), 
aliquoted in 250 micro-litre samples and stored at -20 Centigrade. When needed for use, 
one aliquot was diluted in 10 ml of EDTA solution. 
2.1.5.    Balanced salt solution (BSS)  
The following were dissolved into distal water to make a final volume of 10 litres. 
Seventy-nine and a half gram of sodium chloride NaCl,  2.2gm of potassium KCl, 2.1gm 
of potassium monophosphate KH2PO4, 1.1gm of sodium bi-phosphate Na2HPO4. 
Solution PH was adjusted to 7.2 and was ready to use. 
70 
 
2.1.6. Antibiotic solution 
To prevent colonisation of cell cultures by microbes and fungi, an antibiotic solution was 
used in all cell media and standard solution. 
Dissolving the following in 500ml of BSS made the stock solution: 
3.3gm Penicillin  
12.5gm Amphotericin B  
5gm Streptomycin 
Due to lipophilic nature of Amphotericin B, it was first dissolved into dimethyl 
sulphoxide (DMSO) solution to yield a 30mg/ml solution. Once fully dissolved, the 
solution was passed through a 0.4 filtration unit and was stored at -20C in 5ml universal 
tubes, ready to be added to the 500ml bottle of the culture medium (Dulbecco's 
Modified Eagle's Medium DMEM), resulting in the following final concentrations. 
100 U / ml Penicillin 
0.25 microgram/ml Amphotericin B 
0.1 mg / ml Streptomycin 
2.1.7. 2.1.1.5. Normal culture medium  
The normal culture medium used for wild-type cell growth was Dulbecco's Modified 
Eagle's Medium (DMEM) with 10% (50ml) of FCS (Fetal Calf serum or Fetal Bovine 
Serum) and 5ml antibiotics. Cell cultures were grown and maintained in 25 cm2 and 75 
cm2 tissue culture flasks (Grenier Bio-One limited, Gloucestershire UK). 
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2.1.8. Selection culture medium  
Selection culture medium used for the selection of transfected cells contained 
Dulbecco's Modified Eagle's Medium (DMEM) with 10% of FCS (Fetal Calf serum or Fetal 
Bovine Serum) plus antibiotics and also 250 micro-litres of Blasticidin.  
2.1.9. Maintenance culture medium  
Maintenance culture medium used for the transfected cells contained Dulbecco's 
Modified Eagle's Medium (DMEM) with 10% of FCS (Fetal Calf serum or Fetal Bovine 
Serum) plus antibiotics and also 27.5 micro-litres of Blasticidin.  
2.1.10. DPC water 
Two hundred and fifty micro-litres of Diethyl Pyro Carbonate (DPC) was added to 4750 
micro-litres of distilled water. The solution was then autoclaved for use. 
2.1.11. PCR water 
Distilled water was filtered and irradiated with ultraviolet light to ensure the breakdown 
of contaminating nucleic acids. 
2.1.12. T5X Tris, Boric acid, EDTA (TBE) 
A 5 times stock solution was made by using the following: 
• 545gram of Tris-Cl (Melford Laboratories Ltd., Suffolk, UK),  
• 275gram of Boric acid (Melford Laboratories Ltd., Suffolk, UK)  
• 46.5gram of disodium EDTA (Duxhefa Biochemie, Haarlem, The Netherlands) 
The above was dissolved in distilled water to make a final volume of 10 litres. The 
solution was stored at room temperature and was diluted as required for use. 
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2.1.13. RNA-ase free water 
Sigma-Aldrich RNAse water was used. 
2.1.14. Master mix 
Go Taq Green PCR master mix from Promega UK was used. 
2.1.15. RT mix 
PCR master mix was used from Invitrogen Life Science Technologies. 
2.1.16. DNA ladder 
DNA ladder was used to confirm the size of the product on Agarose Gel. 
2.1.17. Electrophoresis gel  
0.8% agarose gel was used by the product size. 
2.1.18. Syber safe 
Syber safe was used for safe DNA staining from Invitrogen Life Science Technologies. 
2.1.19. TBS X 10 
The following were dissolved to make a final volume of 5 litres, adjusted to pH 7.4: 
TRIS 121 grams, NaCl 400.3grams 
2.1.20. Cell lines 
We have used human colorectal cancer cells, namely HT-115, HRT-18 and RKO with 
epithelial morphology established from highly invasive human colorectal carcinoma, 
which expresses high amounts of the tumour marker carcinoembryonic antigen. Human 
gastric cancer cells, namely AGS and HGC-27, were chosen as controls due to consistent 
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lack of MAGI -2 expression on agarose gel electrophoresis following RT PCR. The cells 
were obtained from the European Collection of Animal Cell Culture (ECACC), HECV, 
human endothelial cells were purchased from Interlab, Milan, Italy (Table 2.1.20.1. and 
Table 2.1.20.2.). Different types of cells for both gastric and colonic cancer were chosen 
due to, firstly, their varying invasiveness properties and differential expression patterns 
of types of MAGI proteins i-e, MAGI -1, -2 and -3.  
 
Table 2.1.20.1. Specification of colorectal cancer cell lines 
Cell line HHT -115 HRT -18 RKO  
Species Human Human Human 
Tissue Colon Rectum Rectum 
Age 63 67 82 
Gender Male Male Female 
Morphology Epithelial Epithelial-like Epithelial 
Growth mode Adherent Adherent Adherent 
Karyotype 2n=46 2n=46 2n=46 
Tumorigenic Specified Yes Yes 
Country UK UK UK 
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Table 2.1.20.2. Specification of gastric cancer cell lines 
Cell line AGS HGC - 27  
Organism Human Human  
Tissue Stomach Lymph node  
Age 54 Unspecified  
Gender Female Unspecified  
Morphology Epithelial Epithelial  
Growth 
mode 
Adherent Adherent  
 
2.1.21.  MAGI primers used: 
MAGI-1, MAGI-2 and MAGI-3 primers (table 2.1.21.1) were designed in-house by using 
Beacon Designer Programme, synthesised by Sigma-Aldrich UK, and were stored in -200C 
freezers. The required primers (MAGI -1, -2, -3) were taken out when needed and 
defrosted on room temperature, following which they were diluted to 1:10 
concentration using PCR water. Subsequently, the diluted primers were stored in a 
designated primer fridge for future use, and the originals were returned to the freezer. 
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Table 2.1.21.1. MAGI primer sequences 
2.2. Methods 
2.2.1. Preparation of growth culture medium 
50 ml (10%) of FCS was added to 500ml of DMEM medium inside the hood. Antibiotics 
were taken out of the freezer, defrosted and added to DMEM inside the hood with non-
touch technique.  
2.2.2. Reviving cells 
Stocks of frozen cells were available at the host department, which was securely stored 
away in liquid nitrogen tanks in a room, originally obtained from the European 
Collection of Animal Cell Culture (ECACC), HECV, human endothelial cells, Interlab, 
Milan, Italy. Protective gloves were worn. The safe distance was observed while standing 
close to the tank, while opening it, because of the risk of hypothermic burn. The shelf 
was taken out, and the rod was removed. The desired cell cones were taken out; the box 
Primers Forward Reverse 
MAGI-1 
(F11 R11) 
CTCC AAGAAA CAGCA TTACC CTGAA GTGG AACTT CTCTGG 
MAGI-2 
(F11 R11) 
CAGTG ACTAC GCAA CCT ACA   GGATG TCT GGTTT CACA TCT 
MAGI-2 
(F12 R12) 
TCAAGG ATGCA GGTCTT AGT CTTATT GCTGG TCCA TCTTC 
MAGI-3 
(F12 R12) 
GGGAAA TCA CAC AAACAA GT TGAG ACAG TTCAA CAAT GGA 
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was closed and was put back on the shelf, with the rod back in place. The shelf was 
delivered back into the tank carefully, and the tank was closed. The cells taken out were 
marked in the folder for recording purposes. The room was locked. The cones were 
gently warmed up to the room temperature.  Five universal containers (UC) were taken 
out, and the tops were cleaned. Four were labelled with the cell types names and one 
labelled and used for medium. The 5th UC was a transfer means for the culture medium. 
Four T25 flasks were labelled with the four cell type names and were dated. 5 ml of 
culture medium was poured into each flask. The cells were transferred into labelled UCs 
and mixed with 5 ml of normal medium and then were centrifuged for 8 minutes at 1780 
rpm. The cell sediment formed was re-suspended into 1ml of the normal medium, which 
was carefully transferred to the designated labelled T25 flask. T25 Flasks were put into 
an incubator for cells to grow. 
2.2.3. Maintenance of cells 
All cell culture work was carried out inside a tissue culture facility which had class two 
laminar flow cabinets.  We observed strict sterile and aseptic techniques and 
precautions. Gastric and colorectal cell lines were maintained in T25 and T75 flasks 
(Grenier Bio-One limited, Gloucestershire UK) as required using DMEM/Ham's F12 
medium prepared as described earlier. 
The flasks were maintained in the incubator (Sanyo MDA 15 AC), loosely capped at 37 C 
in 5% carbon dioxide and 95% humidification. Cells were grown to confluence before the 
start of any experimental work. 
2.2.4.  Trypsinization of cells 
Cell lines were grown to reach significant confluence levels which were assessed visually 
first and then under a microscope. The medium was removed from the flask, and the 
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cells were rinsed with BSS and maintained at room temperature. The BSS was then 
aspirated, and 1 to 2 ml of trypsin added to the flask and flask were shaken to spread 
the trypsin equally over the surface of the flask. Flasks were then transferred to the 
incubator for 10 to 20 minutes. The flask was given a gentle tap to detach cells from the 
flask surface. The supernatant was transferred into a 20 ml universal container (Greiner 
Bio-One Ltd., Gloucestershire, UK) and the normal medium was added to make the 
volume to 5ml. The mixture was then centrifuged at 1700rpm for 8 minutes to pellet the 
cells. The supernatant was aspirated, and the pellet was resuspended in 5 ml of normal 
medium. The cells were then counted for immediate experimental work, or were put 
into new flasks to be re-cultured, or were put into cryo-tubes to be frozen down and 
stored in the liquid nitrogen. 
2.2.5.  Cell counting 
Cells were counted using Neubauer haemocytometer (Figure 2.2.5.1 – figure 1&2) 
counting chamber (Mod-FuchsRosenthal, Hawksley, UK) in the haemocytometer 
counting chamber by using an inverted microscope (Reichert, Austria) at 10 x 10 
magnification for in vitro functional assays.  
    
 
 
 
 
 
Figure 2.2.5.1. Haemocytometer grid and cell counting (Stem cell technologies) 
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Using a pipette, 100 µL of cell suspension was removed and applied to 
the haemocytometer. Both the chambers were filled underneath the coverslip, allowing 
the cell suspension to be drawn out by capillary action. The microscope was focused on 
the grid lines of the haemocytometer with a 10X objective. Using a hand tally counter, 
the cells were counted in one set of 16 squares as shown within a red square line in 
figure 2.2.5.1. The cells were only counted when they were set the right-hand or bottom 
boundary line. The full dimension of each 16 square areas, containing cells were 
counted. The dimensions were 1mm x 1mm x 0.2mm  
Following equation was used: 
Cell number / ml = (number of cells counted in 16 small squares / 2) x (1 x 104)  
2.2.6.  Cryopreservation of cells 
Cells were regularly preserved at different stages during the experiments to have 
enough cells available, not only for future work but also in case of loss of cells.  An extra 
set of T25 flasks were run beside the one used in the experiment, which was then used 
to cryopreserve cells. Once these flasks would become confluent, they were trypsinised 
and centrifuged for 8 minutes at 17000rpm. The cells were then re-suspended into 0.9 
ml of normal medium. They were transferred to 1 ml cryo-tubes (Nunc, Fisher Scientific, 
Leicestershire, UK) and 0.1 ml of 10% dimethylsulphoxide (DMSO) (Sigma-Aldrich, 
Gillingham, Dorset, UK) was added on. Once DMSO was added, the cryo-tubes were 
transferred to the -80C freezer without any delay for overnight storage and 
subsequently to liquid nitrogen for long-term storage. 
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2.2.7. Generation of mutant RKO, HT-115 and HRT-18 cell lines with the MAGI-1 
knockdown. 
2.2.8. Discovery and the catalytic mechanism of ribozymes 
To achieve human SOCS-4 mRNA (Figure 2.2.8.1) knockdown, hammerhead ribozyme 
transgenes that specifically target GUC or AUC sites of SOCS-4 mRNA (Figure 2.2.8.2) and 
cleave SOCS-4 transcripts were designed according to the predicted secondary structure 
of SOCS-4 mRNA by Zuker's RNA mFold software (Zuker, 2003). The hammerhead 
ribozyme was first discovered by Forster and Symons in 1987 as a self-cleaving domain 
in the RNA genome in a variety of plant viroids and virusoids (Forster and Symons, 
1987). Such hammerhead motifs can form short synthetic oligonucleotides, acting as 
multiple turnover catalysts which are capable of cleaving RNA targets (Uhlenbeck, 1987, 
Haseloff and Gerlach, 1988). A general universal secondary structure which is integrated 
by several invariant nucleotides and consists of three helical stems (I, II and III) could be 
found in all hammerhead motifs. Stem II is incorporated intramolecular in such 
secondary structure, whereas stem I and III are formed by hybridisation based on the 
complementary sequences of the targeted substrate. Moreover, the best cleavage sites 
were discovered to be AUC, GUC and UUC.  
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Figure 2.2.8.1.  Diagram of the predicted secondary structure of human SOCS-4 mRNA 
 
 
Figure 2.2.8.2. Diagram of hammerhead ribozyme secondary structure 
Hammerhead ribozymes consist of three helices. Stem II, containing highly conserved 
sequences, is flanked by stem I and III that are adjacent to the cleavage site and are 
base-paired to the RNA substrate. Dash line indicates the Watson-Crick base pairs. 
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2.2.9. TOPO TA gene cloning and generation of stable transfectants 
 
The pEF6/V5-His TOPO® TA expression system (Invitrogen, Paisley, UK) provides a highly 
efficient one-step cloning technique which does not require ligase, post-PCR procedures, 
or PCR primers containing specific sequences. Such an approach allows the direct 
insertion of Taq polymerase-amplified PCR products into a plasmid vector for 
constitutive expression in mammalian cells after transfection. The line raised pEF6/V5-
His TOPO® vector in the kit consists of single, overhanging 3' deoxythymidine (T) 
residues which allow Taq polymerase-amplified PCR products, containing a single 
deoxyadenosine (A) at the 3’ ends, to ligate efficiently. The EF-1α promoter in pEF6/V5-
His TOPO® then enables the constitutive expression of the PCR product after the 
transfection of the plasmid (figure 2.2.9.1). 
 
 
 
 
 
 
 
 
Figure 2.2.9.1. Diagram of the pEF6/V5-His TOPO® vector feature (From pEF6-His 
TOPO® TA Expression Kit manual) 
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The PCR products were cloned into a pEF6/V5-His TOPO® plasmid, and the total 6µl 
cloning reaction was mixed and stored on ice in advance to the One Shot Chemical 
Transformation (Invitrogen, Paisley, UK). The condition used for TOPO cloning reaction 
was as follows: 
• PCR product - 4µl 
• Salt solution - 1µl 
• TOPO vector - 1µl 
5µl of TOPO cloning reaction was added into each vial of One Shot TOP10 Chemically 
Competent E. coli. (Invitrogen, Paisley, UK) and mixed gently by stirring using the pipette 
tip. The vial was stored on ice for 5-30 minutes (based on the product size) before heat-
shocking at 42ᵒC for 30 seconds followed by immediately transferring into ice. To each 
vial, 250µl of room temperature S.O.C medium was added, and the tubes were shaken 
at a 45ᵒ angle at 225rpm on a horizontal orbital shaker (Bibby Stuart Scientific, UK) at 
37ᵒC for 1 hour. After the incubation period, the transformed products from each vial 
were spread in different seeding density on a pre-warmed agar petri dish containing 
100µg/ml ampicillin followed by incubating overnight at 37ᵒC. Several colonies from 
each petri dish were randomly picked, and the PCR product insertion and orientation of 
the incorporated PCR product were checked by PCR using primer combination of T7F vs 
BGHR and T7F vs specific forward or reverse primer respectively. The reaction mix is 
outlined as follows:  
PCR product insertion primer pair mix (used for over-expression sequences) 
• GoTaq Green master mix - 8µl 
• T7F plasmid specific forward primer - 1µl 
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• BGHR plasmid specific reverse primer - 1µl 
• PCR water -6µl 
For ribozyme transgene insertion and orientation checking, the molecule specific 
forward and reverse primer was replaced in the above mixtures with forwarding 
(RbToPF) and reverse (RbBMR) sequences to the common region of the ribozyme 
transgene. Each colony was inoculated into both reaction mixes using a sterile pipette 
tip, and the reaction mixes were placed in a 2720 Thermal Cycler (Applied Biosystems, 
Paisley, UK). The PCR reaction conditions were used as follows: 94ᵒC for 5 minutes, 
followed by 30 cycles of 94ᵒC for 30 seconds, 55ᵒC for 40 seconds and 72ᵒC for 1 minute 
with a final extension step of 72ᵒC for 10 minutes. Gel electrophoresis on a 2% agarose 
gel stained with SYBR safe DNA gel stain was utilised to visualise the conventional PCR 
reaction products. Colonies with correctly orientated PCR product inserts were 
inoculated into universal tubes containing 5ml of selective LB broth (containing 
100µg/ml ampicillin) followed by being incubated overnight at 37ᵒC while being shaken 
with a 45ᵒ angle at 225rpm. 
 
2.2.10.  Plasmid amplification and extraction 
Plasmid extraction was undertaken using the Sigma GenElute Plasmid MiniPrep Kit 
(Sigma, Dorset, UK) based on the protocol provided. The overnight incubated universal 
tubes containing the chosen colonies were centrifuged at 5,000RCF to acquire a 
bacterial pellet. The supernatant in each tube was discarded, and the bacterial pellet 
was re-suspended thoroughly using 200µl Resuspension Solution containing RNase A 
and transferred into a 1.5ml Microfuge tube. To the Microfuge tube was added 200µl of 
Lysis Solution followed by eight gentle inversions. This lysis stage was conducted within 
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5 minutes to avoid permanent plasmid denaturation. Then, 350µl of Neutralisation 
Solution was added, and the Microfuge tube was gently inverted six times followed by 
centrifugation at 12,000g for 10 minutes to pellet the cell debris. The clear lysate in the 
Microfuge tube was transferred into a Mini-prep Binding Column which was placed into 
a micro-centrifuge Tube. Such Mini-prep Binding Column was washed with Column 
Preparation Solution in advance to maximise plasmid binding capacity. The clear lysate 
added micro-centrifuge Tube was then centrifuged for 1 minute at 12,000g to enable 
the plasmid binding to Mini-prep Binding Column. The flow-through liquid was 
discarded, and 700µl of Wash Solution (containing ethanol) was added to the Mini-prep 
Binding Column followed by centrifugation at 12,000g for 1 minute before discarding the 
flow-through liquid. The Micro-centrifuge Tube had then centrifuged again at 12,000g 
for 1 minute to remove the remaining Wash solution before the Mini-prep Binding 
Column was transferred into a fresh Collection Tube. The plasmid was eluted by adding 
50µl of Elution Solution followed by spinning the fresh Collection Tube at 12,000g for 1 
minute and was stored at -20°C for further use. Knockdowns (KDs) were created by 
using ribozymes containing purified plasmids for MAGI -1 gene KD. 2 different ribozymes 
were used for each WT cell line. Electroporation was used to introduce the plasmids into 
the cells. 
2.2.11. Transfection by electroporation 
The WT cancer cells were grown in T25 flasks to reach full confluence so that the TJs had 
formed and well established. The culture medium was removed, and the flasks were 
washed with BSS solution twice. 1 ml of TRI Reagent (Sigma-Aldrich) was added to the 
flask, and the flask was kept in the incubator for 5 minutes. After 5 minutes the 
detached cells floated in the reagent. The leftover attached cells were detached by 
gently from the surface by gently tapping on the flask. The cell lysate was transferred 
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into the pre-labelled universal tube, and 4ml of the normal medium was added to make 
up the total volume to 5ml. The mixture was centrifuged at 1700rpm for 8 minutes to 
pellet the cells. The supernatant was aspirated, and the pellet was re-suspended in 2 ml 
of normal medium. 
500 micro-litres of the stock was transferred into pre-labelled four electroporation 
sterile cuvettes for each cell type. These included WT, two different ribozymes 
containing purified plasmids for MAGI -1 gene (KD1 and KD2), and ribozymes containing 
empty plasmids (PEF). The WT and PEFs were used as controls. Once the vector was 
added, 30 seconds were given for dispersion. The cuvettes were sealed by placing the lid 
back on and were put into the electroporation chamber. Standard settings were used for 
electroporation. Cells were subjected to electrical pulse 1500 farads and 300 volts. The 
injured cells were transferred to T25 flasks with 5ml of normal growth medium and were 
incubated at 37C, 5% CO2 and 95% humidity. 
2.2.12.   Stabilisation and maintenance of transfected cells   
Following 48 hours of incubation of transfected cells in to normal medium, the medium 
was changed to the selection medium, containing Dulbecco's Modified Eagle's Medium 
(DMEM) with 10% of FCS (Fetal Calf serum or Fetal Bovine Serum) and antibiotics from 
the stock (see above) and in addition 250 micrograms of Blasticidin (0.5microgram /ml). 
The transfected cells were kept in the selection medium for 5 to 7 days. This resulted in 
the selection of transfected cells and apoptosis of non-transfected cells. The medium 
was then changed to maintenance medium. Successful KDs were confirmed by 
microscopy, cell imaging, qPCR, agarose gel PCR and immunofluorescence.  
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2.2.13. RNA isolation using TRI reagent (Sigma)  
Confluent T25 flasks of the desired cell lines were selected, and the cell culture medium 
was aspirated. Flasks were then washed twice with the BSS. 1 ml of TRI reagent was 
added to the flasks. Cells were scrapped, and cell lysate was passed several times 
through the pipette to produce a homogenous lysate. The sample was transferred to a 
sterile Microfuge tube and allowed to stand at room temperature for 5 minutes. 0.2ml 
chloroform TRI reagent was added to each tube and shaken for 15 seconds and was left 
to stand at room temperature for 2-15 minutes, then centrifuged at 12000 for 15 
minutes at 4C. Three phases appeared. The bottom red phase was the protein. In 
between white phase was DNA and the clear top phase was the RNA. The clear top 
phase was carefully transferred to a fresh Microfuge tube. 0.5 ml of isopropanol was 
added to the Microfuge tube, mixed by shaking and was left for 5-10 minutes at room 
temperature, then centrifuge 12000 for 10 minutes at 4C. A pellet appeared at the base 
(not always clearly visible). The supernatant was discarded. The pellet was washed with 
75% EtOH which was made up of RNA-ase free water and then centrifuged at 7500 for 5 
minutes. 75% EtOH was removed, and the sample was air dried for 5-10 minutes. The 
pellet was dissolved in 20 micro litres of RNA-ease free water. RNA concentration was 
measured on the nano-photometer. Lid factor used for most samples was 50. A lid 
factor of 10 was used for more concentrated samples, and 100 was used for more 
diluted samples. Dilution of concentrated samples was achieved by gradually adding ten 
micro litres of RNAase free water and measuring the new concentration. Few of the RNA 
samples were stored at -80C freezer and others were used for immediate reverse 
transcription (RT). 
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2.2.14. RNA quantification 
The concentration of RNA extracted from the cells was measured using a UV101 Biotech 
Photometer (WPA, Cambridge, UK), which was set to detect single strand RNA in 
micrograms per micro-litres at 260 nanometers. Samples were measured by using 
Starna glass cuvette (Optiglass limited, Essex, UK). 
 
2.2.15. Reverse transcription polymerase chain reaction (RT-PCR) of RNA 
Once RNA had been isolated and quantified, RT-PCR was carried out to convert RNA into 
complementary DNA (cDNA) using DuraScriptTM RT PCR kit (Sigma-Aldrich, Dorset, UK). A 
fixed amount of 0.5 micrograms of RNA was converted to cDNA as per protocol. 
Standardized RNA concentrations were achieved by adding RNA-ease free water. The 
dilution amount of RNA-ease free water was calculated by 0.5 divided by the RNA 
concentration measured by the nano-photometer from earlier. Once diluted to 
standardised concentration forms, the new RNA concentration was measured on the 
nano-photometer.  The Abgene reverse transcription kit was used for RT PCR. The 
following volumes were used: 
Volume reaction was 20 micro-litres: 
PCR water was added to RNA to make volume 10 micro-litres 
ten micro-litres of AB RT Mastermix 2X 
All of above were added to a dome-capped Microfuge tube's and placed into a thermo-
cycler (Applied GeneAmp PCR sys 2700). Each reaction was run as per the following 
protocol: 
Stage 1: 25◦C for 5 minutes 
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Stage 2: 37◦C for 120 minutes 
Stage 3: 85◦C for 5 minutes 
Stage 4: held at 4◦C 
The final product was diluted with PCR water in 1:3 resulting in a final volume of 80 
micro-litres, which was then labelled and stored at -80C. 
 
2.2.16.  Real-time quantitative polymerase chain reaction (q-PCR) 
q-PCR was undertaken to analyse the transcript expression level of target genes. Such a 
technique is more sensitive than conventional RT-PCR and capable of detecting small 
quantities of cDNA, providing a more reliable value of the template copy number in each 
sample. This method requires a sequence-specific DNA-based fluorescent reporter 
probe which only quantifies the target transcript containing such a probe sequence to 
greatly improve the specificity of the detection. AmplifluorTM UniprimerTM Universal 
system (Intergen company®, New York, USA) was available at the home department and 
was used in this study. The Amplifluor probe consisted of a 3' region specific to the Z-
sequence, which acted on the target-specific primers and a 5' hairpin structure labelled 
with a fluorescent tag (FAM). While in the hairpin structure, such a fluorescent tag was 
linked to an acceptor moiety (DABSYL) which effectively quenched the fluorescence and 
produced no fluorescence signal. Primers were designed to the specific target transcript 
using Beacon Designer Software. To each of the primer pairs specific to the target 
sequence, a Z-sequence was added to allow incorporation of the Amplifluor uni primer 
probe during PCR. Such Z-sequence incorporated DNA transcript that acted as a 
template for the Amplifluor uni primer probe, and the hairpin structure in the probe was 
subsequently degraded and unfolded by DNA polymerase disrupting the stable structure 
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between fluorophore and quencher to enable sufficient fluorescence emission to be 
detected. The principle of this process was demonstrated in figure 18. Pre-prepared 
cDNA samples were amplified and detected on a Step One Plus Real-Time PCR System 
(Applied Biosystems, Paisley, UK), using Precision FAST 2X q-PCR Master-Mix 
(Primerdesign Ltd, Chandler's Ford, UK), specific forward primer (10pM), reverse primer 
containing the Z sequence (1pM) and the FAM-tagged Uni-primer probe (10pM). Each 
sample was loaded into a 96-well plate and the reaction mixture. The q-PCR conditions 
used are shown below: 
q-PCR Reaction mix: 
• Precision FAST 2X q-PCR MasterMix - 5µl 
• Specific forward primer - 0.3µl 
• Specific reverse primer with Z-sequence - 0.3µl 
• Amplifluor probe – 0.3µl 
• PCR H2O – 3.1µl 
• Prepared cDNA sample - 1µl 
q-PCR conditions:  
• Step 1: Initial denaturation - 94ᵒC for 10 minutes 
• Step 2: Denaturation - 94ᵒC for 10 seconds 
• Step 3: Annealing - 55ᵒC for 30 seconds 
• Step 4: Extension - 72ᵒC for 10 minutes 
Step 2 - 4 were repeated for 100 cycles. 
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The fluorescent signal was detected at the annealing stage, and the fluorescent signal 
emitted during PCR correlated to the amount of DNA template that had been 
incorporated into Z- sequence. The geometric increase in fluorescent signal directly 
correlated to the exponential increase of DNA template, which was used to determine a 
threshold cycle for each reaction. The transcript copy number was determined by the 
time/cycle number when fluorescent signal reached a specific threshold. Expression of 
the target sequence was detected in conjunction with a range of standards of the known 
transcript, PDPL, that are used to generate a standard curve to enable the calculation of 
transcript copy number in each unknown sample (Figure 2.2.16.1 and 2.2.16.2). Finally, 
the transcript copy number was normalised by the detected copy number of GAPDH. 
 
Figure 2.2.16.1.  Diagram indicating the principle of the Amplifluor Uniprimer 
Universal system.  (Intergen company®, New York, US)
  
 
Figure 2.2.16.2. Figure 19: Diagram of standard curve generation (Intergen company®, 
New York, UK. 
 
Reaction curves for serial diluted standard samples (108 to 10 copy number) using 
StepOne Plus Real-Time PCR System; The standard curve generated based on the 
threshold cycle and copy number of the serial diluted standard samples. Red line 
indicates the standard curve generated and blue dots stand for different standard 
samples with known copy number. 
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2.2.17. Agarose gel electrophoresis, DNA staining and visualisation 
The amplified DNA products from the PCR were analysed using 2% agarose gel 
electrophoresis. The analysis was based on the separation of DNA products according to 
their size on electrophoresis. The procedure was as follows: 
2.2.18.  Formation of 0.8% agarose gel 
3 grams of agarose (Melford chemicals, Suffolk, UK) was added to 150 ml of TBE solution 
in a flask. The mixture was heated in the microwave to boiling temperature, and the 
agarose was fully dissolved, and the mixture became transparent in colour. Then the gel 
was left to cool down on room temperature just for a few minutes, and ten micro-litres 
of the cyber safe was added into it, following which the liquid gel was poured down into 
the electrophoresis cassette. Plastic combs were already inserted into the 
electrophoresis cassettes, and the gel was allowed to settle down at room temperature, 
which took between 30-40 minutes. The plastic combs were then carefully removed, 
leaving indentation slots for loading of the PCR products for later on. 
2.2.19.  TBE Buffer 
Once the gel was set, TBE buffer was carefully poured into the electrophoresis tank, 
directly on top of the gel, filling up to the maximum fill mark on the tank. 
2.2.20.  Loading gel with PCR products 
Five micro-litre of 100 Kb DNA ladder (Invitrogen, Paisley, UK) was loaded into the first 
indentation slot which was used as a reference guide in measuring of the DNA products 
once the electrophoresis was completed. Ten micro-litres of the PCR products were 
carefully loaded into the rest of the indentation slots on the gel. 
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2.2.21.  Electrophoresis 
The electrophoresis cassette was connected with the power supply by its leads, making 
sure that the flow of the charge/current is in the right direction, that is from the positive 
to the negative electrode, which separated the DNA products out on the gel. 
Consort EV 243 electrophoresis device was used. The following setting was applied. 
Current: 110mA 
Voltage: 90V 
Time: 42 minutes.   
2.2.22.  Detection of spread of PCR products using UV light 
The TBE was poured away from the gel, and the gel was placed inside the UV light 
container (UVTech. Cambridge, UK). The degree of spread of PCR products was captured 
by using UV camera in the UV Tech. The light settings were optimised. 
 
2.2.23. Electrical Cell Impedance Sensing (ECIS) 
Electrical cell impedance sensing (ECIS) is a technique for analysing cell behaviour based 
on work of Giaever and Keese, who found that it was possible to monitor growth, 
migration and adhesion of cells growing on a small electrode by monitoring changes in 
impedance of the cells, that is, resistance to an alternating current) (Giaever and Keese 
1984). The ECIS apparatus was supplied by Applied Biophysics (New York, USA).  A 96 
well plate array specific to the ECIS machine was used (IBIDI, Germany). Each well inside 
the 96 well plate has a unique design. It is built around two small gold electrodes, in the 
bottom of the wells in which the seeded cells are allowed to grow within the incubator. 
These electrodes work as sensing the impedance or resistance between the cells and the 
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cell and the bottom of the array. Each Individual well is a part of plate array, which 
consists of a plastic housing encasing an integrated circuit incorporating all the 
electrodes included in the array. An array can contain various numbers of wells and 
types of plates, but a 96 well plate is the most widely used configuration. The plate slots 
into a dock, in the incubator, which connects it to the ECIS machine. The incubator in the 
apparatus does not provide carbon dioxide; therefore DMEM used has to contain HEPES 
to compensate. 
ECIS: Procedure 
The protocol for the procedure was available in the home department (Jiang et al.), 
which had been used extensively in the past for study of tumour cell behaviour (Keese, 
Wegener et al. 2004; Jiang 2012) (Figure 2.2.23.1). A series of these experiments were 
performed in 96 well ECIS plates. All the 96 plates used were new, straight out of the 
packet inside the tissue culture hood, maintaining as sterile conditions as possible. 200 
micro-litres of the normal medium was added to each of the 96 wells on the plate. The 
top cover of the 96 well plate was placed and secured in position by manual pressure 
while was being transferred from tissue culture to the ECIS machine. ECIS machine 
which connected to a computer, which runs the ECIS software and displays the graph by 
the cell impedance changes.  
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Figure 2.2.22.1. How ECIS works. The ECIS machine provides detailed readings on cell 
adhesion and growth, which is recorded in real time. Also, there is provision for 
inflicting the cells with a uniform wound by electroporation, thereby providing further 
detail of their migratory function. The home department not only has the largest array 
of ECIS machines in the country but also has published one of the most useful texts in 
regards to its uses (Jiang 2012). (http://www.biophysics.com/ecis-theory.php) 
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HRT-18 WT, HT-115 WT and RKO WT were the wild types used with their respective 
HRT-18 PEF, HT115-PEF and RKO PEF. Amongst the transfected types, two knockdowns 
were created and verified for each cell type, labelled as HT-115 KD1 and KD2, RKO KD1 
and KD2 and HRT-18 KD1 and KD2. The cell flasks were trypsinised and centrifuged at 
17000 revolutions per minute (RPM) for 5 minutes in universal containers (UCs), 
following which they were re-suspended in 1 ml of medium. Cell dilution was measured 
by using the following. http://www.celeromics.com/en/support/cell-dilutio-
calculator.php 
Each well was seeded with 100,000 cells in 200 micro-litres. Once final dilution volumes 
were measured, they were added to the ECIS plate, and the plate was taken back and 
put into the ECIS machine. Once the plate was fixed firmly into position inside the ECIS 
machine, the plate electrode connection with the machine electrodes was checked, 
which showed all the wells lit up in the green colour, meaning a good connection 
between electrodes had established. The incubator settings were set to 37°C and 95% 
humidity. 
The experiment was then started and delayed wounding was enabled from options and 
the setting was set for eight hours for colorectal cancer cell lines and12 hours for gastric 
cancer cell lines. The current used for wounding was 3000 micro-amperes at a frequency 
of 4000 hertz with time set to 20 seconds. The cells impedance and resistance 
measurements were displayed on the screen off the monitor and were recorded for the 
all-new addition of the experiment and were also saved for a later reference. The 
average of the percentage of increase in impedance of the cells in the initial hours was 
calculated to study cell adhesion. Similarly, the average percentage of increase after a 
successful wounding to the cells was used to calculate the conventional migration essay. 
Once the experiment was completed, used plates were carefully washed with bleach, 
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and disposed of in the yellow clinical waste bins. In the end, the ECIS program was shut 
down, and the computer was switched off. The incubator was cleaned from inside with 
70% ethanol. That experiment was repeated three times for each colorectal cancer and 
gastric cancer cell line. 
The problems encountered during the ECIS experiments were to make sure that there 
were no quality control issues. It was realised that contamination could affect the 
quality of the readings generated inside the wells. 
Great care was taken to prevent any infection or contamination of the cells inside the 
wells. We were also aware that sometimes air bubbles inside the wells could lead to 
defective functioning of the electrode sensors great care was taken to avoid it. Several 
repetitions of the ECIS experiment were undertaken to make sure that the readings 
were consistent and any errors were filtered out and were not included in the final 
analysis. 
2.2.24. Trans-Epithelial Resistance (TER)   
Trans-epithelial or trans-endothelial resistance (TER) is an excellent method for 
assessing barrier function of the reconstructed epithelial of the grown cell lines. It has a 
become method of assessing cell-to-cell tight junction function in vitro. The cells are 
cultured over a porous membrane and grown to become dense, forming cell-to-cell tight 
junctions and establishing cellular polarity. With the help of the chopstick type of 
electrodes in the apparatus, the electrical resistance across the barrier between the cell 
layers can be determined by applying a small AC voltage with varying frequency (Figure 
2.2.24.1& 2.2.24.2).  
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Figure 2.2.24.1: TER How it works  
(http://sites.mc.ntu.edu.tw/sysdata/81/81/doc/efb6ccdbf3aa0193/attach/946.png) 
 
Figure 2.2.24.2: TER Mechanism of action 
(http://sites.mc.ntu.edu.tw/sysdata/81/81/doc/efb6ccdbf3aa0193/attach/946.png) 
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2.2.25. TER: Procedure 
The cells were trypsinised and re-suspended in DMEM, and cell count performed and 
cells diluted to 100,000 per 500 micro-litres. The cell mixture was added to the 
transparent 0.4 micrometre pores sized inserts (Greiner bio-one, Stonehouse, UK). The 
0.4 micro-litre- sized pores membrane acts as a medium for selective diffusion. The 
inserts were placed inside a 24 wells plate. 400 micro-litres of the cell mix was added to 
the inserts and 1000 micro-litres to the wells, containing the inserts. The cells were 
grown to confluence. The medium was replaced with fresh DMEM containing 15Mm 
HEPES, L-gLutamine. (Lonza Laboratories, Verviers, Belgium). Medium alone was added 
to the base of the well (controls) (Martin et al. 2008).  The classical way of measuring 
TER is by the use of hand held electrodes (chopstick-type electrodes). The electrode set 
up allows cell layer impedance measurements. We used the same method by using hand 
held static electrodes (WPI, FL, USA) and EVON volt-ohmmeter (EVON, World Precision 
Instruments, Aston, Herts, UK) (Martin et al. 2004a). Both electrodes were placed inside 
the well, one inside the insert and the other one outside the well.  The resistance was 
measured across the colorectal cancer cell lines - HRT-18 WT, HT-115 WT and RKO WT 
were the wild types used with their respective KDs at intervals from 0 to 240 minutes. At 
the end of each experiment, the medium was removed, and the cells were stained with 
crystal violet and were examined under the microscope to ensure that the cell layers 
had remained attached throughout the experiment. TER experiments give us a relative 
estimation of cell functions such as migration, adhesion and resistance and comparison 
being made between the wild types and transfected cell lines, which are discussed in 
detail in the results section.    
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2.2.26. Immunofluorescence (IF) 
2.2.27. Immunofluorescent Staining of Cells 
Immunofluorescence technique is used for light microscopy with a fluorescent 
microscope. The technique uses specificity of antibodies to their antigen to target 
fluorescent dyes to specific biomolecule targets in a cell, which allows visualisation of 
the presence and distribution of the target molecule.  
 
Figure 2.2.27.1. The basic mechanism of immunofluorescence. (By Alizee Pathology 
LLC. - http://alizeepathology.com) 
 
Figure 2.2.27.1. demonstrates the basic mechanism of immunofluorescence. To the left, 
Primary immunofluorescence is depicted, which shows an antibody with a fluorophore 
group bound directly to the epitope of the specific antigen. Once the antibody binds to 
the epitope, the sample can be viewed under a fluorescent microscope to confirm the 
presence of the antigen in the sample. The right side of the figure shows secondary 
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immunofluorescence, which shows that first, an untagged primary antibody binds to an 
epitope of an antigen in a mechanism similar to the one described above. Once the 
primary antibody has bound to the target, a secondary antibody (which is specific for 
the primary antibody already bound to the antigen) binds to the primary antibody, thus 
increasing the fluorescent signal during microscopy. 
30,000 cells were seeded into each chamber of 8 chamber slides x 8 (Millipore). The cells 
were incubated at 37C in 5% CO2 overnight to achieve confluence and development of 
tight junctions. The media was aspirated, and cells were fixed in 4% formalin for 10 
minutes. The cells were rehydrated in BSS for 20minutes at room temperature. Cells 
were then permeabilised with 1% Triton x 100 made (made in BSS) for 5 minutes. 5% 
serum or TBS diluent was prepared while the cells were getting fixed and washed, which 
was used to dilute the primary and secondary FITC/TRITC reagents as well as blocking 
any non-specific staining. Each good chamber was covered with 150µl to cover the 
whole layer. The serum used in the diluent was from the animal in which the secondary 
was made. 
Non-specific binding was blocked by covering the cells with the diluent and incubated at 
RT for 1 hour.  The reagents were added very carefully on the side walls of the chamber, 
thus preventing any accidental detachment of cells. It was washed three times with TBS. 
Incubation was done with primary antibody at the concentration of 1:100 (made in 
dilute) for 1 hour. The following antibodies were used.  
Primary antibodies used were as follows: 
MAGI-1   SC – 25663  Rabbit  (Santa Cruz Biotechnologies) 
 
Secondary antibodies used were as follows: 
Anti-rabbit IgG  Sigma Aldrich  Rabbit (for MAGI-1) 
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50µl of primary antibody (Rabbit) was added per 5 ml of solution, and secondary 
antibody concentrations were achieved by adding 5µl per 5ml solution for the anti-
rabbit antibody. The negative control was diluted with no primary antibody added. 
Wash was repeated for another three times with TBS. Appropriate sections of were 
incubated with FITC / TRITC solution (stock = 4mg/ml, used 0.5µl per 100µl, gave final 
concentration of 2µg/100µl). TBS wash was repeated three times. Plastic frame from the 
slide was removed, and a coverslip was mounted over the cells using FluorSaveTM, 
avoiding any air bubbles. Slides were placed on a tray, wrapped with foil to prevent any 
fading, and store in the fridge until were viewed under the fluorescent microscope. 
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R O L E  O F  M A G I  P R O T E I N S  I N  I N V A S I V E N E S S  O F  H U M A N  C O L O R E C T A L  
C A N C E R  
 
C H A P T E R  3 :  
E X P R E S S I O N  O F  M A G I  P R O T E I N  I N  H U M A N  C O L O R E C T A L  C A N C E R  
A N D  I T S  C L I N I C A L  C O R R E L A T I O N  
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C H A P T E R  3 :  E X P R E S S I O N  O F  M A G I  P R O T E I N  I N  H U M A N  C O L O R E C T A L  
C A N C E R  A N D  I T S  C L I N I C A L  C O R R E L A T I O N     
3.1. Introduction 
Bowel cancer is the third most commonly diagnosed cancer in the UK. 41,000 new cases 
of bowel cancer were diagnosed in the UK during 2013. Overall survival depends on the 
degree of spread of cancer at the time of diagnosis since it is a metastasis of colorectal 
cancer which often leads to the death of the patient. Cancer spreads by cancer cells 
invading the surrounding tissues. Tight Junctions play an important role in the 
prevention of cancer spread. (Chlenski et al. 1999, Latorre et al. 2005). TJs have been 
widely accepted as the starting point for metastasis in the epithelial cell linings of cancer 
tissues. (Kominsky et al. 2003). The optimising function of TJs can decrease penetration 
of cancer cells through the mesothelial cell linings. (Tobioka et al. 1996). Membrane-
Associated Guanalytes Inverted Orientation (MAGI) -1, -2, -3, play a key role in the 
assembly and maintenance of TJs (Martin et al. 2011). MAGI -1 is widely expressed at 
and have been found to be localised to the epithelial and endothelial cell to cell TJs, and 
acts as a scaffolding molecule to stabilise cadherin-mediated adhesions and to recruit 
molecules in TJ. (Laura et al. 2002). Roles attributed to MAGI include organisation of 
protein complexes at the cell and synaptic junctions, regulation of cell polarity, 
connecting trans-cellular proteins with the cytoskeleton in TJs. (Martin et al. 2011). 
MAGI have also been reported to be involved in cancer cell signaling as a tumour 
suppressor regulator protein (Matsuda et al. 2013). Kranjec et al. highlighted the fact 
that MAGI-1 expression can induce cell growth arrest and apoptosis in Human Papilloma 
Virus (HPV) tumour cells. (Kranjec et al. 2014). MAGI-2 has been shown to play a critical 
role in inhibition of cell migration and proliferation function in hepatic cancer cells (Hu 
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et al. 2007). MAGI -2 may act as a tumour suppressor by its actions, which result in 
stabilising PTEN expression. This binding region is deleted in uterine leiomyomas, 
prostate cancer, and glioblastoma (Wu et al. 2000). MAGI -2 has also been identified as 
playing an important role in human prostate cancer. (Berger et al. 2011), human 
melanomas (Pleasance et al. 2010), cervical cancer (Chen et al. 2014) and in advanced 
adenocarcinoma of the lungs (Kitamura et al. 2014). MAGI -3 may relate to the 
pathogenesis of HTLV-1-associated diseases. (Ohashi et al. 2004). MAGI -3 is a possible 
target site for the Human Papilloma Virus 6 (HPV-6), which is responsible for some 
human cancers. (Thomas et al. 2002). Increased expression of MAGI -1 was identified as 
a suppressor of colorectal cancer and its metastatic activity. (Zaric et al. 2012). MAGI -3 
inhibited LPA induced migration and invasion of colon cancer cells (Lee et al. 2011). 
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3.2. Aims 
We aimed to look at the clinical correlation of expression of MAGI proteins in human 
colorectal cancer, with metastasis and patient survival. For this purpose, we analysed 
quantitative expression levels of MAGI -1, -2 and -3 on Q-PCR in human colorectal 
cancer tissue, compared normal colorectal tissue, about Dukes and TNM staging, with 
attention to local and distal metastasis. We also assessed and compared the level of 
MAGI -1, -2 and -3 expressions on Q-PCR with patient survival. 
   
3.3. Materials and methods 
3.4. Cell lines 
HT-115, HRT-18 and RKO, human colorectal cancer cells with epithelial morphology 
were established from highly invasive human colorectal carcinoma, which expresses 
high amounts of the tumour marker carcinoembryonic antigen. The cells were obtained 
from the European Collection of Animal Cell Culture (ECACC), HECV, human endothelial 
cells were purchased from Interlab, Milan, Italy (Table 3.4.1). Different types of cells for 
both gastric and colonic cancer were chosen due to, firstly, their varying invasiveness 
properties and differential expression patterns of types of MAGI proteins i-e, MAGI -1, -2 
and -3.  
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Table 3.4.1. Specification of colorectal cancer cell lines 
Cell line HHT -115 HRT -18 RKO  
Species Human Human Human 
Tissue Colon Rectum Rectum 
Age 63 67 82 
Gender Male Male Female 
Morphology Epithelial Epithelial-like Epithelial 
Growth mode Adherent Adherent Adherent 
Karyotype 2n=46 2n=46 2n=46 
Tumorigenic Specified Yes Yes 
Country UK UK UK 
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3.3.1.  MAGI primers used 
MAGI-1, MAGI-2 and MAGI-3 primers were designed in-house by using the Beacon 
designer programme, synthesised by Sigma-Aldrich UK, and were stored in -200C 
freezers. The required primers (MAGI -1, -2, -3) were taken out when needed and 
defrosted on room temperature, following which they were diluted to 1:100 
concentration using PCR water. Subsequently, the diluted primers were stored in a 
designated primer fridge for future use, and the originals were returned to the freezer. 
3.3.2. Reverse transcription polymerase chain reaction (RT-PCR) of RNA 
Once RNA had been isolated and quantified, RT-PCR was carried out to convert RNA into 
complementary DNA (cDNA) using DuraScriptTM RT PCR kit (Sigma-Aldrich, Dorset, UK). A 
fixed amount of 0.5 micrograms of RNA was converted to cDNA as per protocol. RNA 
concentrations were Standardised and used in Q-PCR.  
3.3.3. Quantitative Polymerase Chain Reaction (Q-PCR) 
Q-PCR is an exceedingly sensitive technique for measuring and quantifying minute 
amounts of genetic material. The c-DNA of HRT-18, RKO and HT-115 colorectal cancer 
cell lines was used. The thermo-cycler settings were set to 36 cycles as the standard for 
expression of MAGI. 
 
3.4. Data analysis 
The relationship between MAGI -1, -2 and -3 expression and tumour grade, TNM staging 
and nodal status was analysed using Mann-Whitney U tests. Survival analysis curve was 
performed using Kaplan-Meier survival analysis and Kruskal – Wallis tests. Differences 
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were considered to be statistically significant at p<0.05.  
 
3.5. Results 
3.5.1. Q-PCR analysis of MAGI expression in human colorectal cancer 
The expression of MAGI -1, -2 and -3, on Q-PCR, were plotted on to the tables below 
(3.5.1.1, 3.5.1.2 and 3.5.1.3). Data were analysed using Mann-Whitney U tests, and 
differences were considered statistically significant where p value was equal to or less 
than 0.05. We analysed MAGI -1, -2 and -3 expressions in normal tissue and tumour 
tissue in our cohort, which showed consistent trends of lower expression of MAGI in 
tumour tissues. 
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Table 3.5.1.1. Correlation between expression of MAGI -1 and clinical parameters 
  
MAGI-1 GAPDH normalised 
 N Median Significance 
Normal 72 1437 0.225 
Tumour 90 1  
    
Paired Normal 60 1220 0.023 
Paired Tumour 65 2  
    
Normal 72 1437 0.802 
Differentiation 1 2 0.533  
    
Normal 72 1437 0.263 
Differentiation  2 & 3 65 1  
    
Differentiation 1 2 0.533 0.671 
Differentiation  2&3 65 1  
    
Node 0 36 1 0.914 
Node 1&2 31 0.7  
    
Normal 72 1437 0.593 
TNM1 9 0.17  
    
Normal 72 1437 0.659 
TNM4 6 0.1  
    
TNM 1 9 0.17 0.061 
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TNM 2&3&4 59 2  
    
Normal 72 1437 0.802 
T 1 2 42.7  
    
Normal 72 1437 0.263 
T 2&3&4 65 1  
    
T 1 2 42.7 0.955 
T 2&3&4 65 1  
    
Normal 72 1437 0.635 
Dukes A 7 0.3  
    
Normal 72 1437 0.269 
Duke-BC 62 2  
    
Dukes A 7 0.3 0.237 
Dukes BC 62 2  
    
Treat Non 38 1 0.166 
Chemo Radio 5 3.74  
    
Non Invasive 47 1 0.929 
Invasive 25 1.7  
    
No Dis Met 47 1 0.815 
Dis Met 19 1.7  
    
Alive 34 1.68 0.965 
Died 21 0.71  
112 
 
The clinical correlation in MAGI -1 expression and clinical parameters is depicted in 
Table 3.5.1.1. We investigated MAGI -1 expression in 162 (normal background = 72; 
tumour = 90) samples of which 126 were paired samples (n = 63 pairs) of patients with 
colorectal adenocarcinoma using real-time PCR. The p-value marked in red shows a 
significant reduction in expression of MAGI -1, in paired tumour tissue when compared 
to paired normal colorectal tissue (P-value 0.023). The other value which reaches near 
to statistical significance (0.061 - marked in green), shows that there was a marked 
reduction in expression levels of MAGI -1 mRNA transcripts on Q-PCR in the tumour 
tissue when compared with the normal colorectal tissue between the TNM1 and TNM 
2,3 & 4 stages of tumours. However most of the results did not achieve statistical 
significance, but overall trends were of significance for their consistent pattern of the 
same theme, that was a reduced expression of MAGI -1 in tumour tissues when 
compared to the normal tissue. A marked reduction in expression levels of MAGI -1 
mRNA transcripts on Q-PCR in Dukes A and Dukes B & C colorectal cancer tissue, when 
compared with normal colorectal tissue was noticed, which suggested an important 
correlation between cancer metastasis and reduced levels of MAGI -1.  Also of note was 
a marked reduction in expression levels of MAGI -1 mRNA transcripts on Q-PCR in TNM1 
and TNM4 colorectal cancer tissue, when compared with normal colorectal tissue. All of 
the above findings suggest an important correlation between cancer metastasis and 
reduced levels of MAGI -1.  
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Table 3.5.1.2. Correlation between expression of MAGI -2 and clinical parameters 
  
MAGI-2 GAPDH normalised 
 N Median Significance 
Normal 71 5132 0.416 
Tumour 94 3  
    
    
Paired Normal 61 4406 0.001 
Paired Tumour 68 2  
    
Normal 71 5132 0.852 
Differentiation  1 2 111  
    
Normal 71 5132 0.476 
Differentiation  2 & 3 68 3  
    
Differentiation  1 2 111 0.943 
Differentiation 2&3 68 3  
    
Node 0 39 2 0.594 
Node 1&2 31 4.6  
    
Normal 71 5132 0.686 
TNM1 9 0.6  
    
Normal 71 5132 0.739 
TNM4 6 7.5  
    
TNM 1 9 0.6 0.829 
TNM 2&3&4 62 4  
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Normal 71 5132 0.852 
T 1 2 1.43  
    
Normal 71 5132 0.476 
T 2&3&4 68 4  
T 1 2 1.43 0.929 
T 2&3&4 68 4  
    
Normal 71 5132 0.720 
Dukes A 7 0.6  
    
Normal 71 5132 0.485 
Duke-BC 65 4  
    
Dukes A 7 0.6 0.856 
Dukes BC 65 4  
    
Treat Non 42 2 0.604 
Chemo Radio 5 25  
    
Non Invasive 50 3 0.681 
Invasive 26 2.9  
    
No Dis Met 50 2 0.951 
Dis Met 19 12.9  
    
Alive 36 1.42 0.097 
Died 22 7.7  
115 
 
 
The clinical correlation in MAGI -2 expression and clinical parameters is depicted in table 
3.5.1.2. We investigated MAGI -2 expressions in 165 (normal background = 71; tumour = 
94) samples of which 130 were paired samples (n = 65 pairs) of patients with colorectal 
adenocarcinoma using real-time PCR. The only p-value to reach statistical significance 
(0.001 marked in red) was between MAGI-2 levels for Paired Normal and Paired Tumour 
samples. There was marked a reduction in expression levels of MAGI -2 mRNA 
transcripts on Q-PCR in a tumour and paired tumour tissue, when compared with 
normal and paired normal colorectal tissue, suggesting the possibility of an important 
correlation between cancer metastasis and reduced levels of MAGI -2.  There was a 
marked reduction in expression levels of MAGI -2 mRNA transcripts on Q-PCR in Dukes A 
and Dukes B & C when compared with normal colorectal tissue, again suggesting the 
possibility of an important correlation between cancer metastasis and reduced levels of 
MAGI -2.  There was a marked reduction in expression levels of MAGI -2 mRNA 
transcripts on Q-PCR in TNM1 and TNM4, when compared with normal colorectal tissue, 
suggesting the possibility of an important correlation between cancer metastasis and 
reduced levels of MAGI -2. However, despite these encouraging trends, we did not find 
positive expression of MAGI -2 in the colorectal cancer cell lines (HT-115, HRT-18 and 
RKO) which we used but in our experimental work (presented later in the Chapter).  
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Table 3.5.1.3 Correlation between expression of MAGI -3 and clinical parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MAGI-3 GAPDH normalised 
 N Median Significance 
Normal 64 1 0.761 
Tumour 74 0  
    
Paired Normal 53 2 0.849 
Paired Tumour 53 2  
    
Normal 64 1 0.837 
Differentiation 1 2 1840849  
    
Normal 64 1 0.693 
Differentiation 2 & 3 54 0  
    
Differentiation 1 2 1840849 0.774 
Differentiation 2&3 54 0  
    
Node 0 31 0 0.830 
Node 1&2 25 0  
    
Normal 64 1 0.692 
TNM1 7 914083  
    
Normal 64 1 0.837 
TNM4 2 0.0436  
    
TNM 1 7 914083 No more data 
TNM 2&3&4 49 0  
    
Normal 64 1  
T 1 2 1.04E+08  
    
Normal 64 1  
T 2&3&4 54 0  
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The clinical correlation in MAGI -3 expression and clinical parameters is depicted in table 
3.5.1.3. We investigated MAGI -3 expressions in 138 (normal background = 64; tumour = 
74) samples of which 106 were paired samples (n=53 pairs) of patients with colorectal 
adenocarcinoma using real-time PCR. There were no statistically significant values with 
regards to the clinical correlation of MAGI -3 expressions in different subgroups of 
colorectal cancer. This may be due to the low level of MAGI -3 expression in our tissue 
samples.   
 
3.6. Correlation between MAGI -1 expression and clinical parameters 
The correlation between expression levels of MAGI -1 on Q-PCR in human colorectal 
cancer tissues, with Dukes’ and TNM staging and overall prognosis, was made. The data 
was analysed, and comparison was drawn. Marked reduction in expression levels of 
MAGI -1 mRNA transcripts were found on Q-PCR in Dukes A, B, C and B & C combined 
when compared with normal colorectal tissue (Figure 3.6.1). This suggested an 
important correlation between cancer metastasis according to Dukes' classification and 
reduced levels of MAGI -1. Marked reduction in expression levels of MAGI -1 mRNA 
transcripts were also found on Q-PCR in TNM1, TNM2, TNM3 and TNM 2&3&4 
combined when compared with normal colorectal tissue (Figure 3.6.2), again suggesting 
an important correlation between cancer metastasis according to TNM classification and 
reduced levels of MAGI -1. Correlation of MAGI -1 expression in normal, non-invasive 
and invasive, disease-free, non-recurrence and recurrence cases of human colorectal 
cancer patients was made. There was marked a reduction in expression levels of MAGI -
1 mRNA transcripts on Q-PCR in colorectal cancer tissues including non-invasive and 
invasive, disease-free, non-recurrence and recurrence types when compared to normal. 
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However, there was no overall significant difference between the expression of MAGI -1 
on Q PCR between non-invasive and invasive, disease-free, non-recurrence and 
recurrence groups (Figure 3.6.3). Therefore, we suggest that MAGI -1 expression has 
little or no effect on overall prognosis of colorectal cancer patients, however, there is a 
clear correlation between reduced levels of MAGI -1 and colorectal cancer metastasis. 
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Figure 3.6.1. Expression of MAGI -1 in Normal and Dukes A and Dukes B & C: There 
was marked a reduction in expression levels of MAGI -1 mRNA transcripts on Q-PCR in 
Dukes A and Dukes B & C colorectal cancer tissue when compared with normal 
colorectal tissue. The above findings suggest an important correlation between cancer 
metastasis and reduced levels of MAGI -1  
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Figure 3.6.2. Expression of MAGI -1 in Normal and TNM1, TNM2, TNM3 and 
TNM2&3&4: There was marked a reduction in expression levels of MAGI -1 mRNA 
transcripts on Q-PCR in TNM1, TNM2, TNM3 and TNM 2&3&4 colorectal cancer tissue 
when compared with normal colorectal tissue. The above findings suggest an 
important correlation between cancer metastasis and reduced levels of MAGI -1. 
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Figure 3.6.3. Relation of MAGI -1 expression in normal, non-invasive and invasive, 
disease-free, non-recurrence and recurrence cases of human colorectal cancer 
patients. There was a marked reduction in expression levels of MAGI -1 mRNA 
transcripts on Q-PCR in normal, non-invasive and invasive, disease-free, non-
recurrence and recurrence cases, when compared to normal, but overall no significant 
difference between non-invasive and invasive, disease-free, non-recurrence and 
recurrence cases. Hence, the level of MAGI -1 expression had no or little effect on 
overall prognosis of the patients. 
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3.7. Correlation between MAGI -2 expression and clinical parameters 
The correlation between expression levels of MAGI -2 on Q-PCR in human colorectal 
cancer tissues, with Dukes’ and TNM staging and overall prognosis, was made. The data 
was analysed, and a comparison was drawn. Marked reduction in expression levels of 
MAGI -2 mRNA transcripts was found on Q-PCR in Dukes A, B, C and B & C combined 
when compared with normal colorectal tissue (Figure 3.7.4). This suggested an 
important correlation between cancer metastasis according to Dukes' classification and 
reduced levels of MAGI -2. Marked reduction in expression levels of MAGI -2 mRNA 
transcripts was also found on Q-PCR in TNM1, TNM2, TNM3 and TNM 2&3&4 combined 
when compared with normal colorectal tissue (Figure 3.7.5), again suggesting an 
important correlation between cancer metastasis according to TNM classification and 
reduced levels of MAGI -2. The relation of MAGI -2 expressions in normal, non-invasive 
and invasive, disease-free, non-recurrence and recurrence, cases of colorectal cancer 
patients was observed. Again, reduced levels of MAGI -2 mRNA transcripts on Q-PCR in 
colorectal cancer tissues, including non-invasive and invasive types, disease-free, non-
recurrence and recurrence type; were found when compared to healthy ones. However, 
there was no overall significant difference found in the expression of MAGI -2 with Q 
PCR between non-invasive and invasive, disease-free, non-recurrence and recurrence 
groups (Figure 3.7.6.1). Therefore, we concluded that MAGI -2 expressions had no or 
little effect on overall prognosis of the patients, but there was a clear correlation 
between reduced levels of MAGI -2 and colorectal cancer metastasis.  
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Figure 3.7.1. Expression of MAGI -2 in Normal and Dukes A and Dukes B & C: There 
was marked a reduction in expression levels of MAGI -2 mRNA transcripts on Q-PCR in 
Dukes A and Dukes B & C colorectal cancer tissue when compared with normal 
colorectal tissue. The above findings suggest an important correlation between cancer 
metastasis and reduced levels of MAGI -2. 
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Figure 3.7.2. Expression of MAGI -2 in Normal and TNM1, TNM2, TNM3 and 
TNM2&3&4: There was marked a reduction in expression levels of MAGI -2 mRNA 
transcripts on Q-PCR in TNM1, TNM2, TNM3 and TNM 2&3&4 colorectal cancer tissue 
when compared with normal colorectal tissue. The above findings suggest an 
important correlation between cancer metastasis and reduced levels of MAGI -2. 
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Figure 3.7.6.1  Relation of MAGI -2 expressions in normal, non-invasive and invasive, 
disease-free, non-recurrence and recurrence cases of human colorectal cancer 
patients. There was a marked reduction in expression levels of MAGI -2 mRNA 
transcripts on Q-PCR in normal, non-invasive and invasive, disease-free, non-
recurrence and recurrence cases, when compared to normal, but overall no significant 
difference between non-invasive and invasive, disease-free, non-recurrence and 
recurrence cases. Hence the level of MAGI -2 expressions had no or little effect on 
overall prognosis of the patients.  
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3.8. Survival Curves 
The difference between the expression of MAGI -1, -2 and -3 combined and individual 
expression of MAGI -1, -2 and -3, about overall survival, and disease-free survival were 
analysed using Mann – Whitney U and Kruskal – Wallis tests. Survival curves were 
plotted by using Kaplan – Meier survival analysis (Figures 3.8.1, 3.8.2, 3.8.3,.3.8.4, 3.8.5, 
3.8.6, 3.8.7 and 3.8.8). Differences were considered statistically significant where the 
value of p was equal to or less than 0.05. We looked at the overall survival rate and 
disease-free survival in our cohort, which showed consistent trends of higher survival 
rate in patients with increased levels of expression of MAGI proteins. Combined analysis 
of all MAGI -1, -2, and -3 proteins showed significant statistical results in both overall 
and disease-free survival rates (Wilcoxon statistical significance of 0.015 and 0.045) in 
patients with increased expression of MAGI proteins (Figure 3.8.1 and 3.8.2). Overall 
survival of patients with increased expression levels of MAGI-1 showed higher survivals 
rates, close to statistical significance (0.074) (Figure 3.8.3).  
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Figure 3.8.1. MAGI-1,-2 & -3 COMBINED ANALYSIS, OVERALL SURVIVAL: Showing 
Kaplan-Meier survival curves in correlation to MAGI -1, -2, and -3 levels combined and 
overall patient's survival. Patients who had low levels of MAGI -1, -2 and -3 combined, 
had a relative reduced survival when compared to patients with higher levels of MAGI 
-1, -2 and -3 combined (P-value 0.015).                        
Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
5.888 1 .015 
a. Comparisons are exact. 
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Figure 3.8.2. MAGI-1,-2 & 3 COMBINED ANALYSIS, DISEASE FREE SURVIVAL: Showing 
Kaplan-Meier survival curves in correlation to MAGI -1, -2, and -3 combined and 
overall patient's disease-free survival. Patients who had low levels of MAGI -1, -2 and -
3 combined, had a relatively reduced disease-free survival when compared to patients 
with higher levels of MAGI -1, -2 and -3 combined (P-value 0.045).                        
Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
4.004 1 .045 
a. Comparisons are exact. 
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Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
 
 
3.188 1 .074 
a. Comparisons are exact. 
 
Figure 3.8.3. MAGI -1 OVERALL SURVIVAL: Showing Kaplan-Meier survival curves in 
correlation to MAGI -1 and overall patient survival. Patients who had low levels of 
MAGI -1, had a relatively reduced overall survival when compared to patients with 
higher levels of MAGI -1. 
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Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
1.731 1 .188 
a. Comparisons are exact. 
 
Figure 3.8.4. MAGI -1 DISEASE-FREE SURVIVAL: Showing Kaplan-Meier survival curves 
in correlation to MAGI -1 and disease-free patient survival. Patients who had low 
levels of MAGI -1, had a relatively reduced disease-free survival when compared to 
patients with higher levels of MAGI -1. 
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Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
1.868 1 .172 
a. Comparisons are exact. 
Figure 3.8.5. MAGI -2 OVERALL SURVIVAL: Showing Kaplan-Meier survival curves in 
correlation to MAGI -2 and overall patient survival. Patients who had low levels of 
MAGI -2, had a relatively reduced overall survival when compared to patients with 
higher levels of MAGI -2.                        
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Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
.141 1 .707 
a. Comparisons are exact. 
 
Figure 3.8.6. MAGI -2 DISEASE-FREE SURVIVAL: Showing Kaplan-Meier survival curves 
in correlation to levels of MAGI -2 and patients' disease-free survival. Patients who 
had low levels of MAGI -2 had a relatively reduced disease-free survival when 
compared to patients with higher levels of MAGI -2.                        
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Figure 3.8.7. MAGI -3 OVERALL SURVIVAL: Showing Kaplan-Meier survival curves in 
correlation to MAGI -3 and patients overall survival. Patients who had low levels of 
MAGI -3, had a relatively reduced overall survival when compared to patients with 
higher levels of MAGI -3.        
Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
.979 1 .323 
a. Comparisons are exact. 
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Figure 3.8.8. MAGI-3 DISEASE-FREE SURVIVAL: Showing Kaplan-Meier survival curves 
in correlation to MAGI -3 and patients' disease-free survival. Patients who had low 
levels of MAGI -3, had a relatively reduced disease-free survival when compared to 
patients with higher levels of MAGI -3.                        
 
Overall Comparisons 
Wilcoxon 
(Gehan) 
Statistic 
df Sig. 
.602 1 .438 
a. Comparisons are exact. 
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Survival curves showed an increase in overall survival and disease-free survival 
in our cohort with consistent trends of higher survival rates with increased MAGI -1, -2 
and -3 expression levels in patients. This was consistent with MAGI -1, -2 and -3 
expression on Q-PCR in normal tissue and tumour tissue in our cohort, which showed 
consistent trends of higher expression levels of MAGI in the normal tissue in comparison 
to tumour tissue.  Survival curves were also consistent with the increased expression of 
MAGI -1 and -2 in normal colorectal tissue when compared to a metastatic disease. 
3.9. Discussion: 
There is evidence in the literature that MAGI protein plays an important role in 
stabilising TJs, and thereby inhibiting invasion and migration of colorectal cancer cells.  
Landy et al. suggested that the dysregulation of TJs proteins precede the development 
of inflammatory bowel disease (IBD), and also leads to the development of IBD 
associated colorectal cancer (CRC). (Landy et al. 2016) Zaric et al. identified MAGI -1 
over-expression as a suppressor of colorectal cancer and its metastatic activity. (Zaric et 
al. 2012) Lee et al. found over-expression of MAGI -3 to inhibit LPA induced migration 
and invasion of colon cancer cells, whereas by knocking down MAGI -3 continues the 
repeated effect of NHERF -2 over-expression (Lee et al. 2011). We found decent 
evidence in the literature that MAGI proteins (-1, -2, and 3) play an important role in 
cancer metastasis; however, there was limited information on their types (MAGI -1, 
MAGI -2 and MAGI -3), especially in human colorectal cancer metastasis. So we decided 
to check MAGI -1, -2 and -3 expression and their significance in human colorectal cancer 
metastasis using Q-PCR and the effect of individual types of MAGI (-1, -2 and -3) 
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expression on survival in patients. We started off by using quantitative PCR to 
demonstrate that expression levels of MAGI-1 were decreased in the paired tumour 
tissues than the normal tissues (statistically significant, p-value 0.023) (Table 3.5.1.1). 
Also, that expression levels of MAGI -1 were decreased in the TNM stage -2, -3 and -4 
when compared with TNM stage -1. The results were consistent with the trend and also 
were near to achieving statistical significance (0.061) (Table 3.5.1.1). Although the 
numbers were small and did not achieve statistical significance, the trends were 
consistent with the low expression of MAGI-1 associated with colorectal cancer 
metastasis (Table 3.5.1.1). It was possible that the few statistically significant results 
were due to the low power of our sample, but the consistency in the trends certainly 
was remarkable and stood out. We had similar results for decreased expression levels of 
MAGI-2 in a tumour paired and normal tissue with statistical significance (0.001) (Table  
3.5.1.2), but we did not have samples achieving statistical significance in MAGI-3 (Table 
3.5.1.3), which was probably due to the small numbers and reduced number of samples. 
Survival curves showed an increase in overall survival and disease-free survival in our 
cohort with consistent trends of higher survival rates from increased MAGI expression 
levels in tissue. Combined analysis of MAGI -1, -2 and 3 (Figure 3.8.1 and 3.8.2) showed 
higher survival rates in both, overall and disease-free survival, which were of statistical 
significance (Wilcoxon statistical significance of 0.015 and 0.045). Survival curves of 
individual MAGI -1, -2 and 3 were consistent with a similar pattern, and showed a higher 
rate of survival with increased expression of individual MAGI type (MAGI -1 and -2) 
(Figures 3.8.1, 3.8.2, 3.8.3, 3.8.4, 3.8.5 and 3.8.6). Although individual MAGI type (MAGI 
-1, -2, -3) results did not reach statistical significance, the trends were consistent with 
increased overall survival and disease-free survival in tissues with increased expression. 
MAGI-1 overall survival was of note as it reached near statistical significance (0.074) 
(Figure 3.8.3). 
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mRNA transcripts of MAGI -1 and -2 expressions were found to be reduced about Dukes' 
and TNM classifications of cancer metastasis when compared with normal colorectal 
tissue (Figure 3.6.1, 3.6.2 and 3.7.4, 3.7.5). However, there was no overall significant 
difference found in the expression of MAGI -1 and -2 on Q PCR between non-invasive 
and invasive, disease-free, non-recurrence and recurrence groups (Figure 3.6.3 and 
3.7.6.1). Therefore, we concluded that MAGI – 1 and -2 expression had no or little effect 
on overall prognosis of the patients, but there was a clear correlation between reduced 
levels of MAGI -2 and colorectal cancer metastasis. As we have mentioned before, from 
literature review and our analysis of MAGI protein expression in human colorectal 
cancer cell lines (presented later in the thesis) and also from the increased disease-free 
survival of our cohort, we had compelling evidence that MAGI proteins play an 
important role in the invasiveness and metastasis in human colorectal cancer, through 
their role in maintenance of TJ functions and strength. MAGI are a novel set of proteins 
and its types MAGI -1, -2 and -3, is a potential area of further research work, which was 
positively supported by the results of our initial experimental work. MAGI proteins have 
significant clinical relevance which makes them worthwhile of not only a fascinating and 
attractive area of research, but moreover has the potential for a future therapeutic 
agent. 
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R O L E  O F  M A G I  P R O T E I N S  I N  I N V A S I V E N E S S  O F  H U M A N  C O L O R E C T A L  
C A N C E R  C E L L S .  
 
C H A P T E R  4 :  
M A G I  -  E X P R E S S I O N  I N  C O L O R E C T A L  C A N C E R  C E L L  L I N E S  A N D  
C R E A T I O N  O F  K N O C K D O W N S  ( K D S )  
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4.1.1. Introduction 
MAGI (Membrane Associated Guanylate Kinase with the inverted arrangement of 
protein-protein interaction domains) are peripherally associated cytoplasmic proteins, 
active in tight junctions (TJ). MAGI proteins were first reported by Dobrosotskaya et al. 
in 1997 as prototypical members of membrane-associated guanylate kinase (MAGUK) 
family as part of Drosophila disc large tumour suppressor protein. (Dobrosotskaya et al. 
1997). MAGUK family of proteins are mainly found in the assembly of multiple protein 
complexes on the inner surface of the plasma membrane at regions of the cell to cell 
contact points (TJs) in epithelial cells and synaptic junctions in neurons. The three types 
of MAGI proteins are MAGI -1, MAGI -2, and MAGI -3, based on their highest degree of 
to the central PDZ domains with the inverted orientation of the GuK domain and SH3 
domain and their significant resemblance in protein to protein interactions. MAGI -1 is 
reported to be expressed widely expressed in different tissues and tumours, whereas 
MAGI -2 whereas MAGI -2 are reported to be predominantly expressed in the brain and 
renal tissue. MAGI -3 is reported to be expressed in various tissues, including foetal and 
adult, and also in tumours. (Wu et al. 2000). MAGI proteins are active in the 
organisation of protein complexes at the cell and synaptic junctions, regulation of cell 
polarity, connecting trans-cellular proteins with the cytoskeleton in TJs. (Martin et al. 
2011). MAGI is expressed in cell-to-cell contact junctions, which are focal points for 
restraining of not only the disruption of junctional complexes but also the 
commencement of tumour cell invasion (Kotelevets et al. 2005). Knocking down of 
MAGI protein causes a loss of junctional compartmentalisation along the lateral 
membrane, and reduces the overall robustness of cell-to-cell adhesion (Stetak et al. 
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2010). Focusing on MAGI -1 in colorectal cancer, it is reported in the literature that over-
expression in colorectal cancer cells, suppresses metastasis (Zaric et al. 2012).  
 
4.1.2. Aims 
We aimed to study the expression of MAGI -1, -2 and -3 in human colorectal cancer 
cells. We expressed MAGI -2 in human gastric cancer cell lines and used it as a control to 
lack of MAGI 2 expression in colorectal cancer cell lines. Furthermore, we aimed to 
create MAGI -1 knockdowns (KD), to study their effect on changes in cell morphology on 
microscopy and on the strength of TJs between cells by using immunofluorescence in 
human colorectal cancer cell lines. We also studied the effect of KD of MAGI -1 on 
colorectal cancer cell invasion and migration (described in next chapter (chapter 5)). 
 
4.1.3. Materials:  
4.1.3.1. Cell lines:  
HT -115, HRT -18 and RKO, three different types of colorectal cancer cell lines were 
chosen and tested for expression MAGI -1, -2 and -3. MAGI -1 and MAGI -3 were found 
to have a positive expression; however, we did not have MAGI -2 expressions in 
colorectal cancer cell lines. Therefore, gastric cell lines (AGS and HGC -27) were used as 
controls for MAGI -2 expressions. The details of colorectal cancer and gastric cancer cell 
lines used were as follows (Table 4.1.3.1.1 & 4.1.3.1.2). 
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  Table 4.1.3.1.1. Specification of colorectal cancer cell lines 
Cell line HT -115 HRT -18 RKO  
Species Human Human Human 
Tissue Colon Rectum Rectum 
Age 63 67 82 
Gender Male Male Female 
Morphology Epithelial Epithelial-like Epithelial 
Growth mode Adherent Adherent Adherent 
Karyotype 2n=46 2n=46 2n=46 
Tumorigenic Specified Yes Yes 
Country UK UK UK 
 
Table 4.1.3.1.2. Specification of gastric cancer cell lines 
Cell line AGS HGC - 27  
Organism Human Human  
Tissue Stomach Lymph node  
Age 54 Unspecified  
Gender Female Unspecified  
Morphology Epithelial Epithelial  
Growth mode Adherent Adherent  
 
(The cells were obtained from the European Collection of Animal Cell Culture (ECACC)) 
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4.1.4. MAGI primers used 
MAGI-1, MAGI-2 and MAGI-3 primers were used, by Invitrogen (Paisley, UK), were 
stored in freezers in the home department. MAGI -1, -2, -3 primers were diluted to 1:10 
concentration by adding PCR water, ready to use (Table 4.1.4.3). 
 
Table 4.1.4.3. Primer sequences 
 
 
     
Primers Forward Reverse 
MAGI-1 
(F11 R11) 
CTCC AAGAAA CAGCA TTACC CTGAA GTGG AACTT CTCTGG 
MAGI-2 
(F11 R11) 
CAGTG ACTAC GCAA CCT ACA   GGATG TCT GGTTT CACA TCT 
MAGI-2 
(F12 R12) 
TCAAGG ATGCA GGTCTT AGT CTTATT GCTGG TCCA TCTTC 
MAGI-3 
(F12 R12) 
GGGAAA TCA CAC AAACAA GT TGAG ACAG TTCAA CAAT GGA 
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4.2. Methods. 
4.2.1. Generation of mutant RKO, HT-115 and HRT-18 cell lines with the MAGI-1 
knockdown. 
 The pEF6/V5-His TOPO® TA expression system (Invitrogen, Paisley, UK) provides a highly 
efficient one-step cloning technique which does not require ligase, post-PCR procedures, 
or PCR primers containing specific sequences. Such an approach allows the direct 
insertion of Taq polymerase-amplified PCR products into a plasmid vector for 
constitutive expression in mammalian cells after transfection. The line raised pEF6/V5-
His TOPO® vector in the kit consists of single, overhanging 3' deoxythymidine (T) 
residues which allow Taq polymerase-amplified PCR products, containing a single 
deoxyadenosine (A) at the 3’ ends, to ligate efficiently. The EF-1 promoter in pEF6/V5-
His TOPO® then enables the constitutive expression of the PCR product after the 
transfection of the plasmid. 
The PCR products were cloned into pEF6/V5-His TOPO® plasmids, and the total 6µl 
cloning  
reaction was mixed and stored on ice in advance to the One Shot Chemical 
Transformation (Invitrogen, Paisley, UK). The condition used for TOPO cloning reaction 
was as follows: 
o PCR product - 4µl 
o Salt solution - 1µl 
o TOPO vector - 1µl 
5µl of TOPO cloning reaction was added into each vial of One Shot TOP10 Chemically 
Competent E. coli. (Invitrogen, Paisley, UK) and mixed gently by stirring using the pipette 
tip. The vial was stored on ice for 5-30 minutes (based on the product size) before heat-
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shocking at 42ᵒC for 30 seconds followed by immediately transferring into ice. To each 
vial, 250µl of room temperature S.O.C medium was added, and the tubes were shaken 
at a 45ᵒ angle at 225rpm on a horizontal orbital shaker (Bibby Stuart Scientific, UK) at 
37ᵒC for 1 hour. After the incubation period, the transformed products from each vial 
were spread in different seeding density on a pre-warmed agar petri dish containing 
100µg/ml ampicillin followed by incubating overnight at 37ᵒC. Several colonies from 
each petri dish were randomly picked, and the PCR product insertion and orientation of 
the incorporated PCR product were checked by PCR using primer combination of T7F vs 
BGHR and T7F vs specific forward or reverse primer respectively. The reaction mix is 
outlined as follows:  
PCR product insertion primer pair mix (used for overexpression sequences) 
o GoTaq Green master mix - 8µl 
o T7F plasmid specific forward primer - 1µl 
o BGHR plasmid specific reverse primer - 1µl 
o PCR water -6µl 
For ribozyme transgene insertion and orientation checking, the molecule specific 
forward and reverse primer was replaced in the above mixtures with forward (RbToPF) 
and reverse (RbBMR) sequences to the common region of the ribozyme transgene. Each 
colony was inoculated into both reaction mixes using a sterile pipette tip, and the 
reaction mixes were placed in a 2720 Thermal Cycler (Applied Biosystems, Paisley, UK). 
The PCR reaction conditions were used as follows: 94ᵒC for 5 minutes, followed by 30 
cycles of 94ᵒC for 30 seconds, 55ᵒC for 40 seconds and 72ᵒC for 1 minute with a final 
extension step of 72ᵒC for 10 minutes. Gel electrophoresis on a 2% agarose gel stained 
with a SYBR Safe DNA gel stain was utilised to visualise the conventional PCR reaction 
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products. Colonies with correctly orientated PCR product inserts were inoculated into 
universal tubes containing 5ml of selective LB broth (containing 100µg/ml ampicillin) 
followed by being incubated overnight at 37ᵒC while being shaken with the 45ᵒ angle at 
225rpm. 
4.2.2.  Plasmid amplification and extraction 
Plasmid extraction was undertaken using the Sigma GenElute Plasmid MiniPrep Kit 
(Sigma, Dorset, UK) based on the protocol provided. The overnight incubated universal 
tubes containing the chosen colonies were centrifuged at 5,000RCF to acquire a 
bacterial pellet. The supernatant in each tube was discarded, and the bacterial pellet 
was re-suspended thoroughly using 200µl Resuspension Solution containing RNase A 
and transferred into a 1.5ml Microfuge tube. To the Microfuge tube was added 200µl of 
Lysis Solution followed by eight gentle inversions. This lysis stage was conducted within 
5 minutes to avoid permanent plasmid denaturation. Then, 350µl of Neutralisation 
Solution was added, and the microfuge tube was gently inverted six times followed by 
centrifugation at 12,000g for 10 minutes to pellet the cell debris. The clear lysate in the 
Microfuge tube was transferred into a Mini-prep Binding Column which was placed into 
a micro-centrifuge Tube. Such Mini-prep Binding Column was washed with Column 
Preparation Solution in advance to maximise plasmid binding capacity. The clear lysate 
added micro-centrifuge Tube was then centrifuged for 1 minute at 12,000g to enable 
the plasmid binding to Mini-prep Binding Column. The flow-through liquid was 
discarded, and 700µl of Wash Solution (containing ethanol) was added to the Mini-prep 
Binding Column followed by centrifugation at 12,000g for 1 minute before discarding 
the flow-through liquid. The Microfuge tube was then centrifuged again at 12,000g for 1 
minute to remove the remaining Wash solution before the Mini-prep Binding Column 
was transferred into a fresh Collection Tube. The plasmid was eluted by adding 50µl of 
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Elution Solution followed by spinning the fresh Collection Tube at 12,000g for 1 minute 
and was stored at -20°C for further use. Knockdowns (KDs) were created by using 
ribozymes containing purified plasmids for MAGI -1 gene KD. 2 different ribozymes were 
used for each WT cell line. Electroporation was used to introduce the plasmids into the 
cells. 
4.2.3. Transfection by electroporation 
The WT cancer cells were grown in T25 flasks to reach full confluence so that the TJs had 
formed and were well established. The culture medium was removed, and the flasks 
were washed with BSS solution twice. 1 ml of TRI Reagent (Sigma-Aldrich) was added to 
the flask, and the flask was kept in the incubator for 5 minutes. After 5 minutes the 
detached cells floated in the reagent. The leftover attached cells were detached from 
the surface by gently tapping on the flask. The cell lysate was transferred into the pre-
labelled universal tube, and 4ml of the normal medium was added to make up the total 
volume of 5ml. The mixture was centrifuged at 1700rpm for 8 minutes to pellet the 
cells. The supernatant was aspirated, and the pellet was re-suspended in 2 ml of normal 
medium. 500 micro-litres of the stock was transferred into four pre-labelled 
electroporation sterile cuvettes for each cell type. These included WT, two different 
ribozymes containing purified plasmids for MAGI -1 gene (KD1 and KD2), and ribozymes 
containing empty plasmids (PEF). The WT and PEFs were used as controls. Once the 
vector was added, 30 seconds were given for dispersion. The cuvettes were sealed by 
placing the lid back on and were put into the electroporation chamber. Standard 
settings were used for electroporation. Cells were subjected to electrical pulse 1500 
farads and 300 volts. The injured cells were transferred to T25 flasks with 5ml of normal 
growth medium and were incubated at 37C, 5% CO2 and 95% humidity. 
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4.2.4. Stabilisation and maintenance of transfected cells   
Following 48 hours of incubation of transfected cells in to normal medium, the medium 
was changed to selection medium, containing Dulbecco's Modified Eagle's Medium 
(DMEM) with 10% of FCS (Foetal Calf serum or Fetal Bovine Serum) and antibiotics from 
the stock (see above) and in addition 250 micrograms of Blasticidin (0.5microgram /ml). 
The transfected cells were kept in the selection medium for 5 to 7 days. This resulted in 
the selection of transfected cells and apoptosis of non-transfected cells. The medium 
was then changed to maintenance medium. Successful KDs were confirmed by 
microscopy, cell imaging, qPCR, agarose gel PCR and immunofluorescence.  
4.2.5. RNA isolation using TRI reagent  
Confluent T25 flasks of the desired cell lines were selected, and cell culture medium was 
aspirated. Flasks were then washed twice with the BSS. 1 ml of TRI reagent was added to 
the flasks. Cells were scrapped, and cell lysate was passed several times through the 
pipette to produce a homogenous lysate. The sample was transferred to a sterile 
Microfuge tube and allowed to stand at room temperature for 5 minutes. 0.2ml of 
chloroform TRI reagent were added to each tube and shaken for 15 seconds and were 
left to stand at room temperature for 2-15 minutes, then centrifuged at 12000 for 15 
minutes at 4◦C. Three phases appeared. The bottom red phase was the protein. The In-
between white phase was DNA and the clear top phase was the RNA. The clear top 
phase was carefully transferred to a fresh Microfuge tube. 0.5 ml of isopropanol was 
added to the Microfuge tube, mixed by shaking and left for 5-10 minutes at room 
temperature, then centrifuged at 12000 for 10 minutes at 4C. A pellet appeared at the 
base (not always clearly visible). The supernatant was discarded. The pellet was washed 
with 75% EtOH which was made up of RNA-ase free water and then centrifuged at 7500 
for 5 minutes. 75% EtOH was removed, and the sample was air dried for 5-10 minutes. 
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The pellet was dissolved in 20 micro-litres of RNA-ease free water. RNA concentration 
was measured on the nano-photometer. The lid factor used for most samples was 50. A 
lid factor of 10 was used for more concentrated samples, and 100 was used for more 
diluted samples. Dilution of concentrated samples was achieved by gradually adding ten 
micro-litres of RNAase free water and measuring the new concentration. Few of the 
RNA samples were stored at -80C freezer and others were used for direct reverse 
transcription (RT). 
4.2.6. RNA quantification 
The concentration of RNA extracted from the cells was measured using a UV101 Biotech 
Photometer (WPA, Cambridge, UK), which was set to detect single strand RNA in 
micrograms per micro-litres at 260 nanometers. Samples were measured by using 
Starna glass cuvette (Optiglass limited, Essex, UK). 
4.2.7. Reverse transcription polymerase chain reaction (RT-PCR) of RNA 
Once RNA had been isolated and quantified, RT-PCR was carried out to convert RNA into 
complementary DNA (cDNA) using DuraScriptTM RT PCR kit (Sigma-Aldrich, Dorset, UK). A 
fixed amount of 0.5 micrograms of RNA was converted to cDNA as per protocol. 
Standardized RNA concentrations were achieved by adding RNA-ease free water. The 
dilution amount of RNA-ease free water was calculated by 0.5 divided by the RNA 
concentration measured by the nano-photometer from earlier. Once diluted to 
standardised concentration forms, the new RNA concentration was measured on the 
nano-photometer.  The Abgene reverse transcription kit was used for RT PCR. The 
following volumes were used: 
Volume reaction was 20 micro-litres: 
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• PCR water was added to RNA to make volume 10 micro-litres 
• ten micro-litres of AB RT Mastermix 2X 
All of above were added to a dome-capped Microfuge tube's and placed into a thermo-
cycler (Applied GeneAmp PCR sys 2700). Each reaction was run as per the following 
protocol: 
Stage 1: 25◦C for 5 minutes 
Stage 2: 37◦C for 120 minutes 
Stage 3: 85◦C for 5 minutes 
Stage 4: held at 4◦C 
The final product was diluted with PCR water in 1:3 resulting in a final volume of 80 
micro-litres, which was then labelled and stored at -80◦C. 
 
4.2.8.  Real-time quantitative polymerase chain reaction (q-PCR) 
q-PCR was undertaken to analyse the transcript expression level of target genes. Such a 
technique is more sensitive than conventional RT-PCR and capable of detecting small 
quantities of cDNA, providing a more reliable value of the template copy number in each 
sample. This method requires a sequence-specific DNA based fluorescent reporter probe 
which only quantifies the target transcript containing such a probe sequence to greatly 
improve the specificity of the detection. AmplifluorTM UniprimerTM Universal system 
(Intergen company®, New York, USA) was available at the home department and was 
used in this study. The Amplifluor probe consisted of a 3' region specific to the Z-
sequence, which acted on the target-specific primers and a 5' hairpin structure labelled 
with a fluorescent tag (FAM). While in the hairpin structure, such a fluorescent tag was 
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linked to an acceptor moiety (DABSYL) which effectively quenched the fluorescence and 
produced no fluorescence signal. Primers were designed to the specific target transcript 
using Beacon Designer Software. To each of the primer pairs specific to the target 
sequence, a Z-sequence was added to allow incorporation of the Amplifluor uni primer 
probe during PCR. Such Z-sequence incorporated a DNA transcript that acted as a 
template for the Amplifluor uni primer probe, and the hairpin structure in the probe was 
subsequently degraded and unfolded by DNA polymerase disrupting the stable structure 
between fluorophore and quencher to enable sufficient fluorescence emission to be 
detected. The principle of this process was demonstrated in figure 18. Pre-prepared 
cDNA samples were amplified and detected on a Step One Plus Real-Time PCR System 
(Applied Biosystems, Paisley, UK), using Precision FAST 2X q-PCR Master-Mix 
(Primerdesign Ltd, Chandler's Ford, UK), specific forward primer (10pM), reverse primer 
containing the Z sequence (1pM) and the FAM-tagged Uni-primer probe (10pM). Each 
sample was loaded into a 96-well plate and the reaction mixture. The q-PCR conditions 
used are shown below:  
q-PCR Reaction mix: 
• Precision FAST 2X q-PCR MasterMix - 5µl 
• Specific forward primer - 0.3µl 
• Specific reverse primer with Z-sequence - 0.3µl 
• Amplifluor probe – 0.3µl 
• PCR H2O – 3.1µl 
• Prepared cDNA sample - 1µl 
q-PCR conditions:  
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• Step 1: Initial denaturation - 94ᵒC for 10 minutes 
• Step 2: Denaturation - 94ᵒC for 10 seconds 
• Step 3: Annealing - 55ᵒC for 30 seconds 
• Step 4: Extension - 72ᵒC for 10 minutes 
Step 2 - 4 were repeated for 100 cycles. 
The fluorescent signal was detected at the annealing stage, and the fluorescent signal 
emitted during PCR correlated to the amount of DNA template that had been 
incorporated into Z- sequence. The geometric increase in fluorescent signal directly 
correlated to the exponential increase of DNA template, which was used to determine a 
threshold cycle for each reaction. The transcript copy number was determined by the 
time/cycle number when fluorescent signal reached a specific threshold. Expression of 
the target sequence was detected in conjunction with a range of standards of the known 
transcript, PDPL, that are used to generate a standard curve to enable the calculation of 
transcript copy number in each unknown sample (Figure 2.2.11.1 and 2.2.11.2). Finally, 
the transcript copy number was normalised by the detected copy number of GAPDH. 
 
4.2.9. Agarose gel electrophoresis, DNA staining and visualisation 
The amplified DNA products from the PCR were analysed using 2% agarose gel 
electrophoresis. The analysis was based on the separation of DNA products according to 
their size on electrophoresis. The procedure was as follows: 
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4.2.10. Formation of 0.8% agarose gel 
3 grams of agarose (Melford chemicals, Suffolk, UK) was added to 150 ml of TBE solution 
in a flask. The mixture was heated in the microwave to boiling temperature, the agarose 
was fully dissolved, and the mixture became transparent in colour. Then the gel was left 
to cool down on room temperature just for a few minutes, and ten micro-litres of the 
cyber safe was added into it, following which the liquid gel was poured down into the 
electrophoresis cassette. Plastic combs were already inserted into the electrophoresis 
cassettes, and the gel was allowed to settle down at room temperature, which took 
between 30-40 minutes. The plastic combs were then carefully removed, leaving 
indentation slots for loading of the PCR products for later on.   
 
4.2.11.  TBE Buffer 
Once the gel was set, TBE buffer was carefully pour into the electrophoresis tank, 
directly on top of the gel, filling up to the maximum fill mark on the tank.   
4.2.12.  Loading gel with PCR products 
Five micro-litres of 100 Kb DNA ladder (Invitrogen, Paisley, UK) was loaded into the first 
indentation slot which was used as a reference guide in measuring of the DNA products 
once the electrophoresis was completed. Ten micro-litres of the PCR products were 
carefully loaded into the rest of the indentation slots on the gel.  
4.2.13.  Electrophoresis 
The electrophoresis cassette was connected with the power supply by its leads, making 
sure that the flow of the charge/current was in the right direction, that is, from the 
positive to the negative electrode, which separated the DNA products out on the gel. A 
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consort EV 243 electrophoresis device was used. The following setting was applied. 
Current : 110mA 
Voltage: 90V 
Time: 42 minutes.   
4.2.13.1.  Detection of spread of PCR products using UV light 
The TBE was poured away from the gel, and the gel was placed inside the UV light 
container (UVTech. Cambridge, UK). The degree of spread of PCR products was captured 
by using UV camera in the UV Tech. The light settings were optimised. 
4.2.13.2. Immunofluorescent Staining of Cells 
The immunofluorescence technique is used for light microscopy with a fluorescent 
microscope. The technique uses specificity of antibodies to their antigen to target 
fluorescent dyes to specific biomolecule targets in a cell, which allows visualisation of 
the presence and distribution of the target molecule. 30,000 cells were seeded into each 
chamber of 8 chamber slides x 8 (Millipore). The cells were incubated at 37C in 5% CO2 
overnight to achieve confluence and development of tight junctions. The media was 
aspirated, and cells were fixed in 4% formalin for 10 minutes. The cells were rehydrated 
in BSS for 20minutes at room temperature. Cells were then permeabilised with 1% 
Triton x 100 made (made in BSS) for 5 minutes. 5% serum or TBS diluent was prepared 
while the cells were getting fixed and washed, which was used to dilute the primary and 
secondary FITC/TRITC reagents as well as blocking any non-specific staining. Each good 
chamber was covered with 150µl to cover the whole layer. The serum used in the 
diluent was from the animal in which the secondary was made. 
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Non-specific binding was blocked by covering the cells with the diluent and incubated at 
RT for 1 hour.  The reagents were added very carefully on the side walls of the chamber, 
thus preventing any accidental detachment of cells. It was washed three times with TBS. 
Incubation was done with primary antibody at the concentration of 1:100 (made in 
dilute) for 1 hour. The following antibodies were used. 
Primary antibodies used were as follows: 
MAGI-1  SC – 25663  Rabbit  (Santa Cruz Biotechnologies) 
 
Secondary antibodies used were as follows: 
Anti-rabbit IgG Sigma Aldrich  Rabbit (for MAGI-1) 
 
 
50µl of the primary antibody (Rabbit) was added per 5 ml of solution, and secondary 
antibody concentrations were achieved by adding 5µl per 5ml solution for the anti-
rabbit antibody. The negative control was diluted with no primary antibody added. The 
wash was repeated for another three times with TBS. Appropriate sections were 
incubated with FITC / TRITC solution (stock = 4mg/ml, used 0.5µl per 100µl, and gave a 
final concentration of 2µg/100µl). TBS wash was repeated times 3. The plastic frame 
from the slide was removed, and a coverslip was mounted over the cells using 
FluorSaveTM, avoiding any air bubbles. Slides were placed on a tray, wrapped with foil to 
prevent any fading, and store in the fridge until were viewed under the fluorescent 
microscope. 
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4.3. Expression pattern of MAGI -1, -2 and -3 proteins in colorectal cancer cell lines 
Our experiments were consistent with the positive expression of MAGI-1 and MAGI-3, 
but lacked expression of MAGI-2, in colorectal cancer cell lines (HT -115, RKO and HRT -
18) on gel electrophoresis, which had profound implications on our work. Gastric cancer 
cell lines (AGS and HGC -27) were used as controls for expression of MAGI -2 (Figure 
4.3.1). Therefore, our further work became more focused on studying the role of MAGI -
1 in invasiveness of human colorectal cancer. If time had allowed, we would also have 
continued studying the role of MAGI -3 in invasiveness of human colorectal cancer cell, 
hence studying all three known types of MAGI proteins. 
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Figure 4.3.1. Expression of MAGI -1-2-3 in colorectal cancer cell lines (HT-115 WT, RKO WT, 
HRT-18 WT) which shows lack of MAGI -2 expressions. Gastric cell lines (AGS & HGC-27 WT), 
which expressed MAGI -2, were used as controls. 
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4.4. Evidence of MAGI -1 KDs on agarose gel electrophoresis 
Successful MAGI -1 KDs were confirmed agarose gel electrophoresis in HT-115 and RKO 
cell types of colorectal cancer cell lines, but not in HRT-18 cell lines, which continued to 
show MAGI -1 expression (Figure 4.4.1) and were used as controls for HT-115 and RKO 
cell lines. The failure of KDs in HRT -18 cell lines could be due to individual variations 
characteristics of this cell line but provided us with the advantage of using it as controls. 
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Figure 4.4.1. Expression of MAGI -1 in HT-115 WT and HT-115 MAGI-1 KDs, in RKO WT 
and RKO MAGI-1 KDs, in HRT-18 WT and HRT-18 MAGI-1 KDs 
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4.5 Colorectal cancer cell lines morphology and changes in morphology after MAGI-1 KD  
The cell morphology and growth pattern of all three colorectal cancer cell types were 
visualised using a high-resolution microscope, and images were captured. Changes in 
the growth pattern and cell morphology were noticed between the WT and KDs of 
individual colorectal cancer cell lines (Figure 4.4.2).  
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RKO WT      RKO MAGI -1KD 
 
 
 
   
 
HT-115 WT      HT-115 MAGI -1 KD 
      
   
 
 
 
HRT-18 WT       HRT-18 MAGI – KD  
    
 
 
 
Figure 4.4.2. Morphology comparison between RKO-WT and RKO MAGI -1 KDs, HT-
115-WT and HT-115 MAGI -1 KDs, HRT-18-WT and HRT-18 MAGI -1 KDs on high-
resolution microscopy. 
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There were notable changes macroscopically and microscopically to the cell morphology 
and growth patterns between the three colorectal cancer cell types (HT-115, RKO & 
HRT-18).  More importantly, significant changes in the growth pattern were noted 
between the wild-type colorectal cancer cell lines and their corresponding KDs. The HRT-
18 cells had a slower growth rate than the other two cell lines (HT-115 & RKO) and were 
more adhesive in character. In the flasks, on naked eye appearance, the WT were 
quicker to grow and would spread in a uniform pattern on the wall of the flask, whereas 
the KDs would grow in clumps at a slower rate, across the board for all the three cell 
lines (HT-115, RKO & HRT-18). This was assumed secondary to the transfection and due 
to use of selection medium in the initial phase. There were also significant 
morphological differences between the wild types and the KD cell lines. The cells grown 
following MAGI -1 gene were knocked down, appeared to be spiky and in clusters, 
whereas the WT were noticed to be more rounded and uniform distribution. The 
differences were noted to be less apparent in the HRT-18 cell lines, possibly be due to 
their slower growth and more adhesive nature. 
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4.5. Absence of TJs on Immunofluorescence between cells as evidence of successful 
KDs  
The slides were prepared with cells and were viewed under the fluorescent microscope. 
Immunofluorescence staining of TJs between cells and viewing them on the microscope 
demonstrated the presence of TJs in WTs and their absence in MAGI -1 KDs in HT115 
and RKO, but to a lesser degree in HRT18 cell lines (Figures 4.5.1, 4.5.2 and 4.5.3). 
Immunofluorescence staining of TJs between cells for ZO -1 -2 & -3 were used as 
controls, which had no or minimal loss of TJs by knocking down MAGI -1 gene (Figures 
4.5.4, 4.5.5 and 4.5.6). Individual cell lines HT-115 WT and HT-115 MAGI-1 KDs showed 
cells absence of TJs in the KDs. RKO WT and RKO MAGI-1 KDs also showed the absence 
of TJs in the KDs. HRT-18 WT and HRT-18 MAGI-1 KDs showed weakness, but not 
complete loss of TJs in the KDs (Figures 4.5.1, 4.5.2 and 4.5.3). ZO-1, ZO-2, and ZO-3 
were used as controls. HRT-18 WT and HRT-18 MAGI-1 KD cells on fluorescent 
microscopy demonstrating some minimal loss of TJs in ZO-1s. RKO WT and RKO MAGI-1 
KD cells on fluorescent microscopy demonstrating no or minimal loss of TJs in ZO-1s. HT-
115 WT and HT-115 MAGI-1 KD cells on fluorescent microscopy demonstrating no loss 
of TJs in ZO-1s (Figures 4.5.4, 4.5.5 and 4.5.6). 
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Figure 4.5.1. Immunofluorescence of HT-115 WT and HT-115 MAGI-1 KD cells on 
fluorescent microscopy destrating presence of TJs in WTs, but in contrast shows 
absence of TJs in the KDs. 
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Figure 4.5.2. Immunofluorescence of RKO WT and RKO MAGI-1 KD cells on fluorescent 
microscopy demonstrating presence of TJs in WTs, but in contrast shows absence of 
TJs in the KDs. 
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Figure 4.5.3. Immunofluorescence of HRT-18 WT and HRT-18 MAGI-1 KD cells on 
fluorescent microscopy demonstrating presence of TJs in WTs but in contrast shows 
only weakness, but not loss of TJs in the KDs. 
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Figure 4.5.4. Immunofluorescence of HT-115 WT and HT-115 MAGI-1 KD cells on 
fluorescent microscopy demonstrating presence of TJs in WTs but also in contrast 
shows no loss of TJs in ZO-1s. 
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Figure 4.5.5. Immunofluorescence of RKO WT and RKO MAGI-1 KD cells on fluorescent 
microscopy demonstrating presence of TJs in WTs but also in contrast shows no or 
minimal loss of TJs in ZO-1s. 
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Figure 4.5.6. Immunofluorescence of RKO WT and RKO MAGI-1 KD  cells on fluorescent 
microscopy demonstrating presence of TJs in WTs but also in contrast show minimal 
loss of TJs in ZO-1s. 
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4.6. Discussion: 
MAGI -1 is widely expressed and found to be localised in epithelial and endothelial cell-
to-cell Tight Junctions (TJ), and acts as a scaffolding molecule to stabilise cadherin-
mediated adhesions and to recruit molecules in TJ. (Laura et al. 2002). Stromberg et al. 
reported that invasiveness of colorectal cancer cells had a co-relation with cell adhesion 
proteins and polymorphism in their genes. (Stromberg et al. 2008). Landy et al. 
suggested that the dysregulation of TJs proteins preceded the development of IBD 
associated colorectal cancer (CRC). (Landy et al. 2016). Zaric et al. reported an increased 
expression of MAGI -1 was seen to suppress migration and invasion of the cancer cells. It 
was also seen that knocking down MAGI -1 decreased the localisation of E-cadherin at 
the cell to cell junction, increased disruption of stress fibres and focal adhesion points 
resulting in increased migration and invasion. Inversely, over-expression of MAGI -1 
suppressed the cancer growth and metastasis in colorectal cancer cells. (Zaric et al. 
2012) 
We had a lack of MAGI -2 expression in on qPCR and Agarose gel electrophoresis in 
colorectal cancer cell lines (HT-115, RKO, HRT18), which was consistent with the 
literature, as MAGI -2 is not found to be expressed in human colorectal cancer in the 
literature. Human gastric cancer cell lines (AGS, HGC -27) were used as controls for 
expression of MAGI -2. This had a profound implication on our work, and the further 
focus of our work shifted to concentrate on the role of MAGI -1 proteins in invasiveness 
of human colorectal cancer cell lines.  However, MAGI -3 also remained of high interest 
to us, but due to the time limitation, further experiments was not carried out on MAGI -
3, and as mentioned before, the focus of our work was concentrated on MAGI -1. In fact, 
MAGI -2 and MAGI -3 remains an extremely high area of interest for future, and if time 
would have allowed, we would certainly have had explored these two. The reason for us 
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choosing RKO, HT-115 and HRT-18 cell lines in colorectal cancer cell types was because 
of their high invasive and metastatic potential.  
 
To study the effects of aberrant expression of MAGI -1 in human colorectal cancer, we 
created a different type of cell lines with different expression levels of MAGI -1 proteins. 
We did this by generating colonies of human colorectal cancer cell lines in which we 
knocked down MAGI -1 genes. Hence these cell colonies were not able to produce 
MAGI-1 proteins.  We were able to prove our success in the creation of KDs by the lack 
of MAGI -1 expression in RKO and HT-115 cell lines following Q-PCR and agarose gel 
electrophoresis. The experiments were repeated which showed consistency in the 
results. However, HRT-18 KD cells continued to have some expression of MAGI-1, which 
was either due to their slow growing and more adhesive nature when compared to the 
other two cell lines or due to unsuccessful MAGI-1 KD in them. The similar differences in 
the behaviour were observed between the all three colorectal cancer cell lines (RKO, 
HTT-115 & HRT-18) in morphology and functional studies (discussed in following 
chapters). The changes were distinctive macroscopically and microscopically to the cell 
morphology and growth patterns between the individual colorectal cancer cell lines (HT-
115, RKO & HRT-18).  Once the KD cell lines were generated, significant changes in 
morphology and growth pattern between the wild types colorectal cancer cell lines and 
their corresponding KDs were noted. To the naked eye in the flasks, the WT cells were 
quicker to grow and would spread in a cluster pattern on the wall of the flask, whereas 
the KD cells would grow in uniform pattern and at a slower rate, across the board for all 
the three cell lines (HT-115, RKO & HRT-18) used in our experiments. This was assumed 
secondary to the transfection and due to use of selection medium in the initial phase. 
The cells were grown following MAGI -1 gene knocked down, and appeared to be spiky 
171 
 
and uniform, whereas the WT were noticed to be more rounded and more of cluster 
distribution. The differences were noted to be less apparent in the HRT-18 cell lines, 
could be due to their slower to grow and were more adhesive nature. 
Immunofluorescence staining showed the presence of TJs in WT cells and their absence 
in HT115 and RKO MAGI -1 KD cells. This was noticed to a lesser degree in HRT18 MAGI -
1 KD cell lines. ZO -1 -2 & -3 were used as controls, which had no or minimal loss of TJs 
by knocking down MAGI -1 gene. 
The results of functional tests which we carried out later (discussed in the following 
chapters) were consistent with our initial findings of MAGI -1 expression in different 
colorectal cancer cell lines (HT -115, RKO and HRT -18).  
4.7. Conclusion:  
We concluded that human colorectal cancer cells lacked expression of MAGI -2. We had 
evidence of successful MAGI -1 KDs from differences in the morphology of cells between 
WTs and KDs. We also had evidence of successful KDs from lack of expression of MAGI -
1 in the KDs. We had evidence to suggest that reduction in MAGI -1 expression has a 
profound effect on the strength of presence of TJs in human colorectal cancer. 
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R O L E  O F  M A G I  P R O T E I N S  I N  I N V A S I V E N E S S  O F  H U M A N  C O L O R E C T A L  
C A N C E R  C E L L S .  
 
 
C H A P T E R  5 :  I N F L U E N C E  O F  T A R G E T I N G  M A G I  - 1  O N  A D H E S I O N ,  
P R O L I F E R A T I O N  A N D  M I G R A T I O N  I N  H U M A N  C O L O R E C T A L  C A N C E R  
C E L L S  
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5. Introduction  
MAGI-1 is widely expressed in the epithelial and endothelial cell-to-cell tight junctions 
(TJs), where it acts as a scaffolding molecule to stabilise cadherin-mediated adhesions 
and to recruit molecules in TJ. (Dobrosotskaya et al. 1997, Laura et al. 2002). Roles 
attributed to MAGI include organisation of protein complexes at the cell and synaptic 
junctions, regulation of cell polarity, connecting trans-cellular proteins with the 
cytoskeleton in TJs. (Martin et al. 2011) Stetak et al. reported that the knockdown of 
MAGI protein causes a loss of junctional compartmentalisation along the lateral 
membrane, and reduces the overall robustness of cell-to-cell adhesion. (Stetak et al. 
2010).  
Metastatic spread of cancer is not uncommon, and it directly impacts on the patient's 
survival. Cancer metastasis is a series of complex events, involving the initial dissociation 
of malignant cells from a primary tumour that happens by the loss of cell adhesion 
between cells, which subsequently leads to invasion of the cells to the surrounding 
stroma.  Hence the process of angiogenesis begins involving specific proteins expression 
and suppression, degrading basement membrane and extracellular matrix and also 
affecting the cell motility and migration (Brooks et al. 1996). For cancer cells to 
metastasize successfully, TJs must be disrupted. TJs is a critical structural adhesive 
component that exists, firstly between the cancer cells which prevent detachment, 
secondly between the endothelial and epithelial cell linings which prevent intravasation 
and extravasation of cancer cells (Martin et al. 2011).  
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5.1 Aims 
We aimed to study the effect of MAGI -1 KD on adhesion, proliferation and migration in 
colorectal cancer cell lines. We also looked at the effect of MAGI -1 KDs on barrier 
function. 
5.2 Materials and methods 
 
5.2.1 Cell Lines:  
HT -115, HRT -18 and RKO; human colorectal cancer cell lines were used. The cells were 
obtained from the European Collection of Animal Cell Culture (ECACC).  (Table 5.2.1.1). 
Table 5.2.1.1. Specification of colorectal cancer cell lines 
Cell line HHT -115 HRT -18 RKO  
Species Human Human Human 
Tissue Colon Rectum Rectum 
Age 63 67 82 
Gender Male Male Female 
Morphology Epithelial Epithelial-like Epithelial 
Growth mode Adherent Adherent Adherent 
Karyotype 2n=46 2n=46 2n=46 
Tumorigenic Specified Yes Yes 
Country UK UK UK 
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5.2.2 Electrical cell impedance sensing (ECIS) 
Electrical cell impedance sensing (ECIS) is a technique for analysing cell behaviour based 
on work of Giaever and Keese, who found that it was possible to monitor the growth, 
migration and adhesion of cells growing on a small electrode by monitoring changes in 
impedance of the cells, that is, resistance to an alternating current) (Giaever and Keese 
1984). The ECIS apparatus was supplied by Applied Biophysics (New York, USA).  A 96 
well plate array specific to the ECIS machine was used (IBIDI, Germany). Each well inside 
the 96 well plate has a unique design. It is built around two small gold electrodes, in the 
bottom of the wells in which the seeded cells are allowed to grow within the incubator. 
These electrodes work as sensing the impedance or resistance between the cells and the 
cell and the bottom of the array. Each Individual well is a part of plate array, which 
consists of a plastic housing encasing an integrated circuit incorporating all the 
electrodes included in the array. An array can contain various numbers of wells and 
types of plates, but a 96 well plate is the most widely used configuration. The plate slots 
into a dock, in the incubator, which connects it to the ECIS machine. The incubator in the 
apparatus does not provide carbon dioxide; therefore, DMEM used has to contain 
HEPES to compensate. (Figure 5.2.2.1) 
 
5.2.2.1 ECIS: Procedure 
The protocol for the procedure was available in the home department (Jiang et al.), 
which had been used extensively in the past for study of tumour cell behaviour (Keese, 
Wegener et al. 2004; Jiang 2012) (Figure 5.2.2.1.). A series of these experiments were 
performed in 96 well ECIS plates. All the 96 plates used were new, straight out of the 
packet inside the tissue culture hood, maintaining conditions as sterile as possible. 200 
micro-litres of the normal medium was added to each of the 96 wells on the plate. The 
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top cover of the 96 well plate were placed and secured in position by manual pressure 
while was being transferred from tissue culture to the ECIS machine. ECIS machine 
which connected to a computer, which runs the ECIS software and displays the graph by 
the cell impedance changes.   
 
HRT-18 WT, HT-115 WT and RKO WT were the wild types used with their respective 
HRT-18 PEF, HT115-PEF and RKO PEF. Amongst the transfected types, two knockdowns 
were created and verified for each cell type, labelled as HT-115 KD1 and KD2, RKO KD1 
and KD2 and HRT-18 KD1 and KD2. The cell flasks were trypsinised and centrifuged at 
17000 revolutions per minute (RPM) for 5 minutes in universal containers (UCs), 
following which they were re-suspended in 1 ml of medium. Cell dilution was measured 
by using the following. 
http://www.celeromics.com/en/support/cell-dilutio-calculator.php 
 
Each well was seeded with 100,000 cells in 200 micro-litres. Once final dilution volumes 
were measured, they were added to the ECIS plate, and the plate was taken back and 
put into the ECIS machine. Once the plate was fixed firmly into position inside the ECIS 
machine, the plate electrode connection with the machine electrodes was checked, 
which showed all the wells lit up in the green colour, meaning a good connection 
between electrodes had established. The incubator settings were set to 37°C and 95% 
humidity. The experiment was then started and delayed wounding was enabled from 
options and the setting was set for eight hours for colorectal cancer cell lines and 12 
hours for gastric cancer cell lines. The current used for wounding was 3000 micro-
amperes at a frequency of 4000 hertz with the time set to 20 seconds. The cell’s 
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impedance and resistance measurements were displayed on the screen off the monitor 
and were recorded for the all-new addition of the experiment and were also saved for a 
later reference. The average of the percentage of increase in impedance of the cells in 
the initial hours was calculated to study cell adhesion. Similarly, the average percentage 
of increase after a successful wounding to the cells was used to calculate the 
conventional migration essay. Once the experiment was completed, used plates were 
carefully washed with bleach, and disposed of in the yellow clinical waste bins. In the 
end, the ECIS program was shut down, and the computer was switched off. The 
incubator was cleaned from inside with 70% ethanol. That experiment was repeated 
three times for each colorectal cancer and gastric cancer cell line. 
The problems encountered during the ECIS experiments were to make sure that there 
were no quality control issues. It was realised that contamination could affect the 
quality of the readings generated inside the wells. Great care was taken to prevent any 
infection or contamination of the cells inside the wells. We were also aware that 
sometimes air bubbles inside the wells could lead to defective functioning of the 
electrode sensors, so great care was taken to avoid it. Several repetitions of the ECIS 
experiment were undertaken to make sure that the readings were consistent and any 
errors were filtered out and were not included in the final analysis. 
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Figure 5.2.2.1. Electric cell impedance sensing (ECIS) and its mode of operation. 
The ECIS machine provides detailed readings on cell adhesion and growth, which is 
recorded in real time. Also, there is provision for inflicting the cells with a uniform wound 
by electroporation, thereby providing further detail of their migratory function. The 
home department not only has the largest array of ECIS machines in the country but also 
has published one of the most useful texts regarding its uses (Jiang 2012). 
(http://www.biophysics.com/ecis-theory.php). 
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5.2.3 Trans-epithelial resistance (TER)   
Trans-epithelial or trans-endothelial resistance (TER) is an excellent method for 
assessing barrier function of the reconstructed epithelial of the grown cell lines. It has 
become a method of assessing cell-to-cell tight junction function in vitro. The cells are 
cultured over a porous membrane and grown to become dense, forming cell-to-cell tight 
junctions and establishing cellular polarity. With the help of the chopstick type of 
electrodes in the apparatus, the electrical resistance across the barrier between the cell 
layers can be determined by applying a small AC voltage with varying frequency.  
 
5.2.4 TER: Procedure 
The cells were trypsinised and re-suspended in DMEM, and cell count performed and 
cells diluted to 100,000 per 500 micro-litres. The cell mixture was added to the 
transparent 0.4 micro-metre pores sized inserts (Greiner bio-one, Stonehouse, UK). The 
0.4 micro-litre sized pores membrane acts as a medium for selective diffusion. The 
inserts were placed inside 24 wells plates. 400 micro-litres of the cell mix was added to 
the inserts and 1000 micro-litres to the wells, containing the inserts. The cells were 
grown to confluence. The medium is replaced with fresh DMEM containing 15Mm 
Hepes, L-glutamine. (Lonza Laboratories, Verviers, Belgium). Medium alone was added 
to the base of the well (controls) (Martin et al. 2008).  The classical way of measuring 
TER is by the use of handheld electrodes (chopstick-type electrodes). The electrode set 
up allows cell layer impedance measurements. We used the same method by using hand 
held static electrodes (WPI, FL, USA) and EVON volt-ohmmeter (EVON, World Precision 
Instruments, Aston, Herts, UK) (Martin et al. 2004a). Both electrodes were placed inside 
the well, one inside the insert and the other one outside the well.  The resistance was 
measured across the colorectal cancer cell lines HRT-18 WT, HT-115 WT and RKO WT 
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were the wild types used with their respective KDs at intervals from 0 to 240 minutes. At 
the end of each experiment, the medium was removed, and the cells were stained with 
crystal violet and were examined under the microscope to ensure that the cell layers 
had remained attached throughout the experiment. TER experiments give us a relative 
estimation of cell functions such as migration, adhesion and resistance and comparison 
being made between the wild types and transfected cell lines, which are discussed in 
detail in the results section.    
 
5.3 Results 
5.3.1 Cell-to-cell tight junction function and its relation to MAGI expression 
Trans-epithelial (TER) was used to assess barrier function of the of the cell lines. It 
confirmed cell-to-cell TJ function status in vitro. HT -115 cell lines (WT, PEF and two 
MAGI -1 KDs) showed a significant reduction in TER in the KDs when compared to the 
WTs and PEFs.  This may suggest weakness of TJs secondary to decreased expression of 
MAGI -1 in KDs (p-value 0.037 in KD1 and 0.002 in KD2) (Figure 5.3.1). 
Similarly, the RKO cell lines (WTs, PEF and MAGI -1 KDs) showed significant reduction in 
trans epithelial resistance between cells in the KDs when compared to the WTs and 
PEFs, suggest weakness of TJs secondary to decreased expression of MAGI -1 in KDs (p-
value 0.001 in KD1 and 0.001 in KD2) (Figure 5.3.1.2). 
However, HRT -18 cell lines (WT, PEF and MAGI -1 KDs) showed no reduction in trans 
epithelial resistance between cells in the KDs when compared to the WTs and PEFs, 
suggesting no loss of strength in TJs (p-value 0.13 KD1 and 0.09 KD2) (Figure 5.3.1.1). 
This was possibly due to the unsuccessful creation of MAGI -1 KDs and were used as 
controls for HT115 and RKO cell lines. 
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Overall, the results were consistent with a reduced cell-to-cell tight junction function in 
the HT-115 and RKO KDs in colorectal cancer cell lines due to a decrease in MAGI 
expression when compared with the PEFs and WTs. TER across the HRT18 PEF and KDs 
were not reduced because of possible unsuccessful KDs and not significantly low MAGI 
expression, which was consistent with the ECIS results. 
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Figure 5.3.1. HT -115 WT, PEF and two MAGI -1 KDs cell lines showing significant 
reduction (p-value KD1 = 0.037 and p-value KD2 = 0.002) in trans epithelial resistance 
between cells in the KDs when compared to the WTs and PEFs suggesting weakness of 
TJs secondary to decreased expression of MAGI -1 in KDs. 
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Figure 5.3.1.2. RKO WT, PEF and two MAGI -1 KDs cell lines showing significant 
reduction (p-value KD1 = 0.001 and p-value KD2 = 0.001) in trans epithelial resistance 
between cells in the KDs when compared to the WTs and PEFs suggesting weakness of 
TJs secondary to decreased expression of MAGI -1 in KDs. 
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Figure 5.3.1.1. HRT -18 WT, PEF and two MAGI -1 KDs cell lines showing no reduction 
(p-value KD1 = 0.13 and p-value KD2 = 0.09) in trans epithelial resistance between cells 
in the KDs when compared to the WTs and PEFs suggesting no loss of strength in TJs. 
This was due to the unsuccessful creation of MAGI -1 KDs and was used as controls for 
HT115 and RKO cell lines. 
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5.3.2 ECIS results 
HT -115 cell lines (WT and two MAGI -1 KDs) showed reduced cell adhesion and 
electrical impedance in KDs when compared to the WTs, which suggested a decrease in 
the strength of TJs secondary to decreased expression of MAGI -1 in KDs (Figure 5.3.2.1).  
Similarly, RKO cell lines (WT and two MAGI -1 KDs) showed reduced cell adhesion and 
electrical impedance in KDs when compared to the WTs, which suggested a decrease in 
strength of TJs secondary to the decreased expression of MAGI -1 in KDs (Figure 5.3.2.2).  
However, HRT18 cell lines (WTs and two MAGI -1 KDs) showed no reduction in cell 
adhesion and electrical impedance between KDs and PEFs, which possibly was due to 
the unsuccessful creation of KDs, were used as controls (Figure 5.3.2.3). 
This means that knocking down MAGI -1 in colorectal cancer cell lines leads to increased 
proliferation and migration, hence increase the metastatic potential of cancer cells.  
 
Overall, our ECIS results were consistent with our previous experiments, showing a 
decrease in cell impedance in KDs when compared with WTs in HT-115s and RKOs, but 
not in the HRT18s, which was possibly due to the less successful creation of HRT18 KDs. 
The decrease in cell impedance was due to the loss of TJs function secondary to the 
reduced expression of MAGI -1 in the KDs. 
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Figure 5.3.2.1. Shows ECIS results depicted on a graph for HT -115 WT and two MAGI -
1 KDs cell lines. Electrical resistance is measured on the Y-axis and time is measured 
on the X-axis. Cells were wounded at 8 hours and 16 hours by electric shock. There 
was reduced cell adhesion and electrical impedance in MAGI -1 KDs in comparison to 
WTs, which suggested a decrease in the strength of TJs secondary to decreased 
expression of MAGI -1 in KDs. This leads to increased proliferation and migration, 
hence increase in metastasis of cancer cells. 
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Figure 5.3.2.2. Shows ECIS results depicted on a graph for RKO WT and two MAGI -1 
KDs cell lines. Electrical resistance is measured on the Y-axis and time is measured on 
the X-axis. Cells were wounded at 8 hours and 16 hours by electric shock. There was 
reduced cell adhesion and electrical impedance in MAGI -1 KDs in comparison to WTs, 
which suggested a decrease in the strength of TJs secondary to decreased expression 
of MAGI -1 in KDs. This leads to increased proliferation and migration, hence increase 
in metastasis of cancer cells. 
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Figure 5.3.2.3. Shows ECIS results depicted on a graph for HRT18 and two MAGI -1 KDs 
cell lines. Electrical resistance is measured on the Y-axis and time is measured on the 
X-axis. Cells were wounded at 8 hours and 16 hours by electric shock. There was no 
significant reduction in cell adhesion and electrical impedance between cells in the 
MAGI -1 KDs when compared to the PEFs, which was due to unsuccessful KDs and 
were used as controls. Hence again proving that MAGI -1 expression reduces 
proliferation and migration of cancer cells, hence reduces the metastatic capability of 
cancer cells.  
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5.4 Discussion 
Increased leakiness in TJs during the metastatic process has also been related to the 
oncogene mutations in cancer cell lines. It was reported by Soler et al. that the 
transepithelial resistance (TER) and para-cellular influx rate of TJs were effected in 
colonic cancer cells when compared to normal colonic cells, suggestive of increased 
permeability and decreased barrier function, hence leakier colon cancer epithelial cells 
than that of normal colonic epithelial cells. (Soler et al. 1999, Mullin et al. 2005). Landy 
et al. suggested that the dysregulation of TJs proteins precedes the development of 
inflammatory bowel disease (IBD) and also lead to the development of IBD associated 
colorectal cancer (CRC). (Landy et al. 2016)   
MAGI -1 is widely expressed and is found to be localised at TJs, which acts as a 
scaffolding molecule to stabilise cadherin-mediated adhesions. (Laura et al. 2002) 
Endothelial cell-selective adhesion molecule (ESAM) regulates MAGI-1 recruitment to 
the cell contacts and subsequently promotes actin polymerisation and mature cell-to-
cell adhesion (Kimura et al. 2010).  Stetak et al. reported that the knockdown of MAGI 
protein causes a loss of junctional compartmentalisation along the lateral membrane, 
and reduces the overall robustness of cell-to-cell adhesion. (Stetak et al. 2010). Zaric et 
al. reported that increased expression of MAGI -1 was seen to induce stabilisation of cell 
to cell junctions. Increased expression of MAGI -1 was seen to suppress migration and 
invasion of the cancer cells. It was also seen that knocking down MAGI -1 decreased the 
localisation of E-cadherin at the cell to cell junction, increased disruption of stress fibres 
and focal adhesion points resulting in increased migration and invasion. Also, that the 
MAGI -1 over-expression in colorectal cancer cells suppressed the cancer growth and 
lungs metastasis in vivo in an orthotopic transitional intestinal model. In conclusion, 
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Zaric et al. identified the increased expression of MAGI -1 to suppress migration and 
invasion of the cancer cells, whereas knocking down MAGI -1 resulted in increased 
migration and invasion. (Zaric et al. 2012) Our experimental work was different to Zaric 
et al. as they used SW40, SW680, HCT116, T84 and HT29, which were different cell lines 
to ours, with different characteristics and varying metastatic potential. Also, that we 
used different methods than Zaric et al., that is, we used ECIS and TER to study cancer 
cell behaviour. Soler et al. reported that the transepithelial resistance (TER) of TJs was 
effected in colonic cancer cells when compared to normal colonic cells, suggestive of 
increased permeability and decreased barrier function, hence leakier colon cancer 
epithelial cells than that of normal colonic epithelial cells. (Soler et al. 1999).  
In our experiments, we used TER to assess and compare the barrier function of the 
reconstructed epithelial lining of the grown WT and MAGI -1 KD cell lines. ECIS was used 
to assess cell behaviour based on growth, migration and adhesion by monitoring 
changes in electrical impedance of the cells. The TER experiments were consistent with 
findings of reduced TJs function in the HT115 and RKO KDs colorectal cancer cell lines 
due to decreased MAGI -1 expression in comparison to PEFs. HT -115 WT, PEF and two 
MAGI -1 KDs cell lines showed significant reduction (p-value KD1 = 0.037 and p-value 
KD2 = 0.002) in trans epithelial resistance between cells in the KDs when compared to 
the WTs and PEFs, suggesting weakness of TJs secondary to decreased expression of 
MAGI -1 in KDs. RKO WT, PEF and two MAGI -1 KDs cell lines also showed significant 
reduction (p-value KD1 = 0.001 and p-value KD2 = 0.001) in trans epithelial resistance 
between cells in the KDs when compared to the WTs and PEFs, suggesting weakness of 
TJs secondary to decreased expression of MAGI -1 in KDs. However, HRT -18 WT, PEF 
and two MAGI -1 KDs cell lines showed no reduction (p-value KD1 = 0.13 and p-value 
KD2 = 0.09) in trans epithelial resistance between cells in the KDs when compared to the 
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WTs and PEFs, suggesting no loss of strength in TJs. This was probably due to the 
unsuccessful creation of MAGI -1 KDs and was used as controls for HT115 and RKO cell 
lines. 
In ECIS experiments, HT -115 cell lines (WT and two MAGI -1 KDs) showed reduced cell 
adhesion and electrical impedance in KDs when compared to the WTs, which suggested 
a decrease in the strength of TJs secondary to decreased expression of MAGI -1 in KDs. 
Similarly, RKO cell lines (WT and two MAGI -1 KDs) showed reduced cell adhesion and 
electrical impedance in KDs when compared to the WTs, which suggested a decrease in 
strength of TJs secondary to decreased expression of MAGI -1 in KDs. However, HRT18 
cell lines (WTs and two MAGI -1 KDs) showed no reduction in cell adhesion and electrical 
impedance between KDs and PEFs, which possibly, was due to the unsuccessful creation 
of KDs, were used as controls. This meant that knocking down MAGI -1 in colorectal 
cancer cell lines leads to increased proliferation and migration, hence increase the 
metastatic potential of cancer cells. Overall, our ECIS results were consistent with our 
previous experiments, showing a decrease in cell impedance in KDs when compared 
with WTs in HT-115s and RKOs, but not in the HRT18s, which was possibly due to the 
less successful creation of HRT18 KDs. The decrease in cell impedance was due to the 
loss of TJs function secondary to the reduced expression of MAGI -1 in the KDs. 
 
The TER findings showed a decrease in cell impedance in MAGI -1 KDs in comparison to 
the wild types in HT115 and RKO cell lines, which implied an increase in cell migration 
and invasion potential secondary to break down of the TJs. Again, the findings between 
TER and ECIS were similar in the HRT18 colorectal cancer cell lines, that there was no 
reduction in cell resistance and cell impedance. This was due to possible failure of the 
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creation of successful MAGI -1 KDs in HRT 18 cell lines. Hence these were also used as 
controls. 
 
5.5 Conclusion 
We had convincing evidence from our experiments that MAGI -1 plays an important role 
in the TJ functions and knocking it down results in a decrease in epithelial barrier 
function and also results in decreased cell adhesion and increase in cell proliferation 
migration, hence increasing the invasive potential of the colorectal cancer cells.
 R O L E  O F  M A G I  P R O T E I N S  I N  I N V A S I V E N E S S  O F  H U M A N  
C O L O R E C T A L  C A N C E R  C E L L S .  
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C H A P T E R  6 :  D I S C U S S I O N 
Cancer is the leading cause of human morbidity and mortality worldwide. 14 million new 
cases were diagnosed in 2012, with more than 8 million cancer-related deaths reported 
in one year. (Cancer statistics WHO 2012) Metastatic spread is not uncommon and 
directly impacts on patient's survival. Metastasis is a complex multi-step process 
involving cell and cell-matrix interactions in which various types of cell adhesion proteins 
are involved. Body cavities, lumens and surfaces are lined by epithelial cells. These 
epithelial cells are exposed to repeated insults by the environmental agents and 
carcinogens, which cause repeated damage. To cope with the repeated, ongoing damage, 
the body constantly renews these epithelial cell linings, which have a very high 
regeneration and proliferation rate. This leads to a high probability of acquiring genomic 
mutation, which is probably why nearly ninety percent of cancers arise from epithelial 
cells. There is good evidence in the literature on the loss of TJs and spread of cancer. One 
of the important early steps in cancer metastases is interaction and penetration of the 
vascular endothelium by the cancer cells. The TJs in the vascular endothelium act as a 
barrier to molecules and cells. TJs in the epithelium act as an adhesive, which prevents 
cells from detachment. (Hollande et al. 2001). There has been enough evidence to prove 
that TJs are the first line of defence, which cancer cells must overcome to metastasise. 
(Martin et. al. 2002, Hoevel et. al. 2002, Ren et. al.1990, Satoh et. al.1996, Martin et. al. 
2010, Kominsky et. al. 2003, Sauer et. al. 2005, Seok et. al. 2007, Usami et. al. 2006, 
Krämer et. al. 2000, Osanai et. al. 2006) Increased leakiness in TJs during the metastatic 
process has also been related to the oncogene mutations in cancer cell lines. It was also 
reported by Soler et al. that the Trans-Epithelial Resistance (TER) and para-cellular influx 
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rate of TJs were effected in colonic cancer cells when compared to normal colonic cells, 
suggestive of increased permeability and decreased barrier function, hence the leakier 
colon cancer epithelial cells than that of normal colonic epithelial cells. (Soler et al. 1999, 
Mullin et al. 2005) Stromberg et al. reported that invasiveness of colorectal cancer cells 
had a co-relation with cell adhesion proteins and polymorphism in their genes. 
(Stromberg et al. 2008). Landy et al. suggested that the dysregulation of TJs proteins 
precede the development of inflammatory bowel disease (IBD) and also lead to the 
development of IBD associated colorectal cancer (CRC). IBD results from the 
compromised integrity of epithelial barrier. Intestinal epithelium acts as a static barrier 
and has complex mechanisms to control and regulate bacterial interactions with the 
mucosal surface, during which apical tight junction proteins are critical. Alterations in 
tight junction proteins compromise epithelial barrier function in inflammatory bowel 
diseases. (Landy et al. 2016)  
MAGI is an important novel set of proteins associated with TJs. Many important roles are 
attributed to MAGI, especially regarding maintenance of the integrity of the tight 
junctions, influencing the spread and metastasis of cancer cells. We found that there was 
a particular area of deficiency on MAGI proteins and its types in colorectal cancer cell 
lines. Zaric et al. concluded that over-expression of MAGI -1 was identified as a 
suppressor of colorectal cancer and its metastatic activity. The Increased expression of 
MAGI -1 was seen to suppress migration and invasion of the cancer cells, whereas 
knocking down MAGI -1 resulted in increased migration and invasion. (Zaric et al. 2012) 
Our study had significant differences from Zaric et al. study, who looked at the tumour 
suppressor activity of MAGI -1 in colorectal cancer cells. The key difference being in the 
cell lines as Zaric et al. used SW40, SW680, HCT116, T84 and HT29. Also, that we used 
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different methods than Zaric et al., that is we used ECIS and TER to study cancer cell 
behaviour. Increased leakiness in TJs during the metastatic process has also been related 
to the oncogene mutations in cancer cell lines. It was also reported by Soler et al. 
reported that TER and para-cellular influx rate of TJs were effected in colonic cancer cells 
when compared to normal colonic cells, suggestive of increased permeability and 
decreased barrier function, hence leakier colon cancer epithelial cells than that of normal 
colonic epithelial cells. (Soler et al. 1999, Mullin et al. 2005).  
 
6.1. Expression of MAGI -1, -2, -3 in colorectal cancer cells  
In our experimental work on MAGI proteins in colorectal cancer cell lines, we had 
constant lack of MAGI -2 RNA expression on PCR (figure 4.3.1) in colorectal cancer cell 
lines (RKO, HT115, HRT 18), which was consistent with the literature, as there is nothing 
reported to date about MAGI -2 expressions in colorectal cancer cell lines. MAGI -1 and 
MAGI -3 were used as positive controls, which were expressed and gastric cell lines (AGS 
and HGC -27) were used as controls for MAGI -2 expressions. With the use of quantitative 
PCR (table 3.5.1.1, 3.5.1.2, 3.5.1.3), we demonstrated that expression levels of MAGI-1 
were decreased in the paired tumour tissues than the normal tissues (statistically 
significant, p-value 0.023). Also, that expression levels of MAGI -1 were decreased in the 
TNM stage -2, -3 and -4 when compared with TNM stage -1. The results were consistent 
with the trend and also were near to achieving statistical significance (0.061). It is 
possible that few statistically significant results were due to the low power of our sample, 
but the consistency in trends was remarkable and stood out. We had similar results for 
decreased expression levels of MAGI-2 in a tumour paired and normal tissue with 
statistical significance (0.001), but we did not have samples achieving statistical 
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significance in MAGI-3, which was probably due to small numbers and a reduced amount 
of samples. Our findings were consistent with the literature, as it is well reported that 
increased expression of MAGI -1 is seen to suppress migration and invasion of the cancer 
cells. It is also reported that MAGI -1 overexpression of MAGI -1 is identified as a 
suppressor of colorectal cancer and its metastatic activity. (Zaric et al. 2012) MAGI -3 in 
literature is said to inhibit LPA induced migration and invasion of colonic cancer cells. 
(Lee et al. 2011). Also, we did not come across any publication that reported MAGI -2 
expressions in colorectal cancer cell line, which was again consistent with our work. 
 
6.2. MAGI -1 
MAGI -1 protein has significant clinical relevance, which makes it a very attractive area of 
research, but also has a potential for future diagnostic and therapeutic expression sites in 
cancer treatment. This is not only supported by our experimental work but also is in 
keeping with evidence from the literature. MAGI -1 is widely expressed at and have been 
found to be localised to the epithelial and endothelial cell to cell TJs, and acts as a 
scaffolding molecule to stabilise cadherin-mediated adhesions and to recruit molecules in 
TJ. (Laura et al. 2002). Roles attributed to MAGI include organisation of protein 
complexes at the cell and synaptic junctions, regulation of cell polarity, connecting trans-
cellular proteins with the cytoskeleton in TJs. (Martin et al. 2011), and regulation of 
synapse formation and plasticity. (Emtage et. al.2009). Kimura et al. suggested that 
Endothelial cell-selective adhesion molecule (ESAM) regulates MAGI-1 recruitment to the 
cell contacts and subsequently promotes actin polymerisation and mature cell-to-cell 
adhesion (Kimura et al. 2010).  Stetak et al. reported that the knockdown of MAGI protein  
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in Caenorhabditis elegans epithelia causes a loss of junctional compartmentalisation 
along the lateral membrane, and reduces the overall robustness of cell-to-cell adhesion. 
(Stetak et al. 2010). MAGI have also been reported to be involved in cancer cell signalling 
as a tumour suppressor regulator protein (Matsuda et al. 2013). 
 
6.3. Effects of knocking down MAGI -1 in colorectal cancer cells 
We chose three different human colorectal cancer cell lines for our experiments, RKO, 
HT-115 and HRT-18, because of their high invasive and metastatic potential, which is well 
known and also found in the literature. To start with, we created a different type of cell 
lines and checked the expression of MAGI -1 in them. After that, we created knockdowns 
of MAGI 1, which were confirmed on Q-PCR and agarose gel electrophoresis (figure 
4.4.1). The experiments were repeated which showed consistency in the results. Once 
the KDs were confirmed, cell lines were generated, significant changes in morphology 
and growth pattern between the wild types colorectal cancer cell lines and their 
corresponding KDs were noted. To naked eye in the flasks (figure 4.4.2), WT cells were 
quicker to grow and would spread in a cluster pattern on the wall of the flask, and 
individual cells had rounded appearances, whereas KD cells would grow in a uniform 
pattern at a slower rate and individual cells had spiky appearances. This was noted across 
the board for all the three colorectal cancer cell lines (HT-115, RKO & HRT-18) used in our 
experiments. However, the differences were noted to be less apparent in the HRT-18 cell 
lines, which was possibly due to their slower to grow and more adhesive nature. Also, 
HRT-18 KD cells continued to have some expression of MAGI-1 on Q-PCR and agarose gel 
electrophoresis, which was again either due to their slow growing and more adhesive 
nature when compared to the other two cell lines or was due to the less successful 
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creation of KDs. Electronic microscopy following Immunofluorescence staining (figure 
4.5.1 – 4.5.6) showed the presence of TJs in WT cells and their absence in HT115 and RKO 
MAGI -1 KD cells. This was noticed to a lesser degree in HRT18 MAGI -1 KD cell lines, 
which consistent with our findings on Q-PCR and agarose gel electrophoresis. ZO -1 -2 & -
3 were used as controls, which had no or minimal loss of TJs by knocking down MAGI -1 
gene. 
 
In our experiments, we used TER to assess and compare the barrier function of 
reconstructed endothelial and epithelial of the grown WT and MAGI -1 KD cell lines. ECIS 
was used to assess cell behaviour based on growth, migration and adhesion by 
monitoring changes in electrical impedance of the cells. The TER experiments (figure 
5.3.1, 5.3.1.2 & 5.3.1.1) were consistent with findings of reduced TJs function in the 
HT115 and RKO KDs colorectal cancer cell lines due to decreased MAGI -1 expression in 
comparison to PEFs. The TER findings were consistent with ECIS results (figure 5.3.2.1 – 
5.3.2.3), which also showed a decrease in cell impedance in MAGI -1 KDs in comparison 
to the wild types in HT115 and RKO cell lines, which implied an increase in cell migration 
and invasion potential secondary to break down of the TJs. Again, the findings between 
TER and ECIS were similar in the HRT18 colorectal cancer cell lines in that there was a 
reduction to a lesser degree in cell resistance and cell impedance than HRT18 and HT115. 
As mentioned above, Zaric et al. also reported that knocking down MAGI -1 resulted in 
increased migration and invasion. (Zaric et al. 2012)  Soler et al. also checked trans 
epithelial resistance (TER) in colonic cancer cell lines and compared it to normal colonic 
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cells. He found out that there was a decrease in the barrier function of cancer cell lines 
than that of normal colonic cell lines. (Soler e. al. 1999). 
Survival curves showed an increase in overall survival and disease-free survival in our 
cohort with consistent trends of higher survival rates related to increased expression of 
MAGI. Combined analysis of MAGI -1, -2 and 3 (Figure 3.8.1 and 3.8.2) showed higher 
survival rates in both, overall and disease-free survival, which were of statistical 
significance (Wilcoxon statistical significance of 0.015 and 0.045). Survival curves of 
individual MAGI -1, -2 and 3 were consistent with a similar pattern, and showed a higher 
rate of survival with increased expression of individual MAGI type (MAGI -1, -2 and 3) 
(Figures 3.8.3 – 3.8.8). Although individual MAGI type (MAGI -1, -2, -3) results did not 
reach statistical significance, the trends were consistent with increased overall survival 
and disease-free survival in tissues with increased expression. MAGI-1 overall survival 
was of note as it nearly reached statistical significance (0.074) (Figure 3.8.3). Our work is 
unique as it is the first of its type, considering the effect of MAGI protein expression 
(MAGI -1, -2, -3) on patients (human tissue) survival, as there is nothing published to date 
relating MAGI expression with human survival. However, Balbas et al. have published 
their work on MAGUK (MAGI -2) expression and survival function conducted on mice. 
(Balbas et al. 2014)   
Following studying the expression of MAGI -1 in colorectal cancer cell lines, we 
established that reduced expression of MAGI -1 lead to not only reduced adhesion and 
barrier function, but also an increase in the migratory function. This translates into not 
only increased cancer metastasis in the patient's cohort but also reduced survival. This 
makes MAGI proteins of significant clinical relevance. 
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6.4. Future work 
If time had allowed, we would have done the following: 
• We would have carried out Western Blotting (WB) experiments to confirm 
expression levels of MAGI in colorectal cancer cell lines at the protein level.   
• Further time is permitting we would have also studied phosphorylation status 
and regulation pathways, which were areas of our future interest. 
 
In future, further work is needed on the functions and roles of this essential protein, 
especially in cancer metastasis, which was out of the scope of this study mainly due to 
mainly time constraints. 
 
6.5. Conclusion 
From our analysis of MAGI-1 protein expression in human colorectal cancer cell lines, we 
have compelling evidence that MAGI-1 protein plays an important role in the 
invasiveness and metastasis of human colorectal cancer, mainly by their role in the 
maintenance of TJ structure and function. 
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